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SUMMARY
Two cytokines, transforming growth factor beta (TGFp) and interleukin 1 (IL-1) have 
been implicated to have major roles in bone remodelling. A wealth of data has been 
published on the osteotropic properties of these two cytokines. It is proposed that the 
synthesis of cytokines in the bone microenvironment may control local remodelling. 
Whilst the expression of these two cytokines by osteoblasts from different animal 
species has been demonstrated, it has become clear that their modulation is a highly 
species specific phenomenon.
This study was therefore undertaken to characterise the expression of these factors in 
human bone. Initially the expression of TGFp and IL-1 by human osteoblast-like 
cells was studied in vitro. The effects of various osteotropic agents on the expression 
of these cytokines were then monitored. In addition, the occurrence of cell surface 
receptors for these two cytokines was investigated. Once the expression of these 
factors had been established in vitro, the project was extended to characterise cytokine 
expression in situ using sections of human bone. There is also some evidence that 
matrix components may also have a role in local bone remodelling, therefore the 
expression of an important bone matrix protein osteopontin was also investigated.
The expression of both cytokines by human bone cells was shown to be regulated in a 
distinct manner. TGFp mRNA expression was regulated by the systemic hormones, 
whilst IL-ip mRNA expression was modulated by cytokines and "inflammatory" 
agents. The idea that these factors may control local remodelling was further 
supported by the finding that both TGFp and IL-1 (3 receptors were present on the cell 
surface of human osteoblasts. In addition, the expression of both cytokines was 
detected in situ.
Osteopontin mRNA expression was detected in a variety of cell types in the bone 
tissue. The finding that osteoclasts express mRNA for osteopontin was very novel, 
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C H A P T E R  X :  INTRODUCTION
1.1 BONE AND C A RTILA G E
l(i) Introduction
Bone and cartilage are two specialized connective tissues which together make up the 
skeletal system. There are three main functions of these tissues; firstly to give a 
physical framework for the body and provide sites o f muscle attachment for 
movement, secondly to protect various internal organs, and thirdly to act as a reservoir 
of calcium and phosphate ions. In common with all connective tissues, bone and 
cartilage consist of two components namely matrix and cells. The matrix is composed 
of collagen fibres and a ground substance rich in proteoglycans and proteins. Unlike 
other connective tissues these matrices are unique since they can become calcified. 
The mechanism of calcification is unknown but may involve the non collagenous 
proteins.
Kii) The macroscopic organization of bone
The two types of bone in the skeleton are categorized according to their appearance; 
flat bones (skull bones, scapula, and mandible), and long bones (tibia, femur and 
humerus).
The general structure of long bones consists of three parts, the shaft of bone or 
diaphysis, the intermediate area the metaphysis, and the enlarged ends of bone the 
epiphyses (see figure 1 . 1 ). During growth the epiphysis and the metaphysis are 
separated by a layer of epiphyseal cartilage termed the growth plate. The cartilage cells 
in the growth plate proliferate, differentiate and eventually become calcified, giving 
rise to the longitudinal growth of the bone. The external part of the bone consists of 
hard compact tissue termed cortical bone, which encloses the medullary cavity where 
red bone marrow is found in the diaphysis. Towards the metaphysis and epiphysis 
the cortical bone is thinner, and spongy tissue termed cancellous bone is present 
(Lozupone and Favia, 1990). Cancellous bone (also called trabecular bone), consists
10
of calcified processes (trabeculae) lined with osteoblasts interspersed with bone 
marrow.
Figure 1.1 The macroscopic structure of bone
Articular cartilage
Spongy trabecular boneEpiphysis





The general structure of long bones is shown in the diagram. Redrawn from 
Functional Histology. Churchill Livingston 1979
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The bone surfaces at the epiphyses are covered with articular cartilage which does not 
calcify, and allows interaction with other articular surfaces in the joint. The external 
surface of the diaphysis is covered with vascular elastic periosteal tissue, and the inner 
surface with endosteal tissue. The periosteal tissue consists of; an inner osteogenic 
layer which contains connective cells and osteoblasts, covered by an outer fibrous 
periosteal layer containing blood vessels and nerves.
There are structural and functional differences between cortical and cancellous bone, 
however they consist of the same cell types and matrix. The structural differences are 
largely dependent on the degree of mineralisation of the two types of bone; 80-90% of 
cortical bone is mineralised compared with only 15-20% of cancellous bone. Due to 
its superior strength the cortical bone fulfils mainly a structural and protective role. 
Cancellous bone with its increased surface area is important in the metabolic functions 
of bone.
Hiii) The microscopic organization of bone
The microscopic "scaffolding" material of bone are collagen fibres, which orientate 
together in a preferential direction, and are also associated with the bone matrix. The 
bone matrix consists of many different proteoglycans and proteins which have a very 
high binding capacity for calcium ions, a property which is vital for the mineralisation 
process. Interspersed, in an orientated manner, between the fibres and matrix are 
spindle shaped crystals of hydroxyapatite. The preferential orientation of the collagen 
fibres alternates between layers in adult bone, giving rise to a lamellar structure which 
is birefringent when viewed with a polarizing microscope. These lamellae are 
organized in a concentric manner around a central canal in the shaft of an adult human 
long bone, and form numerous units of bone structure called haversian systems. The 
lamellae arise from layers of osteoblasts that become embedded in bone matrix and 
form "rings" of osteocytes separated by bone matrix. Long thin processes arise from
12
the osteocytes and are arranged in a pattern with respect to the haversian canal with 
which they connect. In addition to the concentric lamellae that make up the haversian 
system, other lamellae occur between systems and around the circumference o f  
systems (see figure 1.2).
In te r s t i tia l
lam e llae
H aversian  sy s te m  (o ste o n )
Inner
c ircu m fe ren tia l
lam ellae O u te r  c irc u m fe re n tia l 
lam ellae
V o lk m a n n 's
can al
H aversian
canal P e r io s te u mE n d o s teu m
Figure 1.2. Schematic drawing of the wall of a long bone diaphysis. Haversian 
systems, and inner and outer circumferential lamellae are evident. The protruding 
Haversian system on the left shows the orientation of collagen fibres in each lamella. 
At the right is a haversian system showing lamellae, a central blood capillary, and 
many osteocytes with their processes. (From F unctional Histology.  C hu rch il l  
Livingston 1979)
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1.1 BONE MATRIX COMPONENTS
Bone matrix is a highly complex network of over two hundred different proteins and 
proteoglycans. It is obviously vital as a ground substance and contributes to the 
microenvironment of the bone cells. Much research has been undertaken to elucidate 
the components of bone matrix. This research however has been hampered in the past 
for several reasons; initial attempts to isolate proteins from bone under strong 
denaturing conditions resulted in the loss of many proteins, also proteins were isolated 
that had not originated from bone, but were merely contaminants from other tissues. 
A major contribution to the field was made by Termine et al. (1980) who developed a 
non enzymatic procedure to purify proteins which were intimately associated with the 
mineralised bone. This approach was used in conjunction with sensitive techniques 
for protein characterisation such as high performance liquid chromatography (HPLC) 
and microamino acid sequencing, and allowed proteins which were present in very 
small amounts to be purified. However, this type of approach did not give any 
information on either the cell source or the regulation of synthesis of the bone matrix 
proteins. In situ hybridization and sensitive immunochemistry techniques were used 
to determine which cells were responsible for matrix protein production. Additionally, 
cell culture model systems were developed to investigate the control of bone matrix 
synthesis.
Uiv) Collagen
Greater than 90% of the protein in bone consists of type I collagen. Other collagens 
are present but only in trace amounts including types III, V, XI, XIII and X collagen 
(Gehron Robey, 1989). Type I collagen is a trimeric heteropolymer consisting of two 
alpha 1 chains [(*,(1 )] and one alpha 2  chain [ot2 (I)j> wound together in a triple helix
14
to form a collagen fibril . The collagen fibrils are stabilized by the formation of 
covalent cross links formed from condensation reactions between allylysine and 
hydroxyallysine residues.
The control of collagen synthesis is obviously a very important step in bone matrix 
formation, and has been investigated in cell culture experiments. The major collagen 
synthesizing cell type in bone matrix is the osteoblast, and collagen synthesis has been 
demonstrated in vitro by osteoblast cultures of many different animal species 
including human, rat, and mouse (Beresford et al. 1986; Canalis, 1986; Weiner et 
al.1989). The expression of type I collagen by osteoblasts is regulated by certain 
systemic hormones and growth factors, including 1,25 D3 (Beresford et al. 1986; 
Rowe and Kream, 1982). Cytokines are also effective agents in modulating collagen 
synthesis, but often have opposing effects. Centrella demonstrated that TGFp 
treatment increases type I collagen synthesis in fetal rat bone (Centrella et al.1987), but 
similar studies revealed that interferon y inhibits collagen synthesis both in vivo in the 
mouse (Granstein et al.1987), and in rat calvarial organ culture (Smith et al.1987). 
Analysis of the type I collagen gene has lead to a greater understanding of the control 
mechanisms affecting this important structural protein. Promoters of the a! and a 2 
genes have been isolated from several different species (Chu et al. 1985; Schmidt et 
al. 1986). Both contain a CCAAT box sequence, but only (Xi contains a TATA 
sequence. Putative enhancer binding sequences have also been identified, and are 
thought to be important in the control of collagen transcription. For example, it is 
postulated that TGFp upregulation of collagen mRNA, is achieved through NF-1 
binding to an enhancer region adjacent to the CCAAT region of the 0 C2 promoter (Rossi 
et al. 1988). The first intron of the gene contains a cis acting sequence which has 
also been shown to increase promoter activity. It is interesting to note that the MOV- 
13 mouse lethal mutation, which is characterized by aberrant collagen production, is 
also localized to this enhancer region (Harbers et al.1984).
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Since two a i polypeptides are required for each 0 1 2 polypeptide to form a collagen 
molecule, it would be expected that the expression of the two subunits would be 
coordinated. This is achieved at the transcriptional le v e l, as it has been shown that 
the a i  gene is twice as transcriptionally active as the (X2  gene (deWet et al. 1983). Cell 
culture experiments and cell free translation systems have shown that collagen 
expression is also regulated by a negative feedback loop (Schlimberger et al. 1988), 
where N terminal collagen polypeptides inhibit collagen synthesis. The mechanism 
of this feedback is unknown but is post transcriptional, and may involve altering 
procollagen mRNA stability, or reducing translational efficiency.
Hv) Osteonectin
Osteonectin is a major constituent of developing bone (Fisher et al.1987), however the 
proportion of osteonectin in the matrix varies according to both developmental stage 
and species (Malaval et al.1987). In bovine matrix less osteonectin (only 40% of the 
maximum) is found in immature woven bone; the majority is incorporated into mature 
lamellar bone (Conn and Termine, 1985). Osteonectin is an acidic glycoprotein which 
binds both calcium ions and hydroxy apatite crystals with collagen fibres. It is thought 
to link various components of the mineralised matrix together (Termine et al. 1981). 
The degree of glycosylation of osteonectin has been shown to be critical for collagen 
binding (Kelm and Mann, 1991).
The cDNA sequences of osteonectin from many species including mouse (Mason et 
al. 1986) and human (Swaroop et al. 1988) have been cloned, and show a very high 
degree of homology reflecting the evolutionary importance of this protein. Human 
genomic clones of osteonectin reveal a classical gene organization of 10 exons. With 
each exon encoding a distinct structural protein domain (Swaroop et al. 1988).
Despite its name, osteonectin is not a bone specific protein (Gehron Robey, 1989). In 
addition to osteoblasts (Yoon et al.1987), osteonectin expression has been detected in 
several connective tissue cells including fibroblasts, tendon cells, and some types of
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chondrocytes (Jundt et al.1987; Wasi et al.1984). Nomura screened all the major 
tissues of mouse and detected osteonectin transcripts in all the tissues except liver 
(Nomura et al. 1988). In situ hybridization studies of fetal mouse and human bone, 
show that osteoblasts in the periosteal tissue and hypertrophic cartilage region express 
very high levels of osteonectin mRNA (Nomura et al. 1988). Osteonectin has also 
been implicated in having a developmental role, as it is expressed in high amounts in 
developing adrenal glands, testes and ovaries (Holland et al.1987).
l(vi) Osteocalcin
Osteocalcin was one of the first described non collagenous bone proteins. It was 
originally named Bone Gla protein, by virtue of the fact that it contains gamma 
carboxyglutamic acid (gla) residues (Price, 1987). Osteocalcin is a comparatively 
small protein with a molecular weight of 5300, and has been shown to have a 
moderate affinity for calcium ions. The binding of these ions is thought to occur via 
two carboxyglutamic acid residues which are closely positioned together in the 
protein. The primary amino acid structure has been determined for osteocalcin by 
both amino acid sequencing (Poser et al. 1980) and a predicted sequence from cDNA 
and genomic clones (Celests et al. 1986). The gene is located on chromosome 1 in 
humans and contains 4 exons (Puchacz et al. 1989). Exon 1 contains a 26 amino acid 
signal peptide, which is adjoined to a propeptide sequence coded by exon 2. The 
carboxyglutamic acid residues are contained in 2  stretches of amino acids coded by the 
third exon.
The tissue specificity of osteocalcin has been investigated by Northern blot analysis of 
RNA isolated from  various tissues (Fraser and Price, 1988) and by 
immunolocalization (Mark et al.1987). These studies revealed that the expression of 
osteocalcin was very specific to mineralised tissues. Young osteoblasts and 
odontoblasts were the major cell types that expressed osteocalcin, and the staining
17
pattern suggested that osteocalcin was deposited in the bone just prior to 
mineralisation.
Several primary osteoblast cultures and osteosarcoma cell lines have been shown to 
produce osteocalcin in vitro (Lajeunesse et al.1990; Beresford et al.1984; Canalis and 
Lian, 1988). In the majority of studies the expression of osteocalcin is modulated by 
treatment with the systemic hormones. Both human and mouse osteoblasts increase 
osteocalcin synthesis following treatment with 1,25 dihydroxyvitamin D 3  (1,25 D3 ) 
(Beresford et al. 1984; Canalis and Lian, 1988). PTH treatment has also been shown 
to increase osteocalcin synthesis in a dose dependant manner in ROS 17/2.8 cells. 
The increased synthesis has been shown to be due to a concurrent increase in the 
steady state levels of osteocalcin mRNA (Noda et al. 1988). The transcriptional rate of 
osteocalcin was constant but it was shown that PTH stabilized osteocalcin mRNA . 
The role of osteocalcin in bone is not known, however it has been suggested that it 
might act to retard mineralisation until the bone matrix has reached the correct stage of 
maturation (Gehron Robey, 1989). This hypothesis would explain why osteocalcin is 
only present in large amounts in mature bone. Alternatively, since some C terminal 
fragments of osteocalcin are chemotactic for osteoblast-like cells (Lucas et al. 1988) it 
may act as a recruitment factor to enhance bone formation. Osteocalcin is a vital 
component of bone, since bone particles devoid of osteocalcin, from warfarin treated 
rats, fail to be resorbed by osteoclasts (Lian et al. 1986).
Osteocalcin gene structure
Osteocalcin expression appears to be regulated in a developmental stage, and cell 
specific manner. To determine the regulatory mechanism of this expression many 
studies have been undertaken to investigate the osteocalcin gene at the molecular level. 
It had been shown that the synthesis of osteocalcin by various osteoblast-like cells was 
upregulated by vitamin D3 . Therefore the first studies concentrated on characterising a 
vitamin D responsive element (VDRE) located upstream to the coding region.
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Yoon et al. (1988) isolated the rat osteocalcin gene, and showed it was a highly 
conserved single copy gene. The upstream portion of the gene was cloned into a 
construct with a chloramphenicol acetyl transferase (CAT) reporter gene, and 
transfected into the rat osteoblastic cell line ROS 17/2.8. Treatment of the 
transfectants with 1,25 D3  induced CAT expression by 5 - 10 fold. Various portions 
of the 5' upstream DNA were then deleted until a region -1035 base pairs to -871 base 
pairs upstream of the start codon was identified as the VDRE. A similar study was 
undertaken with the human osteocalcin gene and a VDRE with the classical half site 
arrangement was identified (Ozono et al. 1990).
The gene structure of the osteocalcin gene has been elucidated from a rat genomic 
clone (Yoon et al. 1988). It has a classical modular organization of 4 exons flanked by 
regulatory sequences both upstream and downstream of the coding region. The gene 
was shown to have 3 types of regulatory elements; an RNA polymerase II site, 
hormone receptor binding sites, and a 42 nucleotide sequence in the proximal region 
containing a highly conserved sequence termed the "osteocalcin box" (Lian et 
al.1989).
In contrast with type I collagen, osteocalcin is only expressed in non-proliferating 
osteoblasts in mineralising matrix. An elegant study by Owen et al. (1990) was 
undertaken to investigate how the expression of these osteoblastic developmental 
markers were regulated. Firstly the sequence of the upstream region of the rat 
osteocalcin gene was analysed. The analysis revealed that there were 2 AP-1 binding 
sites, which overlapped the VDRE and "osteocalcin box".
The nuclear proteins encoded by the protooncogenes c-fos and c-jun interact via a 
leucine zipper to form a stable heterodimer complex that together with other proteins, 
interacts with the AP-1 binding site. Proliferating osteoblasts were shown to contain 
high levels of AP-1 binding activity which dramatically changed after the down 
regulation of proliferation and initiation of extracellular mineralisation. Therefore a 
model was proposed where coordinate occupancy of AP-1, VDRE and "osteocalcin
19
box" sequences in proliferating osteoblasts suppressed basal and vitamin D enhanced 
osteocalcin gene expression. This regulation of transcription of genes associated with 
differentiation was termed "phenotype suppression".
Hvii) Bone sialoproteins
Two important bone matrix components are the sialoproteins, bone sialoprotein 
(formerly BSP II) and osteopontin (formerly BSP I). The latter will only be discussed 
briefly here (see chapter VII for a more extensive review). Both are glycosylated 
phosphoproteins and contain many sialic acid moieties (Midurat et al.1990). BSP is 
fairly prevalent in bone, accounting for approximately 15% of non collagenous 
proteins. Whilst osteopontin is present in far smaller quantities estimated at 
approximately 2% (Franzen and Heinegard, 1985).
A cDNA clone for BSP has been isolated from a ROS 17/2.8 library. The protein has 
an mRNA of 2kb which codes for 320 amino acid residues, of which glutamic acid 
and glycine constitute 32% (Oldberg et al. 1988a). BSP is heavily glycosylated with 
50% of its molecular weight in the form of O and N linked carbohydrate side chains 
(Fischer et al.1983). Both proteins bind tightly to hydroxyapatite in bone. They 
appear to form an integral part of the mineralised matrix, since they can only be 
extracted under denaturing conditions (Franzen and Heinegard, 1985).
BSP expression has been detected in both primary osteoblast cultures and transformed 
cell lines. The expression in the cell lines has been shown to be variable. UMR 106 
cells produce large amounts of BSP constitutively, whilst no constitutive expression 
can be detected in ROS 17/2.8 cells (Midurat et al.1990). BSP expression has been 
detected in osteoblasts obtained from fetal rat calvariae (Yoon et al.1987). The 
regulation of BSP expression has been investigated using osteoblast cultures in vitro . 
1,25 D3  treatment has no effect on BSP synthesis, in contrast BSP transcription is 
stimulated by dexamethasone treatment (Oldberg et al. 1989).
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Oldberg suggested that BSP expression may be restricted to the differentiated 
osteoblast phenotype, as its synthesis follows that of alkaline phosphatase in rat 
osteoblasts (Oldberg et al.1989). This is supported by the in situ hybridization data of 
Bianco et (1991), who demonstrated BSP mRNA expression only in mature 
osteoblasts.
Despite extensive studies on these proteins in several species, their precise function in 
bone formation and remodelling remains to be fully elucidated. BSP can bind to 
collagen, therefore it may function as a link protein between hydroxyapatite and the 
organic bone matrix (Oldberg et al. 1988a). Analysis of the primary structure of BSP 
reveals that it contains an RGD tripeptide sequence (Oldberg et al. 1988a). This 
together with the fact that a BSP integrin receptor has been identified on the surface 
of ROS 17/2.8 cells suggests BSP may be involved in cell attachment (Oldberg et 
al. 1988b). The BSP receptor was later found to be identical to the vitronectin 
receptor, and it was demonstrated that BSP promotes cell attachment in vitro (Oldberg 
et al. 1988b). BSP may also be important for cell growth, since it can be shown to 
promote cell spreading and attachment of ROS 17/2.8 cells and bovine chondrocytes 
in culture (Oldberg et al. 1988b; Sommarin et al.1989).
Originally BSP was thought to be highly bone specific. Northern blot analysis 
showed BSP mRNA to be present in large amounts in bone, but absent from other 
tissues (Oldberg et al. 1988a). However recent research by Bianco et al. (1991) 
demonstrated that BSP could be immunolocalized in hypertrophic chondrocytes and 
placenta.
Hviii) Proteoglycans
The purification and characterisation of bone matrix components has identified 2 
classes of proteoglycan in developing subperiosteal bone (Franzen and Heinegard, 
1984). One large (mol wt. = 600,000) chondroitin sulphate proteoglycan, and two 
smaller (mol wt. = 80,000 - 1 2 0 ,0 0 0 ) chondroitin sulphate proteoglycans have been
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purified. The two small proteins are highly homologous (55%), although genetically 
distinct. It is possible that they may have arisen from the duplication of a proteoglycan 
gene which then evolved to give two forms. The two small proteoglycans, biglycan 
(formerly PGI), and decorin (formerly PGII) are not unique to bone, and have been 
isolated from other tissues including cartilage, skin, and tendon (Heinegard et 
al.1985). However it is interesting to note that whilst these proteoglycans in bone 
contain chondroitin sulphate moieties, those in other tissues are dermatan sulphate 
proteoglycans. Antisera against synthetic peptides specific for N terminal sequences 
of biglycan and decorin, have been used to immunolocalize these molecules in 
developing fetal bone (Bianco et al. 1989). Both proteoglycans were immunolocalized 
to matrix and cells in areas of active bone formation. Biglycan alone was detected in 
osteogenic lacunae and canalicular spaces. The large proteoglycan was localized to 
loose interstitial mesenchyme where it is thought to act as a "space filler" during early 
bone development.
Osteoblasts from several different species including rat, mouse and human have been 
shown to be capable of synthesizing proteoglycans (Hunter et al.1983; Gehron Robey 
and Termine, 1985). Pulse chase protein studies indicate that whilst biglycan and 
decorin are synthesized at similar rates, the turnover of biglycan is much greater as it is 
modified, secreted and degraded at a faster rate than decorin (Fedarko and Gehron 
Robey, 1989). Osteoblasts in culture synthesize proteoglycans which are conjugated 
to dermatan sulphate, a form which is not bone specific. The reason for this is 
unknown but may reflect a dedifferentiation of osteoblast phenotype in culture. Very 
little data have been published on the regulation of proteoglycan synthesis by 
osteoblasts in culture. Treatment with 1,25 D3 decreases the synthesis of biglycan 
but not decorin (Gehron Robey et al. 1987a), which is interesting since 1,25 D 3  is a 
maturation factor for osteoblasts.
The role of the small proteoglycans in bone are unknown. It has been suggested that 
biglycan and decorin may diffuse to the mineralisation front ahead of other proteins
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and facilitate mineralisation (Klein-Nulend et al.1981). Since proteoglycans have been 
shown to be associated with collagen fibres and influence both the rate of fibre growth 
and the diameter of fibre, it is probable that they influence the collagen scaffolding in 
bone (Johannson et al.1985).
Recent research has indicated that the role of proteoglycans in bone may not just be as 
amorphous "glue like" substances, but that they may have an important role as 
modulators o f growth factors. Heparan sulphate proteoglycans have been shown to 
bind fibroblast growth factors (FGFs). The binding appears to protect the growth 
factors from degradation (Hausehka et al.1986). Active FGF can be liberated by 
proteolysis of the proteoglycan core protein or partial degradation of the heparan 
sulphate component. Furthermore it has been shown that the interaction of FGF with 
proteoglycan is essential for its function as an interaction with heparan sulphate is a 
prerequisite of receptor binding (Yayon et al.1991). Presumably the interaction gives 
rise to some conformational change of the FGF. This type of interaction with 
proteoglycans is not limited to FGF. Other growth factors have been shown to bind 
heparin, and heparan sulphate, including GM-CSF and interleukin 3 (Robert et 
al.1988).
The interactions described so far are mediated by the glycosaminoglycan components 
of the proteoglycans. Transforming growth factor beta (TGFp) has been shown to 
interact in a novel manner with proteoglycans by binding to the protein core of a cell 
surface proteoglycan, betaglycan (Andres et al.1989). Unlike the TGFp receptors, 
betaglycan does not transduce an intracellular signal but is thought to present TGFp to 
the receptors. Decorin also binds TGFp through its core protein and neutralizes its 
activity (Yamaguchi et al.1990). It is interesting to note that TGFp upregulates 
decorin synthesis (Ruoslahti and Yamaguchi, 1991). Therefore decorin may be a vital 
component in a negative feedback mechanism for the regulation of TGFp activity. 
Like FGF, TGFp binding to the matrix is reversible and therefore may be an important 
factor in maintaining a reservoir of matrix bound growth factors.
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BONE CELL TYPES
The main cell types present in bone will be discussed in the following sections. For a 
review of the morphological nature of bone cells see Peck and Woods (1988).
l(ix) Osteoblasts
Osteoblasts in their active state occur as a continuous layer of cells. Electron 
microscopic analysis shows that they contain an abundance of intracellular organelles, 
typical of cells vigorously engaged in protein synthesis (Jeansonne et al.1979). They 
form gap junctions both with their neighbours and with adjacent osteocyte processes 
(Doty, 1981), and contain numerous microtubules and bundles of actin filaments 
along the inner surfaces of their plasma membranes. Cells in a resting phase are 
thought to exhibit a flattened morphology, and those that are active, a cuboidal 
morphology. Osteoblasts are the primary cell type responsible for the synthesis of 
bone matrix, and are therefore highly biosynthetically active. They produce several 
characteristic bone matrix proteins including type I collagen, osteocalcin, osteonectin, 
sialoproteins and proteoglycans (Beresford et al.1984; Gehron Robey, 1989). 
Histochemical techniques demonstrate that osteoblasts express a wide range of 
enzymes including those of the citric acid cycle. Additionally they express high levels 
of alkaline phosphatase activity (Fritsch et al.1985) which is often used as a 
biochemical "marker" for these cells.
l(x) Osteocytes
Osteocytes are derived from osteoblasts which have become enclosed within lacunae 
in the bone matrix. Osteocytes are linked together, and to the osteoblasts on the bone 
surface, by thin cytoplasmic processes which extend through canaliculi permeating the 
bone matrix (Jeansomme et al.1979). By this route, osteocytes are able to maintain 
communication with each other and obtain nutrition. Osteocytes in woven bone are
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plump, closely packed and have an appearance similar to osteoblasts. In contrast 
those in lamellar bone are widely spaced and exhibit a more flattened morphology 
(Parfit, 1988). Osteocytes which are positioned deep in lamellar bone are generally 
smaller and contain less developed endoplasmic reticulum characteristic of a less 
biosynthetically active cell.
The function of osteocytes remains undetermined. However since they are in contact 
with large areas of bone matrix, it has been assumed that they have a role in mineral 
exchange between the bone matrix and the circulation. It has also been postulated that 
osteocytes may have some role in transducing and responding to mechanical stress, 
since a variety of enzymes and RNA synthesis can be shown to increase in bones that 
have been subjected to a stress regime (Skerry et al.1989). Osteocytes are vital 
components of the skeleton, if the osteocytes die as a result of injury the "dead" bone 
is resorbed, revascularized and replaced with new bone.
l(xi) Osteoclasts
Osteoclasts are large multinucleated cells that are often attached to the bone surface. It 
has been established that they are the principal bone resorbing cell type, although other 
multinucleated cells have been implicated in bone resorption (Kahn et al.1978; 
Teitelbaum et al.1979). The morphological characteristics of an active osteoclast are 
functionally specialized, and include a ruffled border surrounded by an organelle-free 
actin-containing clear zone (Ryder et al. 1981). Osteoclasts are rich in both 
mitochondria and lysosomes, and appear to contain coated pits that internalize receptor 
bound ligands (Kallio et al. 1971). From scanning electron microscope studies on 
isolated osteoclasts, it has been suggested that the ruffled border of the osteoclast 
makes intimate contact with the bone surface and is the site of resorption (Baron et al. 
1988). Pseudopodia are then thought to extend from the osteoclast and intertwine 
with the mineral crystals and collagen fibres. It is probable that the mineral crystals
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are then phagocytosed into cytoplasmic vacuoles. The fate of the collagen fibres is not 
clear but probably follows an intracellular degradative pathway.
The mechanism of osteoclast mediated resorption has yet to be fully elucidated, 
however it seems to be an amalgamation of protease secretion together with directional 
ionic potential across the ruffled membrane. Osteoclasts have been shown to secrete 
large amounts of tartrate resistant acid phosphatase (TRAP) and other lysosomal 
enzymes including many acid hydrolases (Hammarstrom et al. 1971). Carbonic 
anhydrase is also present in large amounts (Minkin and Jennings, 1972) and this 
enzyme may provide H+ ions to maintain an ionic gradient across the border.
l(xii) Bone marrow
There are two types of bone marrow, red and yellow according to their microscopic 
appearance. Red bone marrow is the primary site of hematopoiesis, it contains an 
abundance of erythrocytes and blood vessels. The supporting tissue in red marrow 
consists of reticular fibres which support various types of progenitor cell and mature 
leucocytes. Red marrow is gradually replaced by yellow marrow in adult bone. 
Yellow marrow is less cellular and is interspersed with a large number of adipose 
cells. It still retains a hematopoietic potential since yellow marrow may revert to red 
marrow in case of severe blood loss.
2.BONE R EM O D E L L IN G
2(i) Introduction
Bone is a very dynamic tissue, its continuous resorption and formation is termed 
remodelling. Remodelling occurs as a result of the activity of the bone cells at the 
surfaces of the bone, mainly the endosteal surface. Depending on the type of bone, 
two characteristic types of remodelling occur, Haversian remodelling and endosteal
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remodelling. However the same sequence of events (termed the remodelling cycle), 
take place in both processes.
2(ii) Bone remodelling cycle
The bone remodelling cycle was first described by Frost (1964), from histological 
observations (see figure 1.3). The most important feature of this process is that bone 
remodelling occurs at discrete sites in a well orchestrated sequence of events. In adult 
man 80% of trabecular and inner cortical bone, and 95% of intra cortical bone is 
inactive at any one time with respect to bone remodelling (Parfitt, 1983). This inactive 
bone is termed quiescent.
The conversion of a small area of surface bone from quiescence to activity is referred 
to as activation. In an adult skeleton of normal size, activation occurs approximately 
every 10 seconds (Parfitt, 1983). Activation occurs partly at random and partly in 
response to focal structural requirements. It is thought that the activation phase begins 
with the recruitment of mononuclear phagocyte precursors to the bone surface, which 
is covered by a layer of lining cells. These mononuclear phagocytic cells achieve 
intimate contact with the bone surface by changing shape and extending pseudopodia 
between the lining cells to reach the mineralised matrix surface (Chambers et al.1985). 
The lining cells may help this process by digesting the endosteal bone membrane and 
retracting to expose the bone surface. The interaction of the phagocytic cells with the 
bone matrix is thought to be the stimulus to promote the fusion of the mononuclear 
cells to form multi-nucleated osteoclast precursors.
In a mature form, the osteoclasts are capable of resorbing the mineralised matrix of the 
bone to produce a cavity or lacuna in the trabecular surface. Scanning electron 
microscopic studies reveal that osteoclasts erode cavities to a mean depth of 
approximately 50um in trabecular bone. The resorption process is thought to take 1-3 
weeks (Parfitt, 1983). The life span of canine osteoclasts has been estimated using 
tritiated nucleic acids and was shown to be approximately 12 days. 8% of the
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osteoclasts were turned over per day (Jaworski et al.1981) which suggests a constant 
supply of precursors is necessary for resorption.
The next step in the cycle is the "reversal" phase during which osteoclast precursor 
recruitment ceases and the resorption cavity becomes populated by highly phagocytic 
mononuclear cells. It is thought that these mononuclear cells are intimately involved in 
the coupling of resorption to formation. The reversal phase is thought to be 
approximately 1-2 weeks in duration in the adult skeleton (Parfit, 1988). Factors 
which may regulate the coupling of resorption to formation, include the release of 
cytokines into the microenvironment of the resorption lacunae, and the bone matrix. 
The bone cement line deposited by these mononuclear phagocytes contains 
glycosaminoglycans which may be chemotactic for osteoblast precursor cells (Kahn et 
al.1984).
The bone formation phase follows in which osteoblasts appear at the remodelling site 
and secrete new matrix over the cement line. The matrix then becomes mineralised by 
a mechanism which remains unclear, but which may involve an affinity of certain 
proteoglycans for calcium ions. Normally homeostasis is achieved when the amount 
of bone formed by the osteoblasts matches that resorbed by osteoclasts.
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Figure 1.3: The bone remodelling cycle
Activation
Mononuclear cells achieve intimate 
contact with the bone surface, 
and fuse to form osteoclasts.
Resorption
Quiescence
Flattened quiescent bone cells line 
the surface of the bone.
Mature osteoclasts resorb bone 
to form lacunae on the bone surface.
Formation
Osteoblasts appear at the remodelling site 
and secrete new bone matrix over the cement 
line.
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1.2 Mechanisms of bone formation
Bone formation is a complex process since it is necessary to maintain skeletal structure 
in conjunction with a continuous and orderly growth of the skeleton. Two types of 
bone formation occur, namely intramembranous and endochondral bone formation 
(figure 1.4 shows the histological appearance of these two types of bone formation). 
Both types of bone formation usually occur independently, although occasionally both 
occur simultaneously at different locations within a single bone. The mechanisms of 
both types of bone formation are described below.
2(iii) Endochondral bone formation
Tubular bones develop predominantly by endochondral bone formation (Baron, 
1991). The most important feature of endochondral bone formation is that it occurs 
from a cartilage template. Cartilage tissue develops from clusters of mesenchymal 
cells which differentiate to form chondroblasts. These chondroblasts synthesize large 
am ounts of cartilaginous matrix which is rich in type II collagen and 
mucopolysaccharides. The chondroblasts eventually become embedded in the matrix 
to form chondrocytes. In addition to developing from mesenchymal cells, 
chondrocytes can also divide to form other chondrocytes in the matrix. Due to this 
cell proliferation cartilage may expand in a widthwise manner. Developing cartilage 
forms a growth plate with 3 distinct zones. The first cartilage zone consists of resting 
cartilage cells next to the epiphyseal bone. Adjacent to the resting chondrocytes, 
proliferating chondrocytes form vertical columns in a proliferating zone. The 
hypertrophic zone where immature chondrocytes enlarge and polarize, adjoins this 
proliferating zone. Hypertrophic chondrocytes in this region produce alkaline 
phosphatase which is thought to promote the mineralisation of the cartilage. The 
mineralised cartilage then acts as a template for the deposition of bone in the primary
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spongiosa. This region of woven bone and cartilage is remodelled at a later stage to 
mature lamellar bone.
2(iv) Intramembranous bone formation
Intramembranous bone formation is characterised by the growth of bone from a cluster 
of ossification centres without a cartilage template. At these centres, groups of 
mesenchymal cells differentiate directly to form preosteoblasts and osteoblasts. These 
cells are capable of synthesizing type I collagen and matrix proteins and produce 
islands of osteoid which may become mineralised. Intramembranous bone contains 
osteocytes that are very numerous and large in size. It has been shown by polarized 
light microscopy, that the collagen synthesized in this immature bone is not highly 
organized, but is present in a disorganized array. Calcification occurs concurrently 
with alkaline phosphatase expression at irregularly distributed patches. The calcified 
osteoid that is formed can be remodelled to give immature woven bone. Trabeculae 
are formed which are lined with osteoblasts which secrete more bone matrix to give 
rise to branches of trabeculae. At the periphery, other mesenchymal cells may 
differentiate to facilitate the outward growth of the bone.
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IFigure 1.4 : The histological appearance of both endochondral (E) and 
intramembranous (I) bone formation. The endochondral bone formation (small 
arrows) can be seen to occur on a cartilage template, whilst islands of 
intramembranous bone (large arrows) arise spontaneously from the newly 
differentiated osteoblasts.
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2(vl Growth and shape modification -modelling
It is important to differentiate between the continuous turnover of bone (remodelling), 
and circumstances of bone growth or repair which are termed modelling. During bone 
remodelling the activation, resorption, formation (ARF) sequence is followed whereas 
during modelling this sequence is modified. For example the growth in diameter of 
the diaphysis of bone is a result of deposition of new membranous bone beneath the 
periosteum. This occurs as a result of bone formation directly after activation (AF) 
with no intermittent resorption. Similarly during the longitudinal growth o f long 
bone, the metaphysis is progressively destroyed by the resorption by osteoclasts 
beneath the periosteum. During this process, resorption follows activation (AR) but is 
not followed by bone formation.
2(Vil Bone and cartilage mineralisation
It has been previously assumed that the mineralisation o f the matrix was a passive 
diffusion based process, however recent data suggest that bone cells may control this 
process (for a review see Termine, 1991). A different mechanism is employed for the 
initial mineralisation of matrix to form woven bone or calcified cartilage than that for 
the synchronous calcification of matrix associated with mature bone.
The initial mineralisation of woven bone or growth plate cartilage obviously requires a 
large local concentration of calcium and phosphate ions to form hydroxyapatite 
crystals. This increase in local concentration is facilitated by small membrane bound 
vesicles which bud off from the cytoplasmic processes of chondrocytes and 
osteoblasts (Bonucci, 1971). These vesicles are thought to be deposited in the matrix 
during its formation and have a high affinity for calcium ions. Large amounts of 
phosphate ions are produced by the hydrolysis o f ATP and pyrophosphate by 
enzymes in the membrane of the vesicles. Calcium and phosphate ions become 
concentrated in the vesicles and form calcium hydroxyapatite crystals. When the
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vesicles membrane ruptures the crystals are released into the matrix and act as 
nucleators of further crystal growth. Providing the matrix is in a competent state to be 
mineralised, the crystals grow in clusters which eventually coalesce to completely 
calcify the matrix.
2(vii) The mineralisation front
The mineralisation of mature bone occurs in a progressive manner from the calcified 
bone to the osteoid. The lag phase between the osteoblastic synthesis of osteoid and 
mineralisation is termed the osteoid maturation period. During this period the matrix 
is modified so that mineralisation can occur. This modification is thought to involve a 
series o f changes in matrix composition, where certain proteoglycans and 
phospholipids are removed, and water is excluded. During the advancement of the 
mineralisation front calcium binds to non collagenous proteoglycans to reduce their 
degree of hydration. This dehydration of the matrix in turn causes an influx in calcium 
from the plasma leading to increased calcification of the osteoid.
1.3.C O N TR O L OF BONE REM O DELLIN G
1.3 THE SYSTEMIC GROWTH HORMONES
The following section will review the influence of systemic growth hormones on bone 
metabolism. For a long time is has been known that these factors are of primary 
importance in bone homeostasis. Many medical conditions exist where a perturbation 
in hormone levels leads to gross skeletal abnormalities. Examples include Vitamin D 
dependant rickets and hyperparathyroidism.
30) Vitamin D^reeulation of Vitamin Dt metabolism
There are many diverse effects of vitamin D3  on skeletal tissue (for review see Deluca, 
1982). The following section concentrates on the regulation of vitamin D 3  action and
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its effects on cells of the osteoblastic and osteoclastic lineages. This vitamin shares 
many properties of a hormone. For example, target tissues such as intestine, kidney 
and bone contain specific high affinity receptors for vitamin D 3 . Vitamin D 3  is 
obtained from the diet or synthesized in the skin from dehydrocholesterol in a reaction 
catalysed by u.v. irradiation.
Once synthesized, vitamin D 3  is conjugated to specific binding proteins and is 
transported via the circulation to the liver. In the liver it is hydroxylated to its 
derivative 25 hydroxy vitamin D3 [2 5 (0 1 -1)0 3 ], The biologically active metabolites of 
vitamin D 3  are the dihydroxylated derivatives, 1,25 dihydroxy vitamin D 3  [1,25 D3 ] 
and 24,25 dihydroxyvitamin D3  [24,25 D3 ]. These metabolites arise as a result of 
further hydroxylation of 25(OH)D3 in the kidney mitochondrion, catalysed by the 
enzymes 1-a-hydroxylase and 24-a-hydroxylase respectively. Relative levels of
1.25 D3  and 24,25 D3  have been shown to depend on the endocrine status of the 
individual. The systemic hormone parathyroid hormone (PTH) stimulates the activity 
of 1-a hydroxylase when there are low levels of circulating 1,25 D 3  The over 
production of this hormone is avoided as there is a negative feed back loop for 1,25 
D3  which inhibits it's own synthesis by suppressing 1-a hydroxylase activity.
3(i) Molecular mechanism of 1.25 D3  action
It is postulated that 1,25 D3 has a mode of action similar to the steroid hormones. 
Circulating 1,25 D3  is thought to pass into the cell due to its solubility in the cell 
membrane. Once in the cell it is thought to bind to a specific high affinity receptor. The
1.25 D3 receptor has been biochemically characterised and is a protein of 61kDa with a 
very high binding affinity for 1,25 D3 (Kd = lx lO '10) (Baker et al. 1988). The steroid 
receptor complex is then thought to be transported to the nucleus, where a distinct 
receptor domain binds with a DNA vitamin D responsive element (VDRE) upstream 
of the target gene. Once the steroid receptor complex has bound to the 5' upstream 
region of the target gene, transcription is thought to be altered by interactions between
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the receptor and repressors or initiation factors. The primary amino acid sequence of 
the 1,25 D 3  receptor shows that this protein contains many regions homologous with 
other steroid receptors (Evans, 1988). The DNA binding domain o f the receptor 
contains clusters of cysteine residues that give rise to two zinc finger-like structures 
which are thought to wrap around the DNA.
Mutation analyses o f VDRE consensus sequences have revealed an exquisite 
selectivity of certain sequences for steroid receptors. It seems that it is not only the 
sequence itself that determines whether a certain receptor will bind, but rather the 
spacing between DNA motifs (half sites). An elegant study by Umesono et al. 
(1991), demonstrated that a thyroid responsive element (TRE), could be converted to a 
retinoic acid responsive element (RARE) by increasing the nucleotide spacing between 
half sites by 1 nucleotide. Decreasing the nucleotide spacing by 1 nucleotide 
converted the TRE to a VDRE.
3 (il The actions of 1.25 Dt on osteoblasts
Table 1 shows that 1,25 D 3  receptors have been found in many osteoblast cell lines. 
The number of receptors present in the osteoblasts may be modulated by many factors 
including the state o f cell confluency and corticosteroid treatment. For example Chen 
et al. (1983b) showed that the number of 1,25 D 3  receptors in mouse, but not rat 
osteoblasts, was dependent on the proliferative status of the cells. In cultures where 
the cells were confluent and had therefore stopped dividing, low concentrations of 
receptors were observed. In contrast cells which were actively dividing contained the 
highest receptor levels.
Proliferation studies o f mouse, rat and human osteoblasts (Beresford et al. 1986; 
Chen et al. 1983a) in vitro have shown that 1,25 D3  is inhibitory in a dose dependent 
manner (lpM-130nM). In many cell types, a decrease in proliferation is often 
associated with an increase in differentiation and vice versa. This is thought to be the 
case for osteoblasts, as many markers of a differentiated phenotype are induced by
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1,25 D 3  such as alkaline phosphatase (Manolagas et al. 1981) and osteocalcin 
synthesis (Beresford et al.1986). The synthesis of another bone protein, Type I 
collagen, by the osteoblastic cell line MC3T3-E1 is also increased following treatment 
by 1,25 D3 (Kurihara et al.1986).
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Table 1.1 : The occurrence of 1,25 D^receptors on bone cells
Cell line/cell Species 1.25 receptors Properties Reference
Normal lining cells fetal rat bone + * Narbeitz et al.1983
Osteoblasts fetal rat bone + * Narbeitz et al.1983
Osteoblasts precursors fetal rat bone + * Narbeitz et al.1983
Osteocytes fetal rat bone - * Narbeitz et al.1983
Osteoclasts fetal rat bone, chick - * Merke et al.1986; 
Narbeitz et al.1983
Normal osteoblasts mouse (calvaria) + D ependent on cell
d e n s i ty  4- by 
glucocorticoids
Chen et al. 1979
Normal osteoblasts rat (cultured) + t by glucocorticoids Chen et al.1983
OS-12 osteosarcoma rat + Rodan et al. 1987
UMR osteosarcoma rat + Partridge et al. 1990
MMB-1 osteoblast line mouse + D ependent on cell 
density
Walters et al. 1982
MC3T3-E1 line mouse + Kurihara et al.1986
ROS17/2 line rat + Dokoh et al. 1984
MG-63 osteosarcoma human + Franceshi et al. 1985
Saos-2 osteosarcoma human + Rodan et al. 1987
t = increase, 4- = decrease, + = present, - = not present. 
* detected by radioligand binding to tissue sections.
3(T) The actions of 1.25 on osteoclasts
1,25 D 3  is a potent stimulator of bone resorption. Physiological doses of 
(8 xlO'n M - 10-1 0M) induce resorption in both organ cultures (Raisz et al. 1972a) and 
in vivo  (Reynolds et al.1973). In vivo administration of 1,25 D 3  to vitamin D 
deficient rats (Holtrop et al.1981) or mice (Tinkler et al.1981) results in an increase in 
osteoclast number in the bone tissue. As shown in Table 1.1 mature osteoclasts do not 
possess 1,25 D 3  receptors, therefore this agent cannot act directly on osteoclasts. 
However it may promote the differentiation of stem cells and progenitors, or stimulate 
fusion of preosteoclasts to form mature osteoclasts. There is some experimental data 
to support this hypothesis, since 1,25 D 3  has been shown to increase osteoclast 
formation in bone marrow cultures from many species. Cultures of feline bone 
marrow, which spontaneously give rise to multinuclear cells, showed an increase in 
cell fusion within 24 hours of 1,25 D3 treatment (Ibbotson et al. 1984). However it is 
controversial whether the multinucleated cells that were generated in the feline bone 
marrow were authentic osteoclasts. Similar studies have shown that 1,25 D 3  
promotes differentiation of monocyte precursor cells in marrow cultures and stimulates 
their fusion to form multinucleated cells (Pharoah and Heersche, 1985). The effect 
was species dependent as treatment of murine bone marrow cultures and fetal rat bone 
rudiments with 1,25 D 3 , failed to stimulate fusion of mononuclear cells (Meer et 
al.1980).
3(iil Oestradiol
Over 40 years ago Albright and Reifenstein noted the high incidence of osteoporosis in 
patients with hypogonadism (Melton and Riggs, 1988). Since then much research has 
been undertaken to determine the importance of sex steroids in the maintenance of 
skeletal integrity. Much circumstantial evidence suggests that the sex hormone status 
of an individual is very important. Women who are amenorrhoeic for a considerable
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time, for example those suffering from anorexia nervosa show a greater incidence of 
osteoporosis (Rigotti et al. 1984). Additionally elite athletes who are oestrogen 
deficient have been shown to have a lower bone mass than age matched controls 
(Drinkwater et al. 1984). Since reasonable amounts of exercise increase bone mass, 
this deficiency highlights the importance of oestrogen in maintaining skeletal bone 
mass in females. Furthermore the administration of exogenous oestrogen to post­
menopausal women retards further reduction of bone, although it does not stimulate 
net accumulation (Christiansen and Lindsay, 1990). Despite the general acceptance of 
the major role of oestrogen in reducing bone loss, there is as yet no consensus on its 
mode of action.
Many in vivo studies have also highlighted the role of oestrogen in maintaining bone 
mass. Histomorphometric analysis of trabecular bone in femurs of ovariectomized 
rats, has shown that ovariectomy causes massive reduction in trabecular bone volume. 
Additionally an increase in both resorption surfaces and osteoclast numbers is 
observed (Takano-Yamamoto and Rodan, 1990). An 8  day infusion of (10_9 M) 17p 
oestradiol largely restored trabecular bone volume and reduced the number of 
osteoclasts present and the resorption surfaces. This study was supported by a similar 
study by Wronski et al. (1988) who obtained very similar results. The data taken 
together from these and other studies suggests that oestrogen gives a protective effect 
on the maintenance of trabecular bone mass.
300 Effects of oestrogen on osteoblasts
Oestradiol has been shown to affect both the proliferation and differentiation of 
osteoblasts in vitro. Two investigators have independently reported that 17p oestradiol 
has an inhibitory effect on the proliferation of the rat osteogenic cell line (UMR-106) 
(Gray et al. 1987; Bankson et al. 1989). In contrast oestradiol has also been shown to 
enhance the proliferation of primary cultures of rat calvarial bone cells (Ernst et al. 
1989). Osteoblast-like cells were prepared from calvariae of new born rats and
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cultured in serum-free medium containing methyl cellulose for 12 days. The 
osteoblasts exhibited a unique spherical morphology under these conditions, and 
proliferated selectively into clonally derived cell clusters. Oestrogen at concentrations 
of 0.1 - 1 nM was shown to enhance osteoblast proliferation by up to 6 8 %. The effect 
was shown to be specific since the anti-oestrogen tamoxifen abolished the stimulatory 
effect of 17p oestradiol. The effect of 17p oestradiol on osteoblast proliferation, has 
been shown to be a species specific phenomenon. The proliferation of primary 
human bone cells is unaffected by oestrogen treatment over a large concentration range 
(Colvard et al. 1989). Oestrogen seems to promote a differentiated osteoblast 
phenotype. It has been demonstrated to upregulate alkaline phosphatase expression 
(Gray et al. 1987) and increase the synthesis of matrix proteins including osteocalcin, 
osteonectin (Glibert et al.1989), and collagen (Ernst et al.1989). Preliminary studies 
suggest that oestrogen may also modulate the expression of cytokines by bone cells. 
Recent data shows that insulin like growth factor 1 (IGFI) synthesis is increased by 
oestradiol treatment in human bone cells in vitro (Gray et al.1989).
3(ii) The oestrogen receptor
Oestrogen, in common with other steroid hormones regulates gene expression in target 
cells through its interaction with specific receptors. Data obtained from studies on 
many tissues suggest that the oestrogen free receptor is localized predominantly in the 
nuclear compartment where it is loosely bound. The binding of oestrogen to its 
receptor is then thought to convert the receptor to an active form which has the ability 
to bind specific promoter elements in oestrogen responsive genes.
The human oestrogen receptor was cloned by Walter et al (1985) from a cDNA library 
constructed from a human breast carcinoma cell line. A 6.2 kb mRNA transcript for 
the oestrogen receptor was identified which coded for a 595 amino acid protein of 
6 6 kDa. Sequence comparisons together with mutation analysis, have defined two 
conserved regions of the oestrogen receptor that correspond to important functional
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domains (see figure 1.5) (Gibson et al.1990). The putative DNA binding domain (C) 
is a highly conserved 6 6  amino acid region, which has the potential to form 2 DNA 
binding fingers via two pairs of cysteine residues. Results obtained from a chimeric 
receptor show that this region determines the specificity of the receptor for the 
transcription of the target gene. The hormone binding domain is located in the C 
terminal half of the receptor (E). There is also a hydrophilic region (D) which may 
correspond to a hinge between DNA and hormone binding domains. There has been a 
suggestion that the region A/B is required for activating transcription.
Hydrophobicity plots and analysis of the amino acid sequence reveal that the oestrogen 
receptor belongs to a steroid receptor superfamily. This family includes the receptors 
for thyroid hormone (originally identified as the cellular homolog of v-erb), 1,25 
dihydroxyvitamin D 3  and retinoic acid. Striking sequence homology exists across all 
these receptors especially in the "C" and "E" regions.
Figure 1.5 : The structure of the human oestrogen receptor.
1 185 251 315 553 595
I-------------- II---------- H------- II------------------ I M
A/ B C D  E F
The letters represent the functional domains (see text) and the numbers, the residues at 
the start and end of each domain.
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SCiii) Oestrogen receptors in bone cells
Despite the well documented effects of oestrogen on bone in vivo, detecting oestrogen 
receptors in bone has proved difficult. Two approaches were used to detect oestrogen 
receptors; high affinity binding of radiolabelled oestradiol, or the use of specific 
monoclonal antibodies. An immunolocalization study by Colsten et al. (1989) failed 
to detect human oestrogen receptor in either primary or transformed human bone cells, 
or in fetal bone sections. Additionally no staining for progesterone receptor was 
detected in the osteosarcoma cell lines TE85C and HT396. The 29 kDa cytoplasmic 
product p29 which was thought to be closely related to the oestrogen receptor, was 
observed in high amounts in all the osteoblast-like cells studied. Chen et al (1977) 
determined the oestradiol receptor content in extracts of rat bone by binding 3H 
oestradiol. Although glucocorticoid receptors were detected, no specific oestrogen 
binding was observed. The results from these initial studies suggested that the 
numbers of oestrogen receptors in osteoblast-like cells were very low.
Using high specific activity 125I labelled oestradiol, oestrogen receptors were detected 
in rat (ROS 17/2.8) and human (HOS TE85) osteoblast-like cells (Komm et al.1988). 
The receptors were present in the osteoblast-like cells at a density of 200 per cell. 
This level of receptor is very low since several cell types including uterus cells contain 
several thousand high affinity oestrogen receptors per cell. The binding affinity was 
shown to be comparable with receptors in other tissues. Dissociation constants of 
0.5nM and l.lnM  were estimated for ROS 17/2.8 and HOS TE85 cells respectively. 
Eriksen et al (1988) subsequently presented evidence that oestrogen receptors were 
present in normal human osteoblast-like cells. Bone cells were obtained from bone 
fragments from seven different donors and all the bone cell populations were shown to 
contain oestrogen receptors at an average density of 1600 per cell. Pretreatment of the 
cells with lOnM oestradiol increased the specific nuclear binding of progesterone in 
vitro in the majority of the strains.
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There has been some data to suggest that osteoclasts might also contain oestrogen 
receptors. Osteoclasts were isolated from the membranous bone of 4 children, 
without metabolic bone disease, who were undergoing a craniotomy for either a 
tumour removal or trauma. Nuclear oestrogen and progesterone receptors were 
demonstrated by both immunolocalization and radioimmunoassay to exist in 
osteoclasts in this tissue. Oestrogen receptor mRNA has also been detected by 
Northern blot analysis in a highly purified population of avian osteoclasts (Oursler et 
al.1990).
In summary these findings highlight a potential mechanism whereby direct modulation 
of bone resorption by the sex steroids, oestrogen and progesterone, may be mediated 
by both osteoblasts and osteoclasts.
3(iii) Glucocorticoids
Effects of glucocorticoids on osteoblasts
In vivo administration of glucocorticoids has been shown to lower bone formation, 
inhibit fracture healing and cause osteoporosis in several species (see Gennam, 1985 
for review). It is controversial whether the decrease in bone mass is due to a decrease 
in osteoblast number or activity, or a combination of the two. It is also possible that 
glucocorticoids have a direct inhibitory effect on osteoblast precursors. In vitro 
studies have been undertaken to address some of these questions.
Experiments with organ cultured bones give diverse and complex effects of 
glucocorticoid administration. The results seem to be dependent on the species and 
upon the time the tissue is in culture. In "bone forming" systems glucocorticoid 
administration gives rise to a short term increase in Type I collagen and alkaline 
phosphatase synthesis, followed in the long term by a decrease in cell proliferation 
(Canalis, 1983). This data is consistent with the idea that glucocorticoids promote an 
early differentiation of osteoblasts but in the long term predominantly inhibit 
proliferation. However this data is to some extent in disagreement with studies of
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Hahn et al. (1984), who treated intact neonatal calvariae with lOOnM cortisol for 24 
hours. A concomitant increase in alkaline phosphatase activity and proliferation (as 
judged by thymidine incorporation) was observed (Hahn et al.1984).
Canalis put forward the idea that since organ cultures contain different populations of 
cells, the net effect of any treatment is the sum of the effects on all the different cells. 
Therefore he examined the effect of glucocorticoids on periosteal tissue and central 
non periosteal bone (osteoblast enriched) (Canalis, 1984). The data obtained 
suggested that mature osteoblasts are not inhibited directly, but that the predominant 
effect of cortisol was to diminish periosteal cell replication. It is generally thought that 
glucocorticoids at physiological concentrations prom ote the acquisition and 
preservation of the differentiated state of osteoblasts. Additionally, at higher 
concentrations or over longer term administration, glucocorticoids reduce the 
replication of osteoblast precursors.
Isolated osteoblasts and osteosarcoma cells contain specific high affinity 
glucocorticoid receptors (Chen et al. 1977; Haussler et al.1980). Treatment of 
osteoblast-like cells in culture with glucocorticoids decreases collagen synthesis (Peck 
et al.1967) and promotes RNA turnover (Peck et al.1969). Glucocorticoids can affect 
both PTH and 1,25 D3 mediated events. For example, the treatment of osteoblast-like 
cells with glucocorticoids greatly magnifies their cAMP response to PTH (Chen and 
Feldman, 1978).
3 (iii) Effects of elucocorticoids on osteoclasts
Although long term in vivo glucocorticoid administration results invariably in bone 
loss, the treatment of organ cultures of bone in vitro with glucocorticoids gives rise to 
a decrease in bone resorption (Raisz et al. 1972b). The mechanism of this 
phenomenon is not clear but may be due to a direct inhibitory effect on osteoclasts, or 
an inhibition of osteoclast formation. There is some evidence for both mechanisms 
since Suda et al (1983) showed that glucocorticoid administration to feline bone
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marrow resulted in a decrease in both the generation of osteoclasts and in the activity 
of existing osteoclasts.
3(iv) Retinoids
Retinoids are a class of vitamin A metabolites. Some of these compounds particularly 
retinoic acid are thought to act as osteoblast differentiation factors. The fact that 
vitamin A has a role in bone metabolism has long been suspected, since is has been 
observed that hypervitaminosis A causes bone destruction. Vitamin A is known to 
stimulate bone resorption in vivo (Fell and Mellanby, 1952) and in vitro (Raisz, 
1965), by an unknown mechanism which requires de novo RNA and protein 
synthesis. It is interesting to note that some of the osteoblastic effects of retinoids 
resemble those of 1,25 D 3 , which is a structurally related steroid with a similar DNA 
binding receptor (Evans, 1988). Retinoic acid also enhances the binding of 1,25 D3  to 
its receptor on osteosarcoma cells (Petkovich et al.1984). Retinoids have been shown 
to induce differentiation in some transformed cell lines including osteoblasts (Heath et 
al.1989).
3(v) Parathyroid hormone (PTH)
Parathyroid hormone is an important osteotropic factor with a number of target organs 
including bone. Within bone, PTH affects the activity of both osteoblasts and 
osteoclasts. PTH is a monomeric 84 amino acid polypeptide, with the receptor 
binding portion of the molecule consisting of the first 26 amino acid residues. It has 
been suggested recently that the N-terminal fragment may also confer some biological 
activity (Murray et al.1989). PTH is synthesized exclusively by the parathyroid 
gland, where its secretion is modulated by serum calcium ion concentrations. The 
regulation of PTH secretion has been studied in vivo and it has been shown that a 
perturbation of calcium concentration of as little as 40uM gives rise to a change in 
secretion rate. Since PTH is such a potent hormone, it is vital that its secretion is
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closely regulated. PTH is also cleared very efficiently from the circulation by both the 
liver and kidney. It has been estimated that the half life for a PTH molecule is only 4 
minutes. It is interesting to note that only 5 - 30% of circulating immunoreactive 
hormone is intact PTH, the remainder consisting of C-terminal fragments. This might 
reflect the efficient clearance mechanism for this hormone or that C-terminal fragments 
are bioactive and play a role in the activity of this hormone.
3(v) The parathyroid hormone receptor
Recently Juppner et al. (1991) used an expression cloning strategy to clone the PTH 
receptor. An opossum kidney cell cDNA library was prepared and transfected into a 
COS expression system. The transfected COS cells were then screened using 
radiolabelled PTH which detected positive clones. Two clones were obtained termed 
OK-O and OK-H, of which OK-O was shown to be a full length cDNA clone. 
Analysis of the clone revealed that the expressed receptor bound both PTH and PTHrP 
(Parathyroid related protein) with equal affinity. The binding of these ligands elicited 
the classical response of an increase in adenylate cyclase activity. The cloning of the 
calcitonin receptor was reported concurrently (Lin et al. 1991). A sequence 
comparison between the two receptors revealed a close homology but no similarity 
with other receptor families. This suggests that the receptors for these two calcium 
regulating hormones are related and may represent a new family of receptors.
PTH is thought to elicit its biological response through a cascade of intracellular 
secondary messengers. As mentioned earlier, the binding of PTH to its receptor gives 
rise to an increase in adenylate cyclase activity. Studies on isolated osteoblast-like 
cells show that the earliest detectable changes are an enhancement of adenylate cyclase 
activity, and an increase in cellular calcium concentration (Dziak and Stem, 1975). It 
is interesting to note that a prolonged stimulation of PTH on osteoblast-like cells 
results in a desensitization to PTH and a diminished cAMP response. The PTH 
receptor has been detected on osteoblasts, lining cells and osteocytes in situ by ^H-
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PTH autoradiography (Barling and Bibby, 1985). Osteoblast-like cells in culture have 
been also shown to express PTH receptors (Pliam et al. 1979).
3(v) The effect of PTH on osteoblasts
PTH has been reported to exert a variety of effects on osteoblasts which are dependant 
on the dose and upon the length of administration. At doses of greater than l x l 0 9 M, 
PTH stimulates osteoblast-like cell proliferation in vitro (MacDonald et al. 1986a). 
However, some osteosarcoma cell lines differ in this property and their replication is 
inhibited with doses of greater than lx lO '10M (Partridge et al. 1985). This may be due 
to the fact that isolated osteoblast-like cells and osteosarcoma cells are at different 
differentiation stages. PTH treatment also modulates the synthesis of osteoblastic 
proteins in a dose dependant manner. For example, the treatment of osteoblast-like 
cells from chick calvariae with a low dose of PTH results in an increase in alkaline 
phosphatase activity, whilst high doses suppress activity (Hall and Dickson, 1985). 
In vivo PTH administration gives rise to a decrease in collagen synthesis in short term 
organ cultures (Dietrich et al.1976). However long term administration of PTH at 
intermittent or low doses stimulates bone formation (Guines-Hey and Hock, 1984).
It is interesting to speculate why PTH shows such varying effects at different doses 
and lengths of administration. The experiments undertaken might represent different 
physiological levels of this hormone in the body. Low levels of circulating PTH may 
result at the end of a resorption period and might then result in a proliferation of 
osteoblasts to ensure efficient bone formation. The results of experiments where 
PTH is administered intermittently should be considered as important findings, as this 
probably mirrors more closely the pulses of secretion of this hormone in the body.
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Table 1.2: The effect of PTH and PTHrP on bone resorption
Agent Dose Culture system Effect Reference
PTH 0.1 - 2.5 
nM
Fetal rat long bones in organ culture. t in resorption Raisz et al. 1990
PTHrP 0.1 - 25 
nM
Fetal rat long bones in organ culture. t in resorption Raisz et al. 1990
PTH 0 . 2  - 2 0  
nM
Neonatal rat osteoclasts on bovine cortical 
bone slices.
t in resorption due to an t in 
number of resorption pits
Murrills et al. 1990
PTHrP 0 . 2  - 2 0  
nM
Neonatal rat osteoclasts on bovine cortical 
bone slices.
t  in resorption due to an t in 
number of resorption pits
Murrills et al.1990
PTH 1 pM Embryonic chick tibia in organ culture t in resorption Howard et al.1981
PTH 40 nM Osteoclast-like cells from neonatal rat long 
bone on cortical bone slices
No effect on bone resorption. McSheehy and Chambers, 1986
PTH 40 nM Same as above plus osteoblast like cells 4 fold increase in resorption. McSheehy and Chambers, 1986
Supernatants 
from  PTH 
treated obs.
n/a Rat macrophages on devitalized particles of 
rat bone.
t bone resorption. Perry et al.1989
Supernatants 
from  PTH 
treated obs.
n/a Fetal bone rudiments of rat radii in organ 
culture. t bone resorption.
Perry et al. 1989
Supernatants 
from  PTH 
treated obs.
n/a Isolated chick osteoclasts on devitalized 
particles of rat bone. t bone resorption.
Perry et al.1989
obs. = osteoblast. n/a = not applicable t = increase.
3(v) The effect of PTH on osteoclasts
PTH has also been shown to affect osteoclast activity. Table 1.2 summarises its 
effects on bone resorption in vivo and in vitro. PTH is a potent resorptive agent 
which gives rise to two phases of osteoclast responsiveness. They appear to involve 
a short term activation of mature osteoclasts and immediate precursors, followed by 
the long term recruitment of newly formed osteoclasts. PTH administration in vivo 
results in an increase in the number of osteoclasts per volume of bone tissue. This 
effect can be seen as early as 2  hours after treatment in mice, and 8  hours in rats 
(Tatevossian, 1973; Baron and Vignery, 1981a). It has been shown that DNA 
synthesis is not required for this short term effect. Therefore it is thought that the 
increase in osteoclast numbers results from the fusion of immediate osteoclast 
precursors. Longer term administration of greater than 3 days also gives rise to an 
increase in osteoclast numbers, presumably by stimulating the differentiation of 
osteoclast progenitor cells. PTH has also been shown to stimulate the resorptive 
activity of existing osteoclasts. It increases motility, ruffled border areas, TRAP, 
carbonic anhydrase and lysosomal enzyme activity (Holtrop et al.1974; Chambers et 
al.1984; Hammarstrom et al.1971).
Isolated osteoclasts have been shown to be unresponsive to PTH, and no PTH 
receptors have been detected on osteoclasts (Silve et al. 1982). It is thought that PTH 
exerts its effects on osteoclasts via osteoclast precursors/progenitors, or other cells in 
the bone microenvironment such as osteoblasts.
3(vi) Calcitonin
Calcitonin is a small (32 amino acid) peptide almost exclusively produced by the 
thyroid gland, although some immune cells and neurones are capable of its synthesis. 
There is a tissue specific transcription of the calcitonin gene to give two different
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mRNA species encoding for calcitonin and calcitonin gene related peptide (CGrP) 
(Deftos and Roos, 1989).
The major skeletal action of calcitonin is the inhibition of osteoclast mediated bone 
resorption. In vivo administration of calcitonin results in the detachment of 
osteoclasts from the bone surface and a decrease in the number of osteoclasts present. 
This occurs in rat rib bone within 30 minutes (Baron and Vignery, 1981 ). In organ 
culture systems calcitonin inhibits not only endogenous resorption, but that stimulated 
by PTH, prostaglandin E (PGE) and 1,25 D 3  (Raisz, 1976).
In vitro bone resorption models have illustrated an important feature of calcitonin 
action. There is a reappearance of resorption after the initial suppression within 24 - 48 
hours even though calcitonin is still present. This phenomenon is termed "escape" 
(Wener et al.1972). "Escape" is thought to be due to a down regulation step at the 
cellular level. There are several mechanisms by which "escape" could conceivably 
occur. They include a reduction in the affinity /calcitonin receptor level, or a change in 
cell dynamics with the emergence of calcitonin insensitive osteoclasts. Isolated 
osteoclasts in culture respond to calcitonin within minutes of treatment by undergoing 
major shape changes. The response is typically characterised by a reduction in ruffled 
border area, retraction of cytoplasmic extensions and a decrease in motility (Chambers 
et al. 1984).
Cyclic AMP has been proposed as a secondary messenger for calcitonin action in 
osteoclasts. Calcitonin has also been shown to decrease cellular calcium ion 
concentrations in a population of osteoclast-like cells in vitro (Schlossman et al.1982). 
Calcitonin also has some anabolic effects in bone. Normal human osteoblasts 
proliferate, and increase alkaline phosphatase and type I collagen synthesis in response 
to calcitonin treatment (Farley et al.1989).
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3(Vii) The role of cytokines in the control of bone remodelling
The role of cytokines in bone remodelling has been the subject of much research in 
the last 20 years. Many different experimental approaches have been used to try to 
identify the components of a cytokine bone network, and define their different 
activities. Studies using culture models of bone cells to monitor the effects of isolated 
cytokines have been very prevalent. Unfortunately .although a large amount of data 
has been published from these studies, the literature is very confused and 
controversial. This confusion is due to the fact that different investigators have used 
bone cells obtained from different animal species and culture protocols. The basic 
nature of the bone cells vary, some bone cells are from primary cultures whereas 
others are transformed cell lines derived from osteosarcomas. The source of cytokine 
is also a cause of discrepancy. The degree of purity varies from cell supernatants to 
purified proteins, to recombinant cytokine. In addition the doses of cytokine and 
duration of treatment are not standard between different studies. For this reason the 
following account reviews the data obtained from in vivo studies, organ cultures and 
cells directly obtained from the organ cultures discussed. Although these studies do 
not pinpoint the exact cellular interactions that take place, they highlight potential roles 
of the cytokines in bone remodelling in vivo. The following section focuses on the 
roles of two important osteotropic cytokines TGFp and IL-1, since these two 
cytokines are the main subject of this thesis.
SCviii) The effects of IL-1 and TGFB on bone resorption
The initial finding that prompted the interest in cytokines as a bone resorbing agents 
came from studies on the mechanism of peridontal disease. Antigen extracts from 
dental plaque were used to stimulate leukocytes from patients with peridontal disease. 
It was observed that the degree of in vitro stimulation was directly proportional to the 
severity of disease. Since severe peridontal disease was associated with increased
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leukocyte infiltration and bone loss, the resorption activity of the supernatants was 
assayed using 45Ca radiolabelled fetal rat bones. The supernatants were shown to 
contain a soluble factor which induced bone resorption in a dose dependant manner 
(Horton et al.1972). A microscopic analysis of the bones after treatment with this 
soluble factor showed that the bone contained increased numbers of osteoclasts as well 
as large areas of resorption. The soluble factor was tentatively named osteoclast 
activating factor (OAF).
These observations prompted the search for the identity of OAF. Gowen et al. (1983) 
demonstrated that supernatants obtained from the monocytes of a patient with chronic 
myelomonocytic leukaemia stimulated bone resorption of neonatal mouse calvarial 
bones. The supernatants were pooled and chromatographed on a molecular sieve 
column followed by isoelectric focussing to reveal an active component with a 
molecular weight of 12 -1 8  kDa. The bone resorbing agent was shown to be active 
in the leukocyte activation (LAF) assay which detects interleukin 1 activity. Therefore 
OAF was proposed to contain as one of its components an "interleukin-1-like factor". 
The identity of this "interleukin-1-like factor" was later confirmed to be IL-1 by 
Dewhirst et al. (1985) who purified the factor by gel filtration and HPLC to obtain a 
single protein band on PAGE. The protein was shown to have the same amino acid 
terminal sequence, isoelectric point and molecular weight as IL-1. However it is 
important to note that the original OAF may have contained other bone resorbing 
agents since the purification protocol was designed to purify an "interleukin-1-like 
activity".
Shortly after this finding, it was demonstrated that purified pig IL-1 stimulated bone 
resorption in the mouse calvariae bone resorption assay (Heath et al.1985). The 
resorption was partially inhibited by indomethacin which suggested that it may be 
mediated by local prostaglandin production. Further studies using recombinant 
murine IL-1 confirmed its potent action as a bone resorbing agent (Gowen and 
Mundy, 1986). Resorption occurred after a 48 hour lag phase with very low doses of
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recombinant IL-1 (as little as 23 pg/ml). The resorption occurred after a stimulation 
of as little as 2  hours, and was shown to be insensitive to indomethacin treatment but 
inhibited by interferon gamma. Similar to the original observations of Horton, an 
increase in the numbers of osteoclasts present and an enlarged marrow cavity was 
observed. The results suggested that IL-1 induced some early event which lead to the 
increase in osteoclast formation from progenitor or precursor cells.
The previously described organ culture experiments prompted an extensive in vivo 
study of the action of IL-1 in normal mice (Boyce et al.1989). The mice were injected 
subcutaneously with human recombinant IL-1 once daily for 3 days over the right 
calvaria. The calvariae were then examined for the effects of IL-1 administration on 
m orphology during the subsequent 4 week period using quantitative 
histomorphometry. The IL-1 treatment was associated with a transient elevated 
plasma level of calcium 24 hours after the last injection . After 3-4 days of treatment, 
most of the bone on the injected side was resorbed. These initial events were 
insensitive to indomethacin treatment, in contrast to those over the longer term where 
most of the resorbed bone was replaced by increased amounts of new bone.
It was demonstrated that soluble IL-1 was not the only form which was capable of 
inducing bone formation. A murine macrophage cell line was stimulated with LPS 
and fixed to provide a membrane bound form of IL-1 (Nishihara et al.1989). This 
membrane bound form, was effective in stimulating bone resorption in organ cultures 
of mouse neonatal calvariae. The effect was blocked by neutralizing antibodies, and 
inhibited with calcitonin and indomethacin.
Similar organ culture studies were undertaken with transforming growth factor beta 
(TGFp). Tashjian et al (1985) demonstrated that TGFp stimulated bone resorption in 
cultured mouse calvariae. Significant resorption, mediated via prostaglandin 
production occurred with as little as 0.2 ng /ml of TGFp. Since epidermal growth 
factor (EGF) had been shown to act synergistically with TGFp during the 
transformation of normal kidney fibroblasts (Roberts et al.1981), it was used in
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conjunction with TGFp in the resorption assay but no synergism was observed. 
Pfeilschifter et al. (1987) investigated the bone resorbing activity of TGFp in the 
alternative rat long bone organ culture model. In contrast to previous findings TGFp 
was shown to inhibit bone resorption. Since the effect was similar to that of 
hydroxyurea (a DNA synthesis inhibitor), it was assumed that TGFp acted by 
preventing the formation of osteoclasts. TGFp treatment was also shown to inhibit 
bone resorption during prolonged culture with submaximal doses of EL-1, PTH and
1,25 D 3 . These data were supported by the fact that TGFp inhibits the formation of 
osteoclasts from precursors in cultures of bone marrow in vitro (Chenu and 
Pfeilschifter, 1988).
In a study similar to that of Boyce et al. (1989), TGFp was injected subcutaneously 
over the calvariae of normal mice. Increased numbers of large multinucleated 
osteoclasts were detected in the marrow spaces (Marcelli et al.1990). Bone resorption 
was enhanced over a 3 - 5 day period. However unlike IL-1 stimulated resorption, no 
degradation of the periosteal layer was seen. Indomethacin inhibited the increased 
appearance of osteoclasts in the marrow space, suggesting that the response was 
prostaglandin mediated.
Since cytokine mediated bone resorption had been suggested to be both prostaglandin 
dependent and independent, Garrett and Mundy (1989) investigated the effect of 
different assay protocols on resorption. The data obtained showed that events during 
the preculture period were important in modulating the later effects of any factor on 
bone resorption. It was shown that osteoclast numbers increased after 24 hours in 
control media due to increased endogenous production o f prostaglandins. 
Additionally the numbers of osteoclasts fell when the calvaria were transferred to fresh 
control media for 72 hours. When IL-1 was added after the preincubation period, 
osteoclast numbers were maintained and indomethacin had no effect on the increased 
resorption. Furthermore IL-1 did not seem to promote precursor proliferation since
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hydroxyurea had no effect on the response. Therefore it was suggested that IL-1 
stimulated bone resorption by acting at a later stage of precursor differentiation.
3(ix) The effects of IL-1 and TGFB on bone formation
There are no reports of IL-1 stimulating bone formation in vitro, although in the study 
by Boyce et al. (1989) there was a transient increase in bone mass in IL-1 treated 
mice. After the initial resorption, bone was replaced in an accelerated manner and 9 
days after treatment the bone volumes of the IL-1 stimulated calvariae were 
significantly higher than those of saline treated controls. It is unlikely that this finding 
reveals a role for EL-1 in bone formation, but rather that the coupling mechanism in the 
calvariae was stimulated so that bone homeostasis was achieved.
In vitro studies suggest that IL-1 may have an anabolic role in bone metabolism. 
IL-1 treatment for a 24 hour period has been shown to stimulate DNA synthesis in rat 
calvariae. A large increase in total protein synthesis, of which collagen expression was 
significantly increased, was also observed following EL-1 treatment (Canalis, 1986). 
In the same study, it was shown that high doses or longer exposure times of IL-1 
inhibited the expression of collagen. It has been reported that the prolonged exposure 
of fetal rat osteoblasts in vitro to EL-1 inhibits the formation of mineralized bone 
nodules (Stashenko et al. 1991). This data suggests that bone is exquisitely sensitive 
to local IL-1 concentrations and the effect of this cytokine is dependent on both dose 
and time of exposure amongst other factors.
Many studies have reported the striking anabolic effect of TGFp treatment on bone. 
The initial study monitored the in vivo stimulation of bone formation in rat calvariae 
injected daily for 12 days over the periosteum of the right pareital bones (Noda and 
Camilliere, 1989). TGFp was shown to increase bone formation in a dose dependent 
manner, with the thickness of the parietal bone increasing by two fold. The bone 
formed after 5 days was shown to be immature woven bone. The second isoform of 
TGFp (TGFP2 ) was also shown to have similar effects. It is important to note that the
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effect of TGFp was not systemic, but occurred in a very localized manner at the site of 
injection, and was not evident in any other bones. In a similar study by Joyce et al. 
(1990), TGFp was shown to be an important factor for the chondrogenesis and 
osteogenesis of rat long bone. The periosteal regions of femurs in new bom rats, 
were injected daily with TGFPi or TGFp2  for 14 days. The femurs were subsequently 
removed at periods after the cessation of treatment and assessed for any morphological 
changes. Three days after the cessation of treatment, the mesenchymal cells in the 
periosteum and endosteum were seen to proliferate and there was also an increase in 
fibrous tissue at the site of injection. At day 5, cartilaginous matrix was detected at 
the injection site, and by day 15 there was a large mass of cartilage at the site of 
injection. This mass of cartilage was flanked by intramembranous bone formed in the 
cortical region. Over the longer term ( 3 - 4  weeks later) the cartilage was replaced 
with bone by endochondral ossification. TGFP2  was shown to be more active than 
TGFp! in stimulating bone mass in vivo , with greater than 300% more bone formed 
at comparable doses. With both isoforms the type of tissue formed was dependent on 
the dose of TGFp. At low doses (20ng/day) proportionately more bone was formed, 
whilst at high doses (200ng/ml) more cartilage was evident. This finding was 
particularly interesting in light of the fact that TGFpi is isolated in a 4:1 ratio to TGFp2  
from mature bone. This data suggests that TGFp is an important regulatory factor in 
the mechanism of proliferation and differentiation of mesenchymal bone precursor 
cells.
A study by Beck et al. (1991) highlighted the importance of the perichondrium in 
TGFp stimulated bone formation. Recombinant human TGFpi (rhTGFPi) was 
shown to accelerate the onset and increase bone formation in a soft tissue wound 
healing model. A single dose of 25-100ng rhTGFpi was applied to the adjacent 
cartilage in a full thickness skin wound. Bone formation was detected at the site of 
application after 21 days and peaked after 42 days. There were two phases of tissue 
repair, initially TGFPi induced the differentiation of perichondrial cells to osteoblasts
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which synthesized osteoid onto a cartilage template. Secondly, continued bone 
formation occurred until remodelling was initiated, during which the cartilage and 
newly formed bone was eroded to form a marrow cavity. No bone formation 
occurred when the perichondrium was intact. Only when it was removed and 
rhTGFpi made direct contact with the damaged perichondrium and cartilage, was 
bone formation induced at the wound margin.
In summary, the consensus of the data suggest that IL-1 is a very important factor in 
promoting bone resorption and has variable effects on bone formation. The 
bidirectional effect of TGFp (which is also seen in other systems) may be dependent 
on the prevailing conditions in the microenvironment of the exposed cell, the dose and 
duration of TGFp and the presence of other growth factors.
Other cytokines that modulate bone formation or resorption
Table 1.3 outlines the effects of other cytokines that modulate bone resorption or 
formation. For the purpose of conciseness, the cytokines have been divided into 4 
groups; inflammatory cytokines, growth factors, colony stimulating factors and 
resorption inhibitors .
3(x) "Inflammatory" cytokines
"Inflammatory" cytokines are defined for this review as those factors which give rise 
to fever, and induce the synthesis of acute phase proteins. They include tumour 
necrosis factor alpha (TNFa), interleukin 6  (IL-6 ) and the IL-ls which have been 
discussed previously.
TN Fa (so named as it is a cytotoxic agent for a number of tumour cell lines) is a 
monomeric 17 kDa protein derived primarily from monocytes. As with many other 
cytokines, TNFa has many diverse biological effects including stimulating T cell 
growth and differentiation (Beutler and Cerami, 1989) and the induction of adhesion 
molecules (Furie and McHugh, 1989). The most striking feature of the osteotropic
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effects of TNFa is that it shares so many activities with IL-1. TNFa like IL-1, 
induces bone resorption (Bertolini et al.1986) presumably by promoting osteoclast 
formation (Pfeilschifter et al.1989) and stimulating prostaglandin production. In 
addition, it promotes osteoblast proliferation (Gowen et al. 1988). TNFa also 
stimulates osteoblasts to release IL-1 and IL - 6  (Hughes et al. 1988; Littlewood et al. 
1991), and therefore acts to promote a cytokine network in bone.
IL - 6  also has many diverse actions; it promotes the maturation of B cells to 
immunoglobulin producing plasma cells (Kishimoto, 1985; Kishimoto and Hirano, 
1988) and acts as a growth factor for many hybridomas and myeloma cell lines (Van 
Damme et al. 1987). IL - 6  is a glycoprotein that is synthesized in a pro-form and 
cleaved to form an active 26 kDa protein. A variety of cells synthesize IL- 6  including 
stimulated monocytes, endothelial cells and fibroblasts (Aarden et al.1985). The role 
of IL - 6  in bone metabolism has not been fully elucidated as it does not seem to 
stimulate the production of any cytokines or resorptive agents by human osteoblast­
like cells (Littlewood et al.l991a). The role of IL - 6  in bone resorption is 
controversial, and it has been reported to have no effect (Al-Humidan et al. 1991), or 
stimulate (Lowik et al.1989) bone resorption, depending on the organ culture system 
used. IL - 6  is an important regulator of hematopoiesis (Wong et al.1988), and is 
synthesized by osteoblast-like cells in culture (Littlewood et al. 1991b). It has been 
postulated to have a role in promoting osteoclast formation (Kurihara et al.1990). It 
is thought that IL - 6  may act in conjunction with other stem cell growth factors to 
promote the differentiation of hematopoietic stem cells to give an increased pool of 
osteoclast progenitor cells. The evidence for this scenario in bone is very 
circumstantial, but includes the observation that EL- 6  has a colony stimulating factor 
(CSF)-like activity and stimulates granulocyte/ macrophage colony formation from 
bone marrow cells (Kurihara et al.1990).
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3(xi) Growth factors
Growth factors are defined as extracellular proteins that affect cell proliferation and/  or 
differentiation. They are often classified according to their origin (eg. PDGF- platelet 
derived growth factor) or their effect (eg. TGFa- transforming growth factor alpha). 
The following growth factors are all reported to have osteotropic actions, but it must 
be borne in mind that these effects might be secondary to their primary roles in growth 
or repair.
Epidermal growth factor (EGF) is a 6  kDa polypeptide originally isolated from the 
mouse submaxillary gland and human urine (Cohen, 1983). Receptors for EGF have 
been identified on osteoblast-like cells including those from mouse calvariae and 
osteosarcoma cell lines (Shupnick et al.1980). EGF has been reported to have 
opposing effects on bone since it increases bone resorption, but also increases 
proliferation of osteoblasts (Raisz et al.1980; Tashjian and Levine, 1978; Canalis and 
Raisz, 1979). EGF is thought to promote an undifferentiated osteoblast phenotype 
since it reduces alkaline phosphatase and type I collagen synthesis in osteoblasts from 
different species (Shupnik and Tashjian, 1981).
EGF shares the same receptor as transforming growth factor alpha (TGFa). TGFa is 
a 50 amino acid polypeptide found in tumour cell culture supernatants. (Todaro et 
al.1980). It is thought to be a possible mediator of hypercalcaemia associated with 
neoplasms (eg humoral hypercalcaemia of malignancy). As expected, TGFa mimics 
the effects of EGF on bone. Signal transduction for both growth factors is thought to 
occur by the phosphorylation of cellular proteins, including the receptor, by specific 
protein kinases.
Fibroblast growth factor (FGF) is isolated from brain tissue and pituitary gland 
(Bohen et al.1985). It is a potent mitogenic cytokine and promotes the proliferation 
o f many cell types including mesenchymal, endothelial and osteoblast-like cells 
(Canalis and Raisz, 1980). PDGF is another mitogenic protein with opposing effects
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on bone. It enhances bone resorption ostensibly via local prostaglandin release 
(Canalis, 1981) and stimulates osteoblast proliferation (Tashjian et al.1982). PDGF is 
not a single factor but rather a family of 30kDa heterodimers consisting of 
combinations o f both a  and p subunits. In contrast to EGF and FGF, PDGF 
increases the synthesis of type I collagen which might also reflect its role in wound 
healing (Canalis et al.1989).
There has been a large amount of interest in the role of insulin like growth factors 
(IGFs) in bone. Two forms have been isolated from bone matrix, namely IGFI and 
IGFII. Their effects in bone are thought to be largely anabolic since both have been 
shown to induce osteoblast mitogenesis in culture (Schmid et al.1983), and stimulate 
the synthesis of matrix proteins including type I collagen (Canalis, 1980). Their 
biological activities are modulated by a series of specific high affinity binding proteins 
which are also synthesized by osteoblasts (Mohan and Baylink, 1991). The synthesis 
of these binding proteins is linked to the expression of other growth factors. It has 
been shown that FGF, TGFa, PDGF, and EGF are potent inducers of the synthesis 
of certain IGF binding proteins by osteoblast-like cells (Chen et al. 1991).
3(xii) Colony stimulating factors
Colony stimulating factors are members of the hematopoietic growth factor group. 
There are at least 5 members in this group, however only granulocyte-macrophage 
colony stimulating factor (GM-CSF) and macrophage colony stimulating factor (M- 
CSF) will be discussed in this review, since they have been shown to target bone cell 
precursors.
GM -CSF is produced by a wide range of cell types including activated T 
lymphoblasts, monocytes, stimulated fibroblasts and endothelial cells (Seelentag et 
al.1987). M-CSF is also secreted by monocytes, but is mainly produced by 
anchorage dependent cells including fibroblasts, keratinocytes, and endothelial cells.
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Osteoblasts from several species have been shown to produce both factors in vitro 
when stimulated with LPS or PTH (Horowitz et al.1989).
The data concerning the effects of GM-CSF on bone resorption is conflicting. GM- 
CSF has been shown to increase the formation of osteoclasts from bone marrow cell 
cultures (MacDonald et al. 1986b). In contrast it has been reported to reduce the the 
rate of appearance of mature osteoclasts in the fetal mouse long bone resorption model 
(Lorenzo et al. 1987). In addition, studies with mouse bone marrow adjacent to slices 
of cortical bone, reveal that the addition of GM-CSF not only inhibits basal bone 
resorption, but also 1,25 D3  stimulated resorption (Hattersley et al. 1988). M-CSF has 
also been reported to enhance the formation of osteoclasts in long term marrow 
cultures. Further enhancement could be achieved by the addition of 1,25 D 3  
(MacDonald et al. 1986b). M-CSF is also active in bone resorption in certain cases, 
resorption is stimulated in cultures of embryonic metacarpal bones (Horowitz and 
Jilka, 1991) but not 6  day old calvariae. This suggests that M-CSF stimulates 
osteoclastogenesis but does not affect mature osteoclasts.
Studies on the osteopetrotic (op/op) mouse yield the most convincing data that M-CSF 
is involved in osteoclast development. These mice are congenitally osteopetrotic due 
to a homozygous recessive mutation which gives rise to a deficiency in osteoclasts and 
macrophages (Wiktor-Jedrzeczak et al. 1982). The osteopetrotic symptoms are not 
alleviated by the transfer of normal bone marrow which suggests that the defect was 
not the result of a lack of precursor cells, but rather an incorrect hematopoietic 
microenvironment. Further investigation showed that the phenotype was due to a 
lack of functional M-CSF. Normal osteoclast and macrophage function including bone 
resorption could be restored by administering large doses of M-CSF. Analysis of the 
M-CSF gene in these mice revealed that a thymidine base had been inserted into the 
gene 3 prime to the initiation codon, which gave rise to a TGA stop codon further 
downstream of the gene (Yoshida, 1990). Northern blotting showed that instead of 
the two mRNA species that were normally seen, cells from the op/op mice only
62
contained a single small transcript representing a secreted form of the protein. Since 
the M-CSF was not functional it is assumed that either the secreted form was defective 
or that a membrane bound form of M-CSF was necessary for activity.
There is little evidence that osteoblasts respond to CSFs but Dedhar et al. (1988) 
reported that the human osteosarcoma cell line MG-63 proliferates in response to 
GM-CSF. In the same study the more mature variant cell line MG-63.3a failed to 
proliferate. This raises the possibility that CSFs may be active differentiation agents 
for immature osteoblasts.
3(xiii) Resorption inhibitors
Interferons are a class of cytokines produced by lymphocytes and macrophages 
following stimulation, and are thought to be important in the antiviral response. Of the 
known interferons interferon gamma (IFN-y) acts to promote the immune and 
inflammatory responses of lymphocytes and macrophages. IFN-y has been shown to 
selectively and completely inhibit only cytokine (IL-1, TNFa, TNFp) stimulated bone 
resorption (Gowen et al.1986), but not 1,25 D 3 or PTH stimulated resorption under 
the same conditions. Three different mechanisms have been proposed for IFN-y 
inhibition of bone resorption. Firstly prostaglandin mediated bone resorption may be 
inhibited by IFN-y acting to block prostaglandin synthesis. There is some evidence to 
suggest that this occurs in neonatal calvariae (Hoffman et al. 1987). Secondly IFNy 
may have a direct calcitonin like effect, or thirdly it might inhibit osteoclast recruitment 
or formation.
IFN-y also has effects on bone formation, as it has been shown to inhibit type I 
collagen synthesis in fetal rat calvariae (Smith et al. 1987 ) and has an additive effect 
with TNFa and TNFp when bone is exposed to both.
Recently some data has been presented which suggests that the T cell product, 
interleukin 4 (EL-4) may have a role in bone metabolism. IL-4 has the ability to induce 
monocyte-macrophage differentiation from precursor cells (Galanaud et al. 1990).
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Since IL-4 induces differentiation of precursors, from a simplistic view it could be 
assumed that it might promote osteoclast formation. However its role in bone 
resorption seems to be inhibitory. Fetal rat long bones exhibited no increases in bone 
resorption after 3 days when treated with recombinant murine IL-4 (rmIL-4). 
However significant inhibition of basal resorption occurred after 5 days (Watanabe et 
al. 1991). In addition IL-4 inhibited both IL-1, prostaglandin and PTH stimulated 
bone resorption in a dose dependent manner. Due to the relatively long period before 
IL-4 exerts its inhibitory actions on resorption, it seems likely that it acts to decrease 
osteoclast formation. This might not be a direct effect, as it is possible that IL-4 acts 
by decreasing the precursor pool available for osteoclast formation by promoting 
differentiation along the macrophage monocyte lineage. In another study by 
Watanabe et al (1990) rmIL-4 was shown to be effective in abrogating PTHrP induced 
hypercalcaemia. A histological examination of the bone revealed a decrease in 
endosteal osteoclast formation.
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Table 1.3: The effect of cvtokines on bone metabolism
O steoc la s t
formation





IL-1 t t t Gowen, 1991
IL-6 t t 4 ■4 Lowik et al.1989; Al-Humidan et al. 1991; Littlewood 
et al. 1991
TNFs t t t Gowen, 1991
CSEl
M- CSF t 14 Horowitz and Jilka, 1991
GM-CSF t* 4 t Horowitz and Jilka, 1991
Growth factors
TGFp t 4 t t Dieudonne et al.l991;Hattersley and Chambers 1991; 
Marcelli et al.1990.
IGFs t t Schmid and Ernst, 1991
PDGF t 4 Rodan and Rodan, 1991
TGFo/EGF t t t D' Souza and Ibbotson, 1991
ResorDtion inhibitors
IL-4 4 4 t Watanabe et al. 1991;Watanabe et al.1990; Lacey et al. 1991
IFN-y 4 4 4 t 4 MacDonald, 1991
t = increase 
4- = decrease 
= no effect
3(xiv) Summary
The previous section has reviewed the current data available for the actions of different 
groups of cytokines in bone. Much of the data are obtained from experiments where 
different cytokines are used in isolation. Whilst the data obtained may highlight some 
functions of the cytokine, it is unlikely that the effects will mirror the in vivo state 
where whole networks of cytokines interact. Hopefully with the advent of more 
molecular biology techniques, where several parameters can be studied at once, a 
greater understanding of the complex actions of cytokines in bone could be achieved.
In summary, this introduction has outlined the structure, and major components of 
bone. The mechanisms by which bone is thought to be formed and remodelled have 
been described. In addition, the available data concerning the role of systemic 
hormones and growth factors has been reviewed. Our understanding of bone 
metabolism, particularly with reference to human bone is at a very preliminary stage. 
Only by characterising the complex events that control bone remodelling will it be 
possible to address the problems of metabolic bone disease. The following chapters 
report the findings of several indepth studies of the role of two cytokines IL-1 and 
TGFp in human bone metabolism. It is hoped that the studies will contribute to the 
understanding of the complex cytokine network present in bone.
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CHAPTER XX : tUA.TEH.XAUS ^ ID  METHODS
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II. 1 MATERIALS
All chemicals were of the purest grade available and were obtained mainly from Sigma. 
The sources of specialist materials are listed below.
Antibodies and cvtokines
Recombinant TGFp - British Biotechnology
Recombinant IL-lp - Glaxo (Greenford)
Recombinant TNFa - Glaxo (Greenford)
Anti TGFp polyclonal antibody - British Biotechnology 
Anti TGFp monoclonal antibody - Celtrix (USA)
Anti IL-lp monoclonal antibody - Roussell (Switzerland)
Culture materials
Gibco - Modified Eagles medium (MEM), fetal calf serum, trypsin/EDTA solution. 
Oxoid Ltd - phosphate buffered saline 
Sigma - sodium selenite, insulin
Sterilin - sterile tissue culture grade plastics, cell scrapers
Miscellaneous biochemical reagents
Biorad - electrophoresis grade acrylamide
Ilford - chemicals for film development
Kodak - film
British biotechnology - TGFp fluorokine receptor kit, IL-lp fluorokine receptor kit 
Molecular probes, Triangle Park N.C. - FITC conjugated beads for FACS analysis.
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Molecular reagents
Restriction enzymes and Taq polymerase were from NBL. Modifying enzymes 
(Klenow, SP6  polymerase, RNase A, T7 polymerase) were from Mannheim- 
Boehringer.
Amersham - LM-1 emulsion, Hybond N+
Oxoid Ltd - yeast extract, bactotryptone, bactoagar
Sigma - MOPS, formamide, salmon sperm DNA (RNAse free)
Stratech Scientific ltd - Geneclean kit 
GIBCO - Phenol, formamide (RNA grade)
Plasmids - pgemillbeta, pGHTGFp-27 and pGEM-IRAP-P5 were kind gifts from Dr. 
A Shaw, Glaxo Geneva. pOP/10 was a kind gift from Dr. M Young NIH Bethesda 
Maryland.
Radioisotopes and related materials
Amersham International pic : deoxycytidine - [a-3 5 S] thiotriphosphate, 
deoxycytidine 5'-[oc-3 2 P] triphosphate, [a-methyl 3 H] thymidine.
n.2 CELL BIOLOGY METHODS 
Tl.Ui) Human bone cell culture.
The human osteoblast-like cells were derived from explants of trabecular bone obtained 
at surgery as previously described (Beresford et al. 1984; Beresford et al.1986). After 
four to six weeks in culture the cells were trypsinized, pooled and then seeded in 9 cm 2  
petri dishes at one million per dish. For the serum-free experiments the cells were 
incubated in serum-free MEM + 0.1% BSA for 24 hours prior to the experiment. 
These cultures have been previously extensively screened for macrophages and 
monocytes using a panel of monoclonal antibodies and both these cell types have been 
shown to be absent (Skjodt et al.1989).
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H I  (if) Interleukin 1 bioassav
The level o f expression of IL-1 activity was assessed using the D 1 0 N4 M bioassay. 
D 1 0 N4 M is a murine T cell line which proliferates in response to IL-1 in the presence of 
IL-2 (Hopkins and Humphreys, 1989). Samples to be assayed were dispensed at 
lOOul per well. After a 72 hour incubation the cells were pulsed with [a-methyl 3 H] 
thymidine (luC i per well) for a further 6  hours. The extent of proliferation and hence 
IL-1 bioactivity present in the samples was determined by harvesting the cells, 
scintillation counting and comparing with a standard curve. The bioassay was sensitive 
down to 0.2 pg /ml IL-1.
ILHiiil Cell proliferation assay
Human osteoblast-like cells were trypsinized and harvested from the 9cm2  petri dishes. 
Cells were then seeded at a density of 2x l05/  well in a 48 well Costar tissue culture 
plate and left overnight in a 5% CO2  incubator at 37°C to adhere. The following day 
the treatments were added to the wells in triplicate, and the cells incubated for a further 
24 or 48 hours depending on the agents. After this time the cells were "pulsed" for 6  
hours with [a-methyl 3 H] thymidine (luC i per well) to assess the proliferation. At the 
end of the pulse period the cells were washed extensively with cold PBS to remove any 
surface bound [a-methyl 3 H] thymidine. The DNA was then harvested by lysing the 
cells with 0.1% SDS/PBS on ice for 5 min and spoting the lysate onto D E I 8  filter 
paper. The filters were washed 3 times in an excess of 0.5M sodium phosphate 
solution to wash away unincorporated [a-methyl 3 H] thymidine. Tritiated thymidine 
incorporation was then estimated by liquid scintillation counting.
H I  (iv) Immunolocalization of cvtokines in cells
Human osteoblast-like cells were plated onto 10 well multispot slides which had 
previously been washed in 70% ethanol and autoclaved. The cells were seeded at a
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density of 3000/spot and settled overnight at 37°C in a 5% CO2  atmosphere. The cells 
were treated with 200 pg/ml IL-1 a  to stimulate IL -lp  expression, or 10"^M 1,25 
dihydroxyvitamin D 3  for TGFp expression, for 24 and 48 hours respectively. To stop 
cytokine secretion cells were treated with 0.5uM monensin at the start of the stimulation 
peroid. After the stimulation the cells were washed briefly in PBS and fixed in 4% 
paraformaldehyde/PBS for 5 mins. The cells were then washed with TBS three times 
for 5 min to remove any traces of paraformaldehyde. The slides were immediately 
stained, or stored air dried for up to 1 month at -20°C. A treatment with 0.1% Triton X 
100 was performed for 5 min to increase the accessibility of the antibodies. Residues 
of Triton X 100 were removed with TBS washes. The primary antibodies in 5% horse 
serum were layered onto the cells for 30 min in a humidified chamber. Excess antibody 
was removed with TBS washing, the cells were then incubated with a secondary 
antibody which was conjugated to alkaline phosphatase. After the excess secondary 
antibody was removed by washing in TBS, an alkaline phosphatase substrate (2mg/ml 
Napthol AS-MX phosphate in 2% N,N-dimethylformamide, 0.1 M Tris pH 8.2, 100 
mM levamisole, 1 mg/ml Fast-Red TR salt) was added to produce a coloured reaction 
product. lOOmM levamisole was found to be the optimal concentration to inhibit 
endogenous alkaline phosphatase activity. The slides were mounted in 90% glycerol, 
10% TBS and sealed. In some cases the cells were reacted with a different coloured 
substrate to show endogenous alkaline phosphatase activity, prior to antibody staining.
II.l(v) Alkaline phosphatase staining
The sections were air dried prior to alkaline phosphatase staining. The reaction buffer 
(0.2 mg/ ml Napthol AS-MX phosphate in 2% N,N dimethyl formamide, 0.1 M Tris 
pH 8.2, 1 mg/ml Fast Blue BB salt) was prepared immediatly before staining, and 
filtered directly onto the sections. The reaction was carried out at room temperature for 
2 - 5 min until a blue precipitate was visible. The sections were then air dried, mounted 
in 90% glycerol, 10% PBS and sealed.
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II.l(VD Tartrate Resistant Acid Phophatase staining (TRAP)
TRAP activity was assayed by the standard napthol AS-BI phosphate post-coupling 
method, using Fast Garnet GBC as the coupler. The reaction was carried out at 37°C 
in a water bath. The sections were incubated with prewarmed reaction buffer (0.25M 
sodium citrate pH 4.5, 0.5 mg/ml Napthol AS-BI phosphate) for 5 -10 min. The 
napthol reaction product was then reacted with Fast Garnet to give a red coloured stain. 
This was achieved by incubating the sections in the post-coupling reaction buffer 
(lmg/ml Fast Garnet GBC salt, 0.1M sodium acetate buffer pH 6.2) at 4°C  for 30 min. 
The sections were then air dried and mounted in 90% glycerol, 10% PBS.
MOLECULAR BIOLOGY METHODS 
n.2 RNA extraction and manipulation
Sterile disposable plasticware was used throughout the preparation of RNA. As 
general laboratory glassware was often a source of RNAse contamination, it was 
treated with a solution of 0.1% diethyl pyrocarbonate (DEPC) for 12 hours at room 
temperature and then autoclaved. DEPC is a strong inhibitor o f RNAses, but it is 
necessary to remove all traces of this compound after treatment as it may inactivate 
RNA by carboxymethylation. Similarly, solutions used for the preparation o f RNA 
were treated with 0.1% DEPC overnight and then autoclaved. Gloves were worn 
during all stages of the preparation of RNA, as RNAses are secreted on the surface of 
hands.
n.2(i) RNA purification
Total RNA was prepared from monolayer cell cultures by a microscale method based 
on that of Chomininski and Sachi, (1987).
Following treatment, the medium was removed from the cells and stored at -20°C for 
bioassay. 500ul o f denaturing guanidine thiocyanate solution (4M guanidinium
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iso th iocyanate , 25 mM sodium  citra te  pH 7.0, 0.5%  sarcosyl, 0.1M  
2 -mercaptoethanol) was added to the petri dishes and the cells harvested with a cell 
scraper. The following solutions were then added sequentially with mixing between 
each addition : 50ul 2M sodium acetate pH 4, 500ul phenol (water-saturated), lOOul 
chloroform/ isoamyl alcohol (49:1). Tubes were vigorously shaken for 10 seconds and 
then cooled on ice for 15 min. The mixture was then centrifuged at high speed in a 
microfuge for 10 min to form two layers. The top aqueous layer which contained the 
RNA was removed and placed into a new tube.
The RNA containing layer was extracted twice with an equal volume of chloroform 
/isoamyl alcohol to remove any traces of phenol. The RNA was precipitated with an 
equal volume of isopropanol at -20°C overnight. The precipitated RNA was pelleted in 
a bench microfuge at 15000 for 10 min, and then resuspended in 150ul of solution D. 
The RNA was reprecipitated using an equal volume of isopropanol at -20°C for at least 
1 hour. Again the RNA was pelleted using a bench microcentrifuge. The pellet was 
washed twice in 2 0 0 ul of 70% ethanol, followed by a single wash in 1 0 0 % ethanol, 
and then dried in a vacuum desiccator. The RNA pellet was then resuspended in 50ul 
of DEPC-treated sterile water. The amount of RNA purified was quantified by 
measuring the absorbance at 260nm and 280 nm of a 1 in 25 dilution of the prepared 
RNA. An absorbance value of 1.0 corresponds to RNA at a concentration of 40ug/ml. 
Typical yields were 50-100ug/106 cells. The RNA was then loaded onto Northern 
blots or slot blots for analysis.
IL2(ifi Northern blotting
Northern blot analysis was earned out according to (Goldberg et al.1979).
Ten microgram aliquots of RNA were precipitated using an equal volume of 
isopropanol overnight at -20°C. The pellets were washed twice in 70% ethanol, and 
once in 100% ethanol and dried in a vacuum desiccator. The dry pellets containing 
lOug of total RNA were dissolved in lOul of loading buffer (IX  MOPS, 50% (v/v)
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formamide, 17% (v/v) formaldehyde, 23% (v/v) DEPC water). The samples were 
denatured at 65°C for 5 min to remove any secondary structure, and quenched on ice 
prior to loading. 2ul of RNA loading dye (10 X = 20% (w/v) Ficoll, 0.25% (w/v) 
bromophenol in lOmM Tris pH 7.8) was then added, and the RNA loaded onto a
1.2% (w/v) agarose denaturing gel in MOPS buffer (10 X MOPS = 0.4M MOPS pH 
7.0, lOOmM sodium acetate, lOmM EDTA).
The gel was run at 30mA for 5 hours until the dye front was approximately 5 cm from
the end of the gel. The gel was then cut to remove the lane with ribosomal markers.
This portion of the gel was stained with 0.01% ethidium bromide solution to visualize
the 28s and 18s ribosomal bands. The Northern blot was then assembled as shown. 
J ^ h t
glass  plate 1— —
■ ■ —  3 sh e e t s  3M filter paper
Hybond N+ ------------------------------------
1 % ag arose  gel
3M filter paper wickg la s s  plate
Tank containing 20  X S S C
The blot was left overnight for the RNA to transfer to the Hybond N+ membrane. The 
RNA was fixed, by placing the membrane on a pad of Whatman 3M paper containing 
50mM sodium hydroxide solution for exactly 5 minutes. The blot was then washed in 
2 X SSC to remove any traces of sodium hydroxide. The membranes were stored 
wrapped in Saran Wrap at 4°C.
II.2(ni) Slot blotting
The slot blot method used purified RNA prepared by a microscale method based on that 
of Chomininski and Sachi, (1987).
Ten microgram aliquots of RNA were mixed with an equal volume of formamide, 
denatured at 65°C for five minutes and then quenched on ice. The salt concentration 
was adjusted to 0.25 M with sodium acetate. Two-fold serial dilutions were then made 
and loaded in lOOul volume onto a GIBCO-BRL slot blot manifold. The samples were
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washed through with a solution of 50% formamide/0.25M sodium acetate pH 5.2. The 
RNA was then fixed to the filter with a solution of 50mM sodium hydroxide for 5 
minutes. The filter was finally washed in 2 X SSC and stored at 4°C  wrapped in Saran 
wrap.
II.2(iv) Quantification of RNA on Northern and Dot blots
Blots were stained with 2% methylene blue, and then destained in 2 X SSPE (20 X 
SSPE = 3M sodium chloride, 0.2M sodium dihydrogenphosphate, 0.02M EDTA) prior 
to hybridization to check for equal loading. After hybridization with the cytokine 
cDNA probe, the blots were stripped and rehybridized with the housekeeping gene 
p-actin. p-actin is thought to be a constitutive non-modulated gene, and therefore the 
hybridization signal should be the same for all the samples. The slots and bands were 
scanned with a hand held densitometer (Genetic Research Inc) for quantification. The 
readings were adjusted for small variations in the amount of RNA in each slot/track by 
normalizing with respect to the p-actin value.
II.2(v) Stripping radioactive probes from blots
The radioactive probe was removed from the Northern blots or slot blots by boiling 
the filter in a solution of 0.1% SDS. After cooling to room temperature and washing in 
2 X SSC, the filters were exposed to film to check that all the probe had been removed.
II.2(vi) Polyacrylamide gel electrophoresis of RNA probes
The sizes of the RNA probes were determined by polyacrylamide TBE vertical gel 
electrophoresis. The gel was prepared by adding 21g of urea to a polyacrylamide gel 
solution (3.5% acrylamide [29:1 acrylamiderbis]) and warming the solution to 37°C 
until the urea dissolved. Once the urea was in solution, lOOul of TEMED and 160 ul 
of 16% ammonium persulphate were added to initiate and catalyse the polymerization of 
the gel solution respectively. The gel solution was then mixed gently and poured onto a
clean glass electrophoresis plate which had 0.5 mm spacers fixed to its edges. As the 
gel was poured, a second sialanized gel plate was moved across the surface of the 
bottom gel plate to form a "gel sandwich". It was necessary to carry out this procedure 
rapidly to avoid the gel solution polymerizing before the gel was prepared. A 0.5 mm 
comb was inserted into the top of the gel to form sample wells. The gel was left at 
room temperature for a hour to fully polymerize, afterwhich the comb was removed and 
the wells rinsed with water. The gel was then attached to the electrophoresis apparatus 
and the reservoirs filled with 1 X TBE running buffer.
The RNA samples were dissolved in 1 X TBE, denatured at 65°C and quenched on ice 
and loading buffer (30% Ficoll, 0.25% bromophenol blue, 0.25% xylene cyanol, 0.2M 
EDTA pH 8.0) was added at a 1 in 10 dilution. The RNA samples were loaded into 
the sample wells using an ultra thin pipette tip. DNA standards from a sequencing 
reaction were electrophoresed alongside the samples for accurate sizing. The gel was 
run at 30mA and the voltage monitored to prohibit it rising over 1500V, electrophoresis 
was stopped when the bromophenol blue dye front was two thirds down the gel. The 
RNA was fixed in position by immersing the gel in 10% methanol, 10% acetic acid for 
30 min. The gel was then carefully mounted on Whatman 3M paper and dried down 
for 1 hour at 70°C. The dried gel was then autoradiographed for 24 hours at room 
temperature.
II.3.DNA purification and manipulation 
II.3(i) Preparation of competent cells
A single colony of the host strain bacteria was isolated from the frozen stock by 
streaking the bacteria onto an agar plate with appropriate antibiotic selection. The single 
colony was used to innoculate a 5ml culture in L-broth (5g yeast extract, 20g 
bactotryptone, 5g sodium chloride/litre of medium), which was then incubated 
overnight at 37°C. A subculture was prepared by diluting the 5 ml aliquot 1 in 20 in
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L-broth. The bacteria were cultured for approximately 2 further hours until the optical 
density of the solution was 0.3 at 600 nm. The flask was quickly chilled on ice to 
arrest bacterial growth, and the bacteria were then spun down into a pellet in a 50 ml 
polypropylene tube at 6000 r.p.m.for 5 min at 4°C. The bacterial pellet was gently 
resuspended in a 2/5 volume transformation buffer I (30mM potassium acetate, lOOmM 
RbCl2 , lOmM CaCl2 , 50mM MnCl2 , 15% (v/v) glycerol pH to 5.8). The bacteria 
were then left on ice for 5 min then pelleted again at 6000 r.p.m 5 min at 4°C . 
Following this the pellet was resuspended in a 1/25 volume of transformation buffer II 
(lOmM MOPS, 75mM CaCl2, 10mM RbCl2, 15%(v/v) glycerol, pH 6.5). The 
bacteria were then left on ice for 15 min during which time the bacterial cell wall 
modifies to give the bacteria a spheroplast morphology. The bacteria could then either 
be transformed immediately, or aliquots of 2 0 0 ul placed into prechilled freezing vials 
and snap frozen in dry ice. The aliquots were stored liquid nitrogen and used within 6  
months. The competency of the bacteria was tested by transforming 10 ng of pUC 19. 
The transformation efficiency was usually in the order of 108  colonies/ng DNA.
II.3(ii) Transformation of competent bacteria.
The aliquot of competent bacteria was thawed at room temperature and stored on ice for 
10 min. The plasmid DNA (lOng-lOOng) was then added directly to 200ul of 
competent bacteria. This mixture was then left on ice for 15 - 45 min so that the DNA 
could become associated with the bacteria. The bacteria were then "heat-shocked" at 
42°C for 2 min and returned to ice for 1-2 min. Two volumes of L-broth were then 
added at room temperature and the tube incubated at 37°C for 60 min with gentle 
shaking. This process allowed the bacteria to recover. It was important that no more 
than 2 volumes of L-broth were added as this is thought to promote bacterial division. 
An aliquot of bacteria (typically 10 ul) was then spread onto agar plates containing 
lOOug/ml ampicillin. The plate was incubated at 37°C overnight.
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II.3(ni) Micropreparation of DNA (Miniprepsl
Small amounts o f plasmid DNA for restriction enzyme analysis were prepared by a 
modified method of Bimboim and Doly, (1979).
A plasmid colony was grown overnight in 10 ml of L-broth containing 50ug/ml 
ampicillin. 4.5 ml of the culture was spun down in a 1.5ml microfuge tube, by repeatly 
adding the bacteria culture medium and removing the supernatant. The bacterial pellet 
was resuspended in lOOul of ice cold Solution I (50mM glucose, 25mM Tris pH 8.0, 
lOmM EDTA, lOug/ml lysozyme) by vigorously vortexing the tube. 200ul of freshly 
prepared Solution II (0.2M sodium hydroxide, 1% SDS) was added to the suspension 
and the tube gently mixed, the samples were left on ice for 30 min to ensure bacterial 
lysis. 150 ul of ice-cold solution III (3M potassium acetate, 5M acetic acid) was mixed 
with the highly viscous lysate, the tubes were left on ice for 30 min to precipitate 
protein. The protein appeared as a white flocuant precipitate, which was removed 
from the supernatant by spinning the lysate in a microfuge. Residual protein was 
removed by phenol extraction of the supernatant followed by 2  chloroform extractions 
to remove traces of phenol. The plasmid DNA was then precipitated with 2 volumes of 
ethanol at 20°C for 1 hour. The plasmid DNA was pelleted in a microfuge for 5 min, 
washed twice in 70% ethanol and once in 100% ethanol and then dried in a vacuum 
dessicator. The DNA was finally dissolved in sterile water. Typical yields attained, 
were 3 - 5 ug per 4.5ml bacterial culture. 2ug of plasmid DNA was then used for 
restriction enzyme analysis.
II.3(iv) Large scale plasmid purification (Maxipreps)
When more than lOOug of plasmid DNA was required, a QIAGEN Maxi prep kit was 
used. Ion exchange columns in this kit bind DNA preferentially and allow its 
purification from the bacterial lysate.
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The following procedure was used: 200ml of bacterial culture was incubated on a 
shaking platform at 37°C overnight, or until the broth was turbid with bacterial growth. 
The bacteria were harvested in a high speed centrifuge at 3000 rpm for 15 min and the 
resulting bacterial pellet was resuspended in 4.0 ml of buffer PI (50mM Tris pH 8.0, 
lOmM EDTA, 400ug RNase A). The bacteria were lysed with 4.0 ml of buffer P2 
(200mM sodium hydroxide, 1% SDS) which was gently added and the solution 
incubated at room temperature for 5 min. 4.0 ml of buffer P3 (2.55 M potassium 
acetate) was added to neutralize the lysate. The lysate was then centrifuged at 5000 rpm 
and 4°C for 30 min to pellet the bacterial protein. The resulting supernatant was 
loaded onto a QLAGEN midi column that had been pre-equilibriated with buffer QB 
(750mM sodium chloride, 50mM MOPS pH 7.0, 15% ethanol). The column was then 
washed with 8.0 ml of buffer QC (1000 mM sodium chloride, 50 mM MOPS pH 7.0, 
15% ethanol) to remove any impurites which may have bound. The DNA was eluted 
with 2.0 ml of buffer QF (1200 mM sodium chloride, 50 mM MOPS pH 8.0, 15% 
ethanol), and then precipitated with 0 . 8  volumes of isopropanol at room temperature for 
5 min. The precipitate was harvested by centrifugation at 13,000 r.p.m./4°C for 30 
min. The pellet was washed twice with 200ul of 70% ethanol, once with 100% 
ethanol and dried in a vacuum dessicator. The DNA was dissolved in sterile water and 
a 1 in 1 0 0  d ilu tion m easured at 260/280 nm in a spectrophotom eter 
(A260 = 1-0 = 50ug/ml of double stranded DNA). Typical yields obtained, were 150 
ug/2 0 0 ml culture of a medium copy number plasmid.
II.3(v) Restriction digests of plasmid DNA
Restriction fragments containing cDNA sequences for the cytokines IL-lp and TGFp, 
were prepared from plasmid constructs. These fragments were purified as probes for 
the hybridization of RNA blots.
Both IL-lp and TGFp cDNAs were 300 bp fragments cloned into pGEM plasmids. 
The IL-lp insert was liberated by digesting lOug of pGEM IL-1 with 20 units of both
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PstI and EcoRI in High buffer (Boeringer Manheim) for 1 hour at 37°C. The TGF|3 
insert was prepared by digesting 10 ug of PGEM TGF in Medium buffer (Boeringer 
Manheim) with 20 units of both Hind III and EcoRI under the same conditions. The 
inserts were then separated by gel electrophoresis, purified by the Geneclean method 
and stored at - 20°C until required for labelling. The osteopontin cDNA was a 1.2 kb 
fragment in Bluescript.
RNA probes were generated for in situ hybridization using linearized plasmid as the 
template. Sense and antisense transcripts were generated using the Manheim Boeringer 
In vitro transcription probe kit, from linear templates prepared using restriction 
enzymes at the 5' and 3'ends of the inserts. The specific activity of the probes were 
routinely in excess of 1 0 8 cpm/ug.
II.3('vi) Electrophoresis of DNA
DNA fragments were separated by electrophoresis on a "submarine" 1% (w/v) agarose 
gel in TAE buffer (10 X TAE = 0.4M Tris, 0.05M sodium acetate, 0 .01M EDTA pH 
7.8) containing 0.5ug/ml ethidium bromide. The DNA was loaded in a solution 
containing a 1/10 volume loading buffer (20% w/v Ficoll, 0.25% w/v bromophenol 
blue, 0.25% w/v xylene cyanol in lOmM Tris pH 7.8, lOmM EDTA). Usually lug of 
DNA was loaded per lane in diagnostic gels. The gels were run at approximately 
60mA, until good separation was achieved. The DNA bands were visualized using a 
transilluminator emiting uv light. The gel was photographed using Polaroid Type 55 
positive/negative film.
II.3(vii) Extraction of DNA fragments from agarose gels
The DNA was purified from the agarose using a Geneclean kit from Stratech Scientific 
Ltd. The principle of this kit is that the DNA fragments bind to glass milk beads once 
released from the dissolved agarose. The DNA can then be eluted directly from the 
beads so avoiding the time-consuming ethanol precipitation step.
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The DNA was electrophoresed on a 1% agarose gel, and the band excised using a 
scapel blade. The slice of gel was then weighed and 2 - 3  times the equivalent weight of 
saturated sodium iodide added, and the agarose melted at 55°C for 5-10 min. 5ul o f 
the glass milk beads (for < 5ug of DNA) were added and the tube mixed before leaving 
at room temperature for 15 min to enable the DNA to bind. The tube was then 
centrifuged for 5 sec and the supernatant removed and saved until the technique was 
completed. The glass milk pellet was washed 3 times in Newash. After the final wash 
all traces of Newash were removed with a fine pipette tip. The DNA was eluted by 
adding 10 ul of sterile DEPC water, heating to 55°C for 5 min before spinning for 30 
sec and removing the supernatant. This elution step was repeated, and the supernatants 
combined. The yield obtained was typically between 70 - 80%.
IT.4. Hybridization techniques 
11.4(0 Radiolabeling probes
The cDNA probes were radiolabelled using the random hexanucleotide priming reaction 
supplied as an Amersham kit. The specific activity was monitored by taking lul from 
the final 50ul volume and "spotting" it onto two D E I 8  filter papers which bind 
polynucleotides. After drying, one of the filter papers was washed 3 times in 0.5M 
sodium dihydrogen phosphate solution to remove any unincorporated radioactive 
nucleotides. Both filters were then scintillation counted. The specific activity of the 
probes were then calculated by expressing the counts on the washed filter as a 
percentage of those of the unwashed filter. The probes were routinely in excess of 
40% incorporation (107 cpm/ug).
11.400 Northern blot /slot blot hybridization
The hybridization step was carried out at 52°C as described by Goldberg et al (1979), 
using a solution containing 33% formamide, 2 X SSC, 10% dextran sulphate, 100 
ug/ml ssDNA and lOOmM EDTA .
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Post-hybridization washes were carried out using 2 X SSC at room temperature, 
followed by 2 X SSC + 0.1% SDS at 65°C. If greater stringency was required, a final 
wash in 0.2 X SSC at room temperature was performed. Autoradiographs were 
established by exposing the filter to X-ray film for 24-72 hours at -70°C with an 
intensifying screen.
4 (nil In situ hybridization
The tissues for in situ hybridization were "snap" frozen in a dry ice ethanol bath in a 
5% solution of PVA immediately after surgery, and then stored at -70°C for up to 3 
months prior to sectioning. The tissue sections were cut on a Bright cryostat, and 
mounted on four well multi spot slides which had previously been treated with TESPA 
to im prove adherance o f the sections. The sections were fixed with 4% 
paraformaldehyde/PBS for 5 minutes and then washed with PBS to remove any traces 
of paraformaldehyde. The slides were dehydrated through an ethanol series and stored 
for up to four weeks at -20°C. The following pretreatments were performed to 
decrease the amount of non-specific binding of the riboprobes to the specimen: using a 
demineralisation 0.25M sodium citrate buffer pH 4.5 for 1 hour at room temperature 
(found to be vital for removing non-specific binding of the probe to the bone matrix). 
Proteinase K (lug/m l) treatment at 37°C for 30 min removed a proportion of the 
structural proteins and the remaining proteins were acetylated with acetic anhydride 
(0.1M at room temp, for 10 min). Finally a prehybridization in 2 X SSC /50% 
formamide was performed at room teperature for at least 1 0  min.
The RNA probes were synthesized using SP6  and T7 RNA polymerases according to 
the Manheim Boeringer transcription kit. The specific activity of the riboprobes were 
in excess of 108 cpm/ug. Sense transcripts were synthesized to act as a negative control 
and assess non-specific binding.
The hybridization was carried out in a solution containing 10% dextran sulphate, 50% 
formamide, lOmM DTT, 2 X SSC, 200ug/ml ssDNA, 1 X Denharts, 50ug/ml tRNA,
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100 U/ml RNAsin at 45°C overnight. The post-hybridization washes were as follows: 
4xl5m ins 2 x SSC at room temperature, 4 X 15mins 2 x SSC at 37°C, RNAse A 
(200ug/ml) in 0.1M Tris/ 50mM EDTA pH 8.0 at 37°C for 30 min. Finally a high 
stringency wash in 0.2 X SSC at 37°C for 30 min was performed to remove any 
residual non specific binding. After washing, the slides were dehydrated through an 
ethanol series, air-dried and dipped in LM-1 photographic emulsion. The slides were 
exposed at 4°C for up to one week prior to developing.
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C h a p te r  XXX : The expression of transform ing grow th  
factor beta by h u m a n  osteobCast-iihe ceiis i n  v i t r o .
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III. 1 ABSTRACT
Transform ing growth factor beta (TGFp) is one o f the most potent osteotropic 
cytokines and is deposited in large amounts in bone matrix. For these reasons the 
expression of TGFp mRNA was studied in human osteoblast-like cells in vitro. These 
cells constitutively expressed TGFpl, as determined by both in situ hybridization and 
Northern blot analysis. Immunolocalization studies confirmed that a population of 
osteoblasts expressed TGFp protein both constitutively and after stimulation with 
1,25-dihydroxy vitam in D 3  (1,25 D3 ). Treatment of the cells with the systemic 
hormones 1,25 D3 (10_8 M) and parathyroid hormone (10'7 M) increased TGFp mRNA 
expression by 3 fold and 9 fold respectively. In contrast, treatment with retinoic acid 
(10_8 M) an osteoblast maturation factor had no effect on TGFp mRNA expression. 
Treatment of the cells with hydrocortisone (10*8 M) resulted in the complete suppression 
o f TGFpi mRNA expression. This inhibition was partially alleviated by the addition 
o f 1,25 D3 (10"8 M), and the expression o f TGFpl mRNA returned to 70% of the 
stimulated level. Physiological doses (10- 9  - 1 0 1 0  M) of 17-p oestradiol resulted in a 5 
fold increase in TGFpl mRNA expression, further confirming the importance of 
systemic hormones as modulating agents of TGFp mRNA expression.
The cytokines IL -la  (200pg/ml), TNFa (17ng/ml), and the bacterial lipopolysaccharide 
(LPS) (500ng/ml) failed to stimulate TGFp mRNA expression. In contrast, TGFpl 
treatm ent (lOOpM) resulted in an autoinductive stimulation of TGFpl mRNA 
expression.
In summary, TGFp expression was found to be modulated by the systemic hormones 
but not by the "inflammatory" cytokines.
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III.2 INTRODUCTION
TGFp is a 25 kDa homodimeric polypeptide first identified by its ability to cause a 
phenotypic transformation of rat fibroblasts (Roberts et al. 1981). It is expressed by 
virtually every cell type and has been shown to have many regulatory actions, including 
the modulation of proliferation, differentiation and protein expression (Roberts et al. 
1985). This cytokine is secreted in a latent form as a 390 amino acid precursor 
molecule which must be cleaved to form an active 112 amino acid monomer. A family 
of at least 5 different highly homologous isoforms (termed TGFp 1 - 5 ) have been 
identified by screening cDNA libraries with TGFpl probes. A high degree of 
conservation (99%), between human and mouse TGFPi sequences argues for a critical 
biological role of TGFp across species.
There has been much interest in the role of TGFp in bone cell biology, since it has been 
found to be deposited in the bone matrix in large amounts (Gehron Robey et al. 1987). 
Initially two isoforms of TGFp, now referred to as TGFPi and TGFp2 , were identified. 
The former was first isolated from human platelets and was found to be identical to 
CIF A, a cartilage inducing factor (Ellingsworth et al. 1986). Both forms are present 
in bone matrix (Celeste et al. 1990), although TGFPi is four times as abundant as 
TGFp2 - They are highly homologous with over 70% identity at the protein level.
The results obtained from many studies of the action of TGFp on bone cells in vitro are 
complex and in some cases conflicting. The consensus of opinion however is that 
TGFp may "couple" bone formation to bone resorption in the bone remodelling cycle. 
TGFp is a very attractive candidate as a coupling factor for many reasons, which are 
summarised in figure III. 1. As mentioned earlier TGFp is deposited in the bone matrix 
in a latent form which must be activated. This can be achieved in vitro by limited 
proteolysis or acidification. In the bone matrix it is thought that TGFp may be 
activated by osteoclasts. There is some evidence to support this idea, since Oreffo et al. 
(1989) demonstrated that isolated osteoclasts are able to activate latent TGFp, 
presumably in the acidic microenvironment under their ruffled border. A variety of
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osteoblastic cell lines, marrow fibroblasts and monocytes were unable to activate latent 
TGFp suggesting this is a highly specific property.
After a period o f resorption it is necessary for the quantity o f bone that has been 
resorbed to be replaced. This requires the availability of large numbers of osteoblasts. 
TGFp may increase the availability of osteoblasts in several ways. Firsdy, it may act as 
a recruitment factor to increase the number of osteoblasts present at the remodelling 
site, since it has been shown to be chemotactic for these cells in vitro (Pfeilschifter et 
al. 1990). Secondly, it has been postulated that TGFp may increase osteoblast numbers 
as it is a potent stimulator of osteoblast proliferation in vitro, although this seems to be 
a biphasic effect and dependent on cell density (Centrella et al. 1987).
Bone formation obviously involves the accelerated synthesis o f the bone matrix by 
osteoblasts. TGFp is thought to be important in promoting the synthesis of 
extracellular matrix. It has been shown to upregulate RNA transcription and translation 
o f many matrix components including type I collagen, fibronectin (Ignotz and 
Massague 1986) and osteonectin (Thiebaud et A1.1990), resulting in an increase in 
matrix deposition of these proteins. In addition to promoting the synthesis of matrix 
proteins, there is evidence to suggest that TGFp may also have a protective role over the 
bone matrix. Studies with mouse fetal calvarial cells show that TGFp increases the 
synthesis of TIMP (tissue inhibitor of metalloproteinases), an inhibitor of type I 
collagenase and stromelysin, two enzymes which can degrade the extracellular matrix 
(M eikleetal. 1991).
The role of TGFp in bone resorption remains controversial since it has been shown to 
inhibit (Pfeilschifter et al. 1988) and promote (Tashjian et al. 1985) bone resorption in 
different model systems (see chapter I). Most of the data suggests that TGFp has a 
largely anabolic effect in bone, since both TGFpl and TGFp2  abolish both 1,25 D 3  and 
IL-1 induced resorption in rat long bone to some degree (Pfeilschifter et al. 1988). It is 
possible that the stimulation of bone resorption seen in the mouse calvarial model is a 
non specific prostaglandin mediated effect. Further evidence that TGFp inhibits
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resorption comes from studies on isolated osteoclasts, where both isoforms of TGFp 
decrease TRAP activity and oxygen free radical generation (Oreffo et al. 1990).
During the quiescent stage of bone remodelling TGFp which has been deposited in the 
matrix by osteoblasts remains bound to matrix proteins. Subsequently it is liberated at 
the initiation of another round of remodelling. In summary, TGFp is thought to have a 
pivotal role in bone remodelling since it may provide the mechanism for the coupling of 
resorption to formation.
The biological effects of TGFp on bone have been well documented, but there is very 
little information about the regulation of TGFp expression in the osteoblast. We 
therefore undertook this study to investigate the modulation of TGFp expression in 
osteoblasts. Since we wanted to assess the results with reference to human disease 
states it was necessary to use human cells, as the effects of many growth factors and 
cytokines on bone cells have been shown to be species specific. For example TGFp 
has been implicated as having an effect on osteoclast formation: at low concentrations it 
inhibits the formation of osteoclasts from long term human marrow cultures (Chenu et 
al. 1987) but promotes their formation in mouse cultures (Shinar and Rodan. 1990).
It was considered to be very important to use primary human osteoblast cultures since 
the popular alternative osteoblastic cell lines derived from osteosarcomas do not express 
the same phenotype as normal osteoblasts in culture (Clover and Rickard, unpublished 
results). Therefore human bone cells were obtained by culture from explants of bone, 
and treated with a variety of cytokines and systemic hormones to determine their effects 
on TGFp mRNA expression. Northern blot analysis was used to monitor TGFp 
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III.3 METHODS AND MATERIALS 
Northern and slot/dot blots
Human bone cells were obtained from explants of bone (as described in chapter 
II.l(i)). After 4 - 6  weeks the osteoblast-like cells were confluent in the 9cm 2  petri 
dishes. Since each petri dish did not contain exactly the same population of osteoblast­
like cells, it was necessary to pool the cells for the different experiments. For the 
Northern and slot blot experiments 10-12  petri dishes of osteoblast-like cells were 
prepared as follows. Firstly a short wash in PBS was undertaken to remove trypsin 
inhibitors, then the cells were treated with trypsin (50U/ml) at 37°C for 5 mins until 
all the cells were detached from the tissue culture plate. The trypsinization reaction was 
then stopped by the addition of medium containg 10% fetal calf serum (FCS). The 
cells were harvested into a sterile tube at 1000 rpm in a bench cenrtifuge for 5 min; the 
resulting pellet was then washed twice in medium (lxM EM , 10% FCS, Im M  
glutamine, lOOU/ml penicillin /streptomyocin pH 7.2). The cells were counted and 
seeded into 9cm2  petri dishes at a density of 0.5 -1  million per dish, and left overnight 
in a 10% CO 2  atmosphere at 37°C to allow the cells to recover and adhere. The 
following day the cells were washed twice with PBS to remove any serum, then fed 
with a synthetic serum-free medium (lxMEM, 0.1% BSA, lOug/ml transferrin, lug/ml 
insu lin , 3 x l0 _8M sodium selenate, Im M  glutam ine, lOOU/ml penicillin  
/streptomyocin). After a further 24 hours the cells were treated with the agents. After 
treatment the medium was removed from the petri dishes, and the RNA harvested by 
adding 0.5 ml of denaturing guanidine hydrochloride solution, and scraping the petri 
dish until all the cells were lysed. The RNA was then purified according to a method 
based on that of Chomininski et al. (1987) (see Chapter II 2(i)). Routinely 1 petri dish 
was used per treatment with a yield of approximately 30 - 50 ug RNA /lx lO  6  cells. 
The Northern blots and slot/dot blots were carried out as described in chapter II.2(ii), 
II.2(iii). Ten micrograms of total cellular RNA was used per lane for Northern blots, 
and 5ug for the highest concentration in slot blots. All filters were stained with
90
following day the cells were washed twice with PBS to remove any serum, then fed 
with a synthetic serum-free medium (lxMEM, 0.1% BSA, lOug/ml transferrin, lug/ml 
insu lin , 3 x l0 _8M sodium selenate, Im M  glutam ine, lOOU/ml penicillin  
/streptomyocin). After a further 24 hours the cells were treated with the agents. After 
treatment the medium was removed from the petri dishes, and the RNA harvested by 
adding 0.5 ml o f denaturing guanidine hydrochloride solution (see chapter II), and 
scraping the petri dish until all the cells were lysed. The RNA was then purified 
according to a method based on that of Chomininski et al. (1987) (see Chapter II 2(i)). 
Routinely 1 petri dish was used per treatment with a yield of approximately 30 - 50 ug 
R N A /lx lO - 6  cells.
The Northern blots and slot/dot blots were carried out as described in chapter II.2(ii),
II.2(iii). Ten micrograms of total cellular RNA was used per lane for Northern blots, 
and 5ug for the highest concentration in slot blots. All filters were stained with 
methylene blue (see chapter II 2(iv)) to check for equal loading. The hybridization was 
carried out according to a method based on that o f Goldberg et al. (1979) (chapter II 
4(ii)). After post hybridization washing the filters were exposed to X ray film for 
1 - 3  days.
In situ hybridization
Human osteoblast-like cells were trypsinized as described above and seeded at a density 
of 3000 /spot on multiwell slides for in situ hybridization. After 24 hours the cells 
were treated with 1, 25 D 3  or incubated with medium for a further 12 hours, then 
washed with PBS and fixed in 4% paraformaldehyde/PBS for 5 mins. The slides were 
then dehydrated through an ethanol series and stored for up to 1 month at -20°C prior 
to hybridization. The TGFp RNA probe was generated from the linearized 
pGHTGFB-27 plasmid which contained a 300 base pair region of the cDNA. Sense 
and antisense transcripts were prepared using SP6  and T7 RNA polymerase promoters 
(see chapter VI.3). The specific activity of the RNA probes was checked to prove they
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were comparable (chapter II.4(i)). The length of both probes were verified by vertical 
polyacrylamide gel electrophoresis (chapter II 2(vi)) to check that the majority of the 
transcripts were of full length. The in situ hybridization of the TGFp riboprobe was 
carried out as described in chapter II 4(iii) with the following modifications: the 
demineralisation step was omitted as there is no mineral present in these cultures, and 
the proteinase K treatment was shortened to 5 mins as the cells contained far less 
protein than the tissue sections.
Immunolocalization
For immunolocalization studies the cells were stained using a murine TGFp monoclonal 
antibody (as described in chapter II.l(iv)).
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III.4 RESULTS
Northern blot analysis demonstrated that human osteoblast-like cells were capable of 
expressing TGFp mRNA in culture. Figure III.2 shows the expression by osteoblast­
like cells from 6  different donors. Although the amount of TGFp expression varied 
according to the donor, mRNA was detected in every population of bone cells studied 
(>30 donors). Two mRNA species were usually detected, the predominant species 
being a 2.5 kb transcript encoding for TG Fpl, a second 4.5 kb species encoding 
TGFP2  was also detected due to the cross reactivity of the TGFpi probe. In certain 
cases a third mRNA species of approximately 7.2 kb encoding for TGFp3  (see fig
III.5) was detected in the bone cell populations, but this was very unusual.
The expression of TGFp! by human bone cells was confirmed by in situ hybridization 
studies. Fig III.3 shows that the entire population of human osteoblast-like cells 
constitutively expressed TGFpi mRNA in culture. Since the presence o f TGFp\ 
mRNA does not confirm the synthesis of TGFpl protein, immunolocalization studies 
were undertaken to confirm the expression of TGFp at the protein level. Figure III.4 
shows a population of human osteoblast-like cells expressing TGFp protein. It must 
be noted that approximately 2 0 % of the cells seemed to be expressing the protein in 
comparison to the entire population expressing the TGFp mRNA. Figure III.4b shows 
a high magnification photograph of a human osteoblast-like cell expressing TGFpi. 
The staining can be seen to be perinuclear, which is typical for a secretory protein 
whose secretion has been blocked at the Golgi apparatus.
After the confirmation that human osteoblast-like cells were capable o f producing 
TGFp, a study was undertaken to determine which cytokines and osteotropic factors 
modulated the expression of TGFp mRNA in these cells. The systemic hormone
1,25 D 3  had been shown previously to increase the amount of TGFp activity in tissue 
culture supernatants from rat osteoblast-like cells in culture (Pfeilschifter and Mundy, 
1987). Therefore the human osteoblast like cells were treated with 1,25 D 3  at 10_8M a 
concentration which had previously been shown to induce alkaline phosphatase activity
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in these cells. Figure III.5 shows that 1,25 D3  treatment gives rise to an increase in 
TGFpi mRNA expression, the induction was fairly small (approximately 3 fold), but 
highly reproducible (5 out of 6  donors). The increase in TGFp mRNA was detectable 
after six hours in most cases, with expression reaching a peak at eight hours, after 1 2  
hours the level decreased to below basal expression (Fig III.6 ). There was some 
variability in the time courses for the 1,25 D3  stimulation. The overall trend in cells 
from different donors was similar, but in some cells the mRNA levels took longer to 
peak and longer to return to a basal expression. Cells were treated with 1,25 D3  for 48 
hours to monitor the effect of this agent on protein synthesis, however there was no 
increase in the number of cells expressing TGFpl in the population (data not shown).
Retinoic acid (10'8 M) is known to act as a differentiating agent in certain osteoblastic 
cell lines (Heath et al. 1989), therefore its effect on TGFp mRNA expression was 
investigated. It had no effect on TGFpi mRNA expression (Fig III.5, lane 2) at 
concentrations which had previously been shown to affect osteoblast activity (Evans, 
unpublished observations).
Parathyroid hormone has been shown to be an important factor in modulating the 
expression of several proteins by osteoblast-like cells. In this study parathyroid 
hormone was shown to be an effective stimulus for TGFpi mRNA expression. 
Treatment of cells with 10'7M PTH for six hours resulted in a 9 fold increase in TGFpi 
mRNA (Fig. III.7). The effect was apparent after six hours, but not sustained, with 
the mRNA levels returning to control levels after 12 hours. It is interesting to note that 
both 1,25 D 3  and PTH have a very similar time course of stimulation with an effect 
being detected after 6 - 8  hours in both cases.
The expression of TGFpl mRNA was completely inhibited by treatment with (10'7 M) 
hydrocortisone (Fig. III.8 , lane 3). When 1,25 D 3  was added in conjunction with
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hydrocortisone the suppression was partially alleviated (Fig III.8 , lane 1) and the 
mRNA level was restored to approximately 70% of the stimulated level.
There is much evidence to suggest that the sex hormone status of an individual 
influences bone mass, particularly in postmenopausal females (Lacey et al. 1991). 
Therefore the effect of 17-p oestradiol treatment on TGFp mRNA was monitored. This 
agent gave rise to a 6  fold increase in TGFp mRNA expression after 8  hours, with 
TGFp mRNA levels returning to basal expression after 24 hours (Fig. III.9). The 
modulation showed a biphasic concentration effect at physiological doses, l x l 0 10M 
was the most effective concentration in stimulating expression, with l x l 0 8M giving a 
slight inhibition of expression (Fig. III. 10).
It has been reported that TGFp is able to autoregulate its own expression (Kim et al. 
1990). Cells treated with lOOpM TGFp in serum free culture showed a small increase 
in TGFp mRNA expression after six hours (Fig. III. 11). The lower dose of lOpM, 
although capable of stimulating proliferation in these cells (Fig. III. 12) did not increase 
TGFp expression.
The "inflammatory cytokines " were screened to determine whether they modulated 
TGFp mRNA expression in human osteoblast-like cells. Treatment of the cells with 
IL -la  (200pg/ml) resulted in no increase in TGFPi mRNA, which remained at the 
basal level (Fig III. 13, lane 2). Tumour necrosis factor alpha also did not appear to 
modulate TGFp expression over a 24 hour timecourse (Fig III. 14). The non specific 
inducer of inflamatory responses, LPS also did not have any effect on TGFpi mRNA 
expression (Fig 12 lane 3).
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III.4 FIGURES
Figure III.2. The constitutive expression o f TGFp m RN A  by hum an osteoblast-like 
cells in culture. Total RNA was extracted from  osteoblast-like cells derived from  six 
different donors (LANES 1 ~b (chapter 2). Ten m icrogram s o f total RNA was loaded 
in each lane o f the Northern blot. Two mRNA transcripts are p re s e n t: the predom inant 
species is 2.5 kb (large arrow ) and encodes T G F p i; the second  tran sc rip t o f  
approxim ately 4.2 kb (small arrow) encodes TGFp2 . The figures 18 and 28 refer to the 
positions o f the 18s and 28s ribosom al bands. These transcripts are approxim ately 2 




Figures III.3a and III.3b. In  situ  hybridization o f TGFp m RN A  in human osteoblast­
like cells.
The in situ  hybridization was carried  out as described  in M aterials and M ethods. 
G rains represent binding o f  the antisense probe. The entire population o f osteoblasts 
expressed TGFp mRNA. Figure 3b shows that very little non-specific hybridization is 
observed with the sense negative control probe.
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X100
Figures III.4a and III.4b. Im m unolocalization o f TG Fp protein in hum an osteoblast­
like cells in culture. Cells were cultured as described in M aterials and M ethods, and 
stained for endogenous alkaline phosphatase activity (blue stain). TGFp expression 
(pink stain) was detected by using a m ouse m onoclonal antibody with an alkaline 
phosphatase conjugated secondary antibody. Figure III.4b is a higher m agnification 
photograph o f a single cell and show s the p erinuc lear stain ing  associated  with 




Figure III.5. The induction o f TGFp m RNA by 1,25-dihydroxy vitam in D 3 .
Northern blot analysis was carried out on total RNA prepared as described in M aterials 
and M ethods. Ten micrograms o f  total RNA was loaded on each lane.
Lane 1 shows the treatm ent with lO '^M  1,25-dihydroxyvitam in D 3 for 8  hours. Lane 
2 shows the treatm ent with K h^M  retinoic acid for 8  hours. Lane 3 show s untreated 
cells. Note the presence o f a TG FP3  transcript (arrow). All lanes w ere norm alized 












Figure III.6 . The time course for 1,25-dihydroxyvitamin D 3  induction of TGFp 
mRNA. Total RNA was prepared from cells treated with 10'8M 1,25 D 3  for 4, 8  , 12 
and 24 hours. The RNA was then loaded onto a dot blot and hybridized with a TGFPi 
probe. The mRNA was then quantified with a scanning densitometer. Each point 
















Figure III.7. Induction o f TGFp m RNA with 1,25 D 3 and parathyro id  horm one. 
M essenger RNA was quantified in the sam e m anner as for figure III.6 . The data 
shows a direct com parison between treatm ent with 1,25 D 3 (10"8 M) and parathyroid 
hormone (10_7 M) for 6  and 12 hours on the same donor's cells .
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Figure III.8. The effect of hydrocortisone on TGFPi mRNA expression.
Northern blot analysis was carried out on total RNA prepared as described in M aterials 
and M ethods. Ten micrograms o f total RNA was loaded on each lane.
Lane 1, treatm ent with both 10_8M  hydrocortisone and 1,25 D 3 for 6  hours. Lane 2, 
trea tm en t w ith  10-8M  1,25 D 3 fo r 6  hours. L ane 3, trea tm en t w ith  1 0 '8M 
hydrocortisone for 6  hours. Lane 4, no treatm ent. All lanes were norm alized using a 
p-actin cDN A probe, as shown in the panel below.
101
Figure III.9. The induction o f TGFp m RNA by 17-p oestradiol.
Slot blot analysis was carried out on total RNA prepared as described in M aterials and 
M ethods. The top slot contains 5 ug o f total RNA, vertical slots below  represent two 
fold serial dilutions o f the samples.
Lanes 1 and 6 : no treatment at 6  and 24 hours respectively.
Treatm ent with 17-p oestradiol ( lO 9  M) for 6 , 8 , 12, and 24 hours (lanes 2, 3, 4  and 5 
respectively). All lanes were norm alized using a p-actin cDNA probe, as shown in the 
panel below.







Figure III. 10 Effect of 17-p oestradiol dose on induction of TGFp mRNA 
Total RNA was prepared from cells treated with 10‘^M, 10'^M, lO ^ M , 10_11M and 
10"12M 17-p oestradiol for 9 hours. The RNA was then loaded onto a Northern blot 
and hybridized with a TGFp probe. The mRNA hybridization signal was then 
quantified with a scanning densitometer. Each point represents a densitometry reading 
corrected for loading differences with a p-actin cDNA probe.
0 - 8  -9 -10 -11 -12
Concentration of 17-p oestradiol (log M)
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Figure HI. 11. Autocrine induction o f TGFp m RNA in hum an osteoblast-like cells. 
Total RNA was extracted from  cells as described in M aterials and M ethods, 5 ug were 
loaded  into the top dot o f the m anifold, subsquent vertical dots represent tw o fold  
dilutions o f the RNA sample.
Lanes 1 and 6 : untreated cells a t 6  and 12 hours, lanes 2 and 3 treatm ent with lOpM  
TGFp for 6  and 12 hours respectively. Lanes 4 and 5 treatm ent with lOOpM TGFp for 
6  and 1 2  hours respectively.
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Figure m .12. The effect of TGFp on the proliferation of osteoblast-like cells in culture. 
The proliferation assay was carried out as described in chapter 2. Purified TGFp was 
added in doses ranging from 1 pM to 1000 pM to triplicate wells of cells for 24 hours, 
after which the cells were "pulsed" with luCi of tritiated thymidine for 6  hours. After 
the pulse period the cells were lysed and the radioactive DNA harvested and quantified 
by liquid scintillation counting. ** and *** denote degree of significant differences 
between control and treatments as judged by the Student's T -te s t. ** = p< 0.01 and 
*** = pcO.001. Vertical bars represent standard errors.
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Figure III. 13. The effect o f IL - la  and LPS on TGF(i mRNA expression.
Northern blot analysis was carried out on total RNA prepared as described in M aterials 
and Methods. Ten m icrograms o f total RNA was loaded on each lane.
Lane 1, no treatment. Lane 2, 200pg/ml IL -la  for 6  hours. Lane 3, 5(X)ng/ml LPS for 
6  hours. All lanes were normalized using a (3-actin cDNA probe, as shown in the panel 
below.
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iFigure III. 14. The effect o f T N F a on TGFp m RN A  expression.
T otal RNA w as extracted from  cells as described in M aterials and M ethods. F ive 
m icrogram s o f RNA were loaded into the top dot o f the m anifold, subsequent vertical 
dots represent two fold dilutions o f the RNA sample.
Lane 1 and 5 untreated cells at 6 and 24 hours, lanes 2, 3, and 4 treatm ent with lTr^g/ml 
T N F a for 6 , 12, and 24 hours respectively. All lanes were norm alized using a p-actin 
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TIT.6 DISCUSSION
The data presented, obtained using a variety o f recombinant DNA techniques, 
demonstrates that mature human osteoblast-like cells are capable of expressing TGFPi 
mRNA. It is interesting to note that human osteoblast-like cells constitutively 
expressed TGFp mRNA, as opposed to transient expression which is typical of many 
cytokines. This may be due to the fact that TGFp is secreted as an inactive propeptide.
TGFp mRNA was detected in all the osteoblast-like cells in the population, in contrast 
with the finding that only 20% of the cells expressed TGFp protein. This observation 
suggests there may be some post-transcriptional control mechanism. Such a 
mechanism could be important in the microenvironment of remodelling. For example, 
it may be advantageous that only certain populations of osteoblasts synthesize TGFp 
protein at any one time. Using this mechanism TGFp deposition in the bone matrix by 
osteoblasts could be controlled in a highly localized manner.
Various cytokines and osteotropic factors were investigated to determine whether they 
modulated the expression of TGFp mRNA. Generally the factors fell into two groups: 
TGFp mRNA levels were induced by the systemic hormones 1,25 D 3 , 17-p oestradiol 
and parathyroid hormone, at physiological concentrations, but remained unaffected by 
the cytokines IL -la  andTNFa at concentrations which previously had been shown to 
stimulate proliferation and prostaglandin release in these cells. Retinoic acid, an agent 
implicated in the maturation of osteoblasts, failed to induce TGFp mRNA in 
physiological conditions in contrast to 1,25 D3  which is also a differentiating agent.
The increase in TGFp mRNA following 1,25 D 3  treatment was not very great when 
compared with the large increase obtained by PTH stimulation. This may suggest that 
the increase is due to a secondary phenomenon, and may not be directly biologically 
relevant. The slight differences in time courses for the 1,25 D3  induction of TGFp 
mRNA may be due to the fact that the bone cells derived from different donors contain 
populations of cells at different stages of differentiation. Alternatively, since some of
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the bone was obtained from very old donors, it is possible that some populations of 
osteoblast-like cells could have reached a more senescent stage of their life cycle, 
making them slow to respond to modulatory agents.
Kim et al. (1990) reported that TGFp expression is autoregulated in the human 
adenocarcinoma cell line A-549. The data from this study also suggest that TGFp may 
have an autocrine role in human bone cells. This would be a very good mechanism 
for amplifying a "bone formation signal" for human osteoblasts. The increase in 
transcription of TGFp mRNA would not only result in more synthesis of TGFp protein 
to create a cascade in TGFp expression, but the increased TGFp would also promote 
osteoblast proliferation and matrix synthesis. It is important to realise that the cascade 
can only occur if the TGFp is activated in the osteoblast microenvironment or if it is 
synthesized in an active form. Western blotting of human osteoblast-like cell culture 
supernatants would determine whether these cells are capable of secreting active TGFp.
The mitogenic nature of TGFp on connective tissue cells is postulated to be due to a 
PDGF autocrine loop (Battegay et al.1990). At low doses TGFp increases PDGF-AA 
release and expression of PDGF receptor subunits. These two effects result in a net 
increase in connective tissue cell proliferation. At high concentrations PDGF-AA is 
further increased, but a net inhibition of proliferation is observed because PDGF 
receptor is down-regulated by high PDGF-AA concentrations. The possibility of two 
autocrine loops being superimposed in human osteoblast-like cells gives rise to a 
massive potential increase in any signal that promotes TGFp expression.
In agreement with studies in other cell types (Waage and Nakke, 1991), hydrocortisone 
markedly decreased the expression of TGFPi mRNA in human osteoblast-like cells. 
Interestingly, the addition of 1,25 D 3  to hydrocortisone treated cells results in a partial 
reduction of the inhibitory effect. This may suggest that 1,25 D 3  is competing with the 
hydrocortisone for some DNA regulatory element of TGFp transcription.
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It is interesting to speculate by which mechanisms the agents modulate the expression 
of TGFp by osteoblast-like cells. It seems likely for the steroid like molecules that 
transcriptional control occurs at the DNA level in the nucleus. Using the criteria 
outlined by Evans et al. (1988), a steroid binding consensus sequence has been 
identified in the regulatory region of the TGFpi gene (M etcalf, personal 
communication). It is also possible that these agents may act by firstly inducing the 
synthesis of a trans-acting factor which then increases TGFp mRNA expression. It 
has been shown for example that treatment with TGFp stabilizes type I procollagen 
mRNA by inducing the synthesis of a trans-acting factor (Raghow et al. 1987).
The finding that TGFp expression in human osteoblast-like cells is increased by 17-p 
oestradiol treatment may have very important consequences in understanding post 
menopausal osteoporosis. The thinning of bone mass associated with this disorder is 
thought to be due to decreases in circulating oestrogen levels. It is possible that 
decreased oestrogen levels might reduce the synthesis of TGFp by human osteoblasts. 
Less TGFp would then become incorporated into the bone matrix and might lead to 
impaired coupling in subsequent remodelling cycles.
The data presented supports the hypothesis that the systemic hormones may be 
important regulatory agents for cytokine synthesis in bone. This study demonstrates 
that all the systemic hormones studied: 1,25 D 3 , PTH, hydrocortisone and 17-p 
oestradiol modulate TGFp mRNA expression. This suggests that the endocrine status 
of an individual may regulate TGFp expression by human osteoblasts and act as 
another regulatory mechanism in the bone remodelling cycle. Since systemic hormones 
are not locally produced and their levels do not fluctuate quickly, it is likely that they 
have a role in bone formation rather than resorption.
It is conceivable that there are different levels of control of bone cell activity. Thus, a 
TGFp-like factor would be produced and incorporated into the bone matrix throughout 
the skeleton over a prolonged period under the influence of the endocrine system of the 
individual. It may then be activated at a much later time in a highly localized fashion
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(such as under an osteoclast). Indeed, Finkelman et al. (1991) have shown that vitamin 
D deficiency causes a selective reduction in the amount of TGFp in rat bone matrix. A 
similar selective depletion in TGFp content in the bone matrix has also been 
demonstrated in ovariectomized mice.
Finally, it is important to realise that these studies look at the modulation of one factor 
after treatment with another factor, this may only highlight a small fraction of all the 
interactions taking place at any one time. It is therefore incorrect to equate mRNA 
levels directly with bioactivities, as other inhibitors and trans acting factors may also be 
present.
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C h a p t e r  W  : Tfve e x p r e s s io n  o f  X L -1 




IL-1 was the first immune cytokine to be positively identified as having an important 
action in the control of bone turnover. IL-1 expression by osteoblasts from several 
species has been documented. This study was undertaken to characterise human 
osteoblastic IL-1 expression and to investigate the mechanisms by which this important 
cytokine is modulated.
The expression of mRNA for IL-1 was studied in human osteoblast-like cells in vitro. 
These cells did not constitutively express either IL -la  or IL-lp mRNA. The cytokines 
IL - la  (200pg/ml), TNFa (17ng/ml) and the bacterial lipopolysaccharide (LPS) 
(500ng/ml) stimulated the production of IL -lp  mRNA, but not IL -la  mRNA. The 
maximal stimulation o f IL -lp  mRNA occurred after 6 - 8  hours, the mRNA then 
quickly fell to undetectable basal levels. This was followed by an increase in protein 
production after 24 hours. IL-lp mRNA expression was detected at the cellular level, 
using in situ hybridization techniques. Immunolocalization studies confirmed that a 
small proportion of the total population of human osteoblast-like cells were expressing 
IL-1 protein.
Treatment of the cells with the systemic hormones 1,25 D 3  (10_8 M), 17-p oestradiol 
(10*7  -10_1 2 M) and parathyroid hormone (PTH) (10_7 M) did not affect the production 
of IL -lp mRNA. Retinoic acid (10_8 M), an osteoblast differentiation agent, also had 
no effect on IL -lp  mRNA expression. The addition of hydrocortisone (10 '8 M), 
resulted in the complete suppression of IL-la-induced IL-lp mRNA expression.
The human osteoblast-like cells were also screened to determine whether they 
expressed IL-1 antagonist protein (IRAP) mRNA. No IRAP mRNA was detected in 
untreated cells, or in cells stimulated with the cytokines; IL -la , TNFa, TGFp, or 
LPS. The systejnic hormones; 1,25 D 3 , 17-p oestradiol, hydrocortisone and PTH 
also failed to affect the expression of IRAP mRNA.
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IV.2 INTRODUCTION
Interleukin 1 (EL-1) exists in two forms termed IL -la  and IL-lp, which are structurally 
related and bind to the same receptor (March et al. 1985). Although the two proteins 
share only small stretches of amino acids and are not highly homologous (26%), they 
have similar actions on a wide range of cellular targets. The genes for both forms are 
located on chromosome 2 and consist of seven exons (Clark et al.1986; Furutani et 
al.1986). The coding sequence encodes a 31 kDa precursor form which must be 
enzymatically cleaved to give the active 17 kDa species.
A third member of the IL-1 gene family has been recently identified, which shows IL-1 
antagonist activity, namely IRAP (IL-1 receptor antagonist protein) (Eisenberg et 
al.1990; Mazzei et al. 1990). This 26 kDa protein was initially purified from culture 
supernatants of IgG stimulated monocytes, and has been shown to block IL-1 activity 
by binding to the IL-1 receptor (Arend et al.1989). In common with the other members 
in the family IRAP is only slightly structurally related, it is 26% homologous with 
IL -lp , and 19% with IL -la  (Arend et al.1989). Other non characterised high 
molecular weight IL-1 inhibitors exist, including a 98kDa protein released by human 
gingival epithelial cells (Walsh et al.1987), and a 40kDa factor produced by u.v 
irradiated murine epidermal cells (Schwarz et al.1987).
IL-1 is synthesized by a wide variety of cells. These include; those of connective tissue 
origin such as synovial fibroblasts, keratinocytes, fibroblasts and chondrocytes; 
immune cells including B cells, T cells, NK cells, monocytes, macrophages and 
neutrophils; and cells of neuronal origin, astrocytes, microglia and glioma cells (for 
review see Dinarello, 1988). The stimulus required for EL-1 synthesis varies according 
to the cell type, but includes cytokines (Littlewood et al.l991a), infectious agents such 
as bacteria and viruses (Giovine and Duff, 1990), and even inorganic substances such 
as bone fragments (Pacifici et al.1990).
Evidence has recently been presented which suggests that different activation signals 
are required for the expression of EL-la and IL-lp genes (Hurme and Serkkola, 1991).
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A study with human peripheral monocytes showed that in contrast with LPS, which 
induced the production of high levels of both IL -la  and IL-lp, the protein kinase C 
activator phorbol myristic acid (PMA) induced only IL-lp synthesis. Nuclear "run 
o ff ' assays revealed that protein kinase C activation alone was sufficient for the 
induction of the IL -lp  gene, but not the activation of IL -la  transcription. The 
proportion of IL -la  to IL-lp produced is dependent on the cell type and in the majority 
of cases IL-lp seems to be synthesized in a great excess to IL -la  (Auron et al.1984). It 
has been suggested that IL -la  is not secreted like IL-lp, but may remain associated 
with the cell membrane (Auron et al.1984). The concept of a membrane bound form of 
IL-1 is thought to explain the ability of IL-1 to participate in localized paracrine and 
autocrine events (for example antigen presentation), without inducing systemic effects. 
IL-1 was one of the earliest cytokines to be identified as having a regulatory role in 
bone cell function, and remains the most potent bone resorbing agent so far described 
(see chapter I for review). It was postulated that the resorption was mediated by an 
increase in osteoclast numbers, rather than an increase in the activity of existing 
osteoclasts, since there was a 24 hr "lag phase" between EL-1 stimulation and enhanced 
resorption (Gowen et al.1986). This idea prompted a study to determine the effect of 
EL-1 on osteoclast formation in long term marrow cultures. Both EL-la and EL-ip were 
shown to stimulate the formation of multinucleated cells in a similar manner to CSFs, 
ie. they were only required to be present during the initial week of the 3 week culture 
period (Pfeilschifter et al.1989). It is also possible that IL-1 stimulated resorption is 
mediated via other cell types. Studies by Thomson et al (1986) showed that isolated 
osteoclasts were only capable of resorbing devitalized bone in the presence of cells of 
the osteoblast lineage. They postulated that IL-1 induces the synthesis of an osteoclast 
activating factor (OAF) by the osteoblasts, although no such factor has ever been 
unequivocally identified.
Anabolic effects of IL-1 in bone metabolism have also been documented. IL-1 has 
been shown to stimulate proliferation in primary cultures of human osteoblasts (Evans
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et al.1990). This finding was supported by Rickard et al. (1991) who used a method 
which involved tritiated thymidine labelling to reveal proliferation, in conjunction with 
the osteoblastic marker alkaline phosphatase. This method revealed that IL-1 
stimulated the proliferation of a specific preosteoblast population. In contrast, the 
proliferation of other osteoblastic cell lines including normal mouse 3T3-E1 cells and 
the osteosarcoma line MG63, is reported to be inhibited by IL-1 treatment (Hanazawa et 
al.1986; Dedhar, 1989). IL-1 has also been shown to be inhibitory in an in vitro 
model of bone formation. Long term EL-1 treatment of cultures of fetal rat osteoblastic 
cells, resulted in a decrease in the number of spontaneously formed mineralised 
nodules (Stashenko et al.1987).
The effects of EL-1 on the synthesis of bone proteins seems to be bidirectional. IL-1 
has been shown to increase collagen synthesis in organ cultured bones (Canalis et 
al.1986), but decrease 1,25 D 3  stimulated production of osteocalcin in human 
osteoblast-like cells (Evans et al.1989). In addition, both basal and 1,25 D 3  induced 
alkaline phosphatase expression by human osteoblast-like cells is reduced by IL-1 
treatment at low doses (Evans et al.1989). Overall IL-1 seems to suppress the 
expression of a differentiated osteoblastic phenotype whilst promoting the proliferation 
of osteoblast precursors. Possibly this might be a mechanism whereby bone formation 
is coupled to IL-1 induced resorption.
IL-1 has also been implicated in a number of bone diseases such as osteoporosis and 
myeloma. Peripheral monocytes from patients with a high rate of bone turnover 
associated with osteoporosis, have been shown to release more IL-1 than those patients 
with low bone turnover (Pacifici et al.1987). Additionally Pioli et al. (1989) 
demonstrated that mononuclear cells from patients with Pagets disease when stimulated 
with LPS in vitro released more IL-1 than age matched controls. However the 
relevance of systemic levels of EL-1 to diseased states is questionable, therefore it was 
important to note that blood cells removed from the illiac crest of these patients also 
spontaneously released IL-1. Finally, IL-1 has been implicated with the local bone
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destruction that is often associated with myeloma. Myeloma cells from some patients 
with local bone damage have been shown to release large amounts of IL-lp (Kawano et 
al.1988).
Preliminary reports have shown that human osteoblast-like cells are capable of 
producing a factor with IL-1-like activity (Hughes et al.1988; Keeting et al.1989), 
although this factor has not been identified. Studies on cytokine release from 
osteoblasts of various species show that cytokine expression is often regulated in a 
species or cell line specific fashion. For example it has been shown that IL - 6  
expression is stimulated by PTH in rat, but not human osteoblast-like cells (Feyen et 
al.1989; Littlewood et al. 1991b). For this reason human osteoblast-like cells were 
studied to verify the production of IL-1 by human osteoblasts, and to determine how 
the expression of IL-1 mRNA is modulated by a range of osteotropic hormones and 
cytokines. Human osteoblast-like cells derived by outgrowth from trabecular bone 
obtained at surgery were cultured in vitro. These cells have been widely used for many 
years as a model of human osteoblasts, and most recently to study cytokine production 
(Gowen et al. 1990). Using this approach it was hoped to gain a greater insight into the 
complex signalling between cell types during human bone remodelling.
IV.3 METHODS AND MATERIALS 
Northern and slot/dot blots
Human osteoblast-like cells were obtained from explants of bone (as described in 
chapter II.l(i)), and were prepared as described in chapter III.2. For the Northern and 
slot blot experiments 1 0  - 1 2  petri dishes of osteoblast-like cells were used for each 
experiment. All treatments were undertaken in a synthetic serum-free medium 
(lxM EM , 0.1% BSA, lOug/ml transferrin, lug/ml insulin, 3 x l0 '8M sodium selenate, 
ImM glutamine, lOOU/ml penicillin /streptomycin), since serum contains components 
such as a 2  macroglobulin which have been shown to bind a spectrum of different 
cytokines. After treatment, the medium was removed from the petri dishes and stored
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at -20°C for the IL-1 bioassay (see chapter Il.l.(ii)). The RNA was harvested as 
described in chapter III and purified according to a method based on that o f 
Chomininski et al. (1987) (see Chapter II 2(i)). Routinely 2 petri dishes were used per 
treatment, yields of approximately 30 - 50 ug RNA /lx lO ' 6  cells were normally 
obtained.
The IRAP probe was prepared from a plasmid construct (pGEM-IRAP-P5) which 
contained a 1.8 cDNA fragment of the coding sequence. The cDNA insert was 
liberated by using the restriction enzyme EcoRl (see Chapter 2 for restriction digests), 
and "gene cleaned" before random hexanucleotide radiolabelling.
The Northern blots and slot/dot blots were carried out as described in chapter II, 2(ii) 
and 2(iii) . Total cellular RNA (10 ug) was used per lane for Northern blots, and 5ug 
for the highest concentration in slot blots. All filters were stained with methylene blue 
(see chapter II 2(iv)) to check for equal loading. The hybridization was carried out 
according to a method based on that of Goldberg et al. (1979) (chapter II 4(ii)). After 
post hybridization washing, the filters were exposed to X-ray film for 1 - 3  days.
In situ hybridization
Human osteoblast-like cells were trypsinized and seeded at a density of 3000 /spot on 
multi well slides for in situ hybridization. After 24 hours the cells were treated with 
IL -la  (200pg/ml) or incubated with media for a further 6  hours, then washed with PBS 
and fixed in 4% paraformaldehyde/PBS for 5 mins. The slides were then dehydrated 
through an ethanol series and stored for up to 1 month at -20°C prior to hybridization. 
The IL-lp RNA probe was generated from the linearized pgem2illbeta plasmid which 
contained a 300 bp section of the cDNA. Sense and antisense transcripts were prepared 
using SP6  and T7 RNA polymerase promoters (see chapter VI.3). The specific 
activities of the RNA probes were checked to prove they were comparable (chapter II 
4(i» . The length of both probes were verified by vertical polyacrylamide gel 
electrophoresis (chapter II 2(vi)) to check that the majority of the transcripts were of full
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length. The in situ hybridization of the IL-lp RNA probe was carried out (as described 
in chapter III 4(iii))
Immunolocalization
For immunolocalization studies the cells were stained using a murine IL-lp monoclonal 
antibody (as described in chapter n  l(iv)).
IL-1 bioassav
The IL-1 bioassay was carried out as described in Chapter II l(ii). Cell supernatants 
were obtained from the Northern blot experiments (lx l06/dish) and cultures of 48 well 
dishes, which had been seeded with bone cells from the same donor (ZxK^/well). 
Triplicate wells were assayed in duplicate for the 48 well plate cultures.
Preparation of peripheral blood polymorphonuclear cells (PBMCsI from human blood 
Peripheral blood (30 ml) was obtained from normal healthy volunteers, and dispensed 
into heparinized (lOOu/ml) tubes. After diluting 1:1 with sterile PBS, the blood cells 
were separated by density-gradient centrifugation on Ficoll-hypaque. The mononuclear 
cell layer was extracted from the serum/Ficoll-hypaque interface. Cells were washed 
tw ice in m edia (lxR P M I, 10%FCS, Im M  glutam ine, lOOU/ml penicillin  
/streptomycin), and resuspended at a density of lxlOfyml. For the IRAP studies cells 
were dispensed into T25 culture flasks and treated with PMA (InM) or left untreated. 
Subsequently, an aliquot of PMA stimulated cells were stimulated with 500ng/ml LPS. 
Finally the PBMCs were harvested by centrifugation, and lysed in guanidine chloride 
solution for RNA extraction.
IRAP induction in U937 cells
U937 cells were dispensed at a density of 2x l06/ml into T25 culture flasks. The cells 
were treated with PMA for 48 hrs, which induced the cell suspension to differentiate
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into adherent cells. After this period the cells were treated with 500ng/ml LPS for a 
further 6  hours. The adherent cells were then harvested into guanidine hydrochloride 
solution with a sterile scraper for RNA extraction.
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IV.4 RESULTS
Northern blot analysis showed that there was no constitutive expression of IL -lp or 
IL -la  mRNA in human osteoblast-like cells. Messenger RNA for type I collagen (a 
bone matrix protein) was detected in large amounts (see figure IV. 1), which confirmed 
that the cells were actively metabolising. No IL -la  mRNA expression was detected in 
the cells from more than 10 donors either with or without IL-1 stimulation (data not 
shown). IL-lp mRNA was detected when the human osteoblast-like cells were treated 
with EL-la (200pg/ml) or the bacterial polysacharide LPS (500ng/ml) (see figure IV.2). 
Treatment with IL -la  gave a 20 fold increase in IL-lp mRNA after 6  hours. LPS was 
a less potent stimulating agent, giving rise to a 5 fold increase in IL-lp mRNA over the 
same time period.
A bioassay for IL-1 using the D 1 0 N4 M cell line was optimized. A typical standard 
curve obtained with rhIL-lp is shown in figure IV.3. This assay was used to quantify 
the amounts of IL-1 bioactivity produced by the LPS stimulated human osteoblast-like 
cells. There was a lag phase between IL-1 mRNA expression and the synthesis of 
EL-1 protein (compare fig IV.2 lane 2, and fig IV.4). EL-1 bioactivity was detectable at 
12 hours and rose over a 48 hour time period. The amount of IL-1 bioactivity detected 
in the supernatants from LPS stimulated cells was very low (see figure 4).
The expression of IL-lp mRNA was confirmed at the cellular level by in situ 
hybridization. Figure IV.5a shows human osteoblast-like cells that have been 
stimulated IL -la  (200pg/ml) for 6  hours then hybridized with an IL-lp RNA probe. 
All the cells in the population were seen to express IL-lp mRNA. A sense IL-lp RNA 
probe was used as a negative control and gave very low levels of background 
hybridization (see figure IV.5b).
Immunolocalization studies were undertaken to confirm the expression of IL -lp at the 
protein level. The cells were treated with 0.5uM monensin which had previously been 
shown to increase IL-1 production (Rubartelli et al.1990). IL -lp  expression was
1 2 2
detected in a very small proportion of the human osteoblastic cells (see figure IV.6 a). 
The staining appeared to be perinuclear, and there was also some staining on the cell 
membrane (see figure IV.6 b for high magnification photograph).
Another "inflammatory" cytokine TNFa (17 ng/ml) induced a transient increase in 
IL -lp  mRNA. A peak in IL-lp mRNA expression was detected after 8  hours (figure
IV.7), which fell sharply to basal levels after 12 hours. There was a lag phase between 
peak IL-lp mRNA expression and protein synthesis, since IL-1 bioactivity was not 
detected until 24 hours after stimulation (figure IV.8 ). Again the amount of IL-1 
bioactivity that was detected was very low. In contrast, treatment with another cytokine 
TGFp (10 - 100 pM) failed to induce IL-lp mRNA expression over a 24 hour time 
course (data not shown).
The systemic hormones had previously been shown to modulate TGFp expression in 
human osteoblast-like cells (see chapter III). Therefore their effect on IL-lp mRNA 
expression was investigated. 1,25 D 3 , PTH, and 17-p oestradiol treatments failed to 
stimulate IL-lp mRNA expression, which remained at a basal undetectable level (data 
not shown). Treatment with hydrocortisone, which had previously been shown to 
abrogate cytokine expression, resulted in the complete suppression of IL-la-induced 
IL -lp mRNA expression (figure IV.9).
Since the stimulated-IL-lp mRNA levels appeared to be fairly abundant, but the 
bioactivity levels were low, populations of human osteoblast-like cells were screened 
for IRAP mRNA. It was thought that the IRAP might be interfering with the D 1 0 N4 M 
bioassay and giving artificially low IL-1 bioactivities. Conditions which induced IRAP 
expression in human peripheral blood mononuclear cells (PBMCs) and U937 cells, 
failed to stimulate IRAP mRNA expression in human osteoblast-like cells (see figure
IV. 10). No IRAP mRNA expression was detected in cells treated with the cytokines 
I L - la ,  IL -lp , TN Fa, TGFp or the lipopolysacharide LPS (data not shown). 
Additionally the systemic hormones 1,25 D3  (1 0 8 M), PTH (10_7 M), 17-p oestradiol 
(10 7  - 10*1 2 M) and hydrocortisone (10*8 M) failed to induce the expression of IRAP
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mRNA (data not shown). Populations of human osteoblast-like cells from over 10 
different donors were screened and none expressed IRAP mRNA.
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IV.5 FIGURES
Figure IV. 1: The expression of type I collagen mRNA by human osteoblast-like cells. 
Lanes 1, 2, and 3 represent RNA extracted from 3 different populations of bone cells. 
The filter was initially probed for IL-lp and IL -la  mRNA but none was detected. 
Subsequent hybridization with a type I collagen probe reveals high expression of two 




Figure IV.2. The induction of IL-lp mRNA by IL -la  and LPS
Northern blot analysis was carried out on total RNA prepared as desribed in Materials
and Methods, ten micrograms of total RNA was loaded on each lane.
Lane 1 shows the treatment with IL -la  (200pg/ml) for 6  hours. Lane 2 shows the 
treatment with LPS (500ng/ml) for 6  hours. Lane 3 Untreated cells. A 1.8 kb 
transcript characteristic for EL-ip is present in lanes 1 and 2. All lanes were normalized 
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Figure IV.3. Standard curve for IL-1 bioassay
Human recombinant IL-lp was used to obtain a standard curve of IL-1 concentration 
versus D 1 0 N4 M cell proliferation. Each point represents 3 replicate wells, the standard 
curve can be seen to be useful over the range 0. 2 - 20 pg/ml IL-1.
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Figure IV.4: Induction of IL-1 bioactivitv bv LPS






Cell supernatants were assayed for IL-1 bioactivity at 6 , 8 , 12, 24, and 48 hours after 
stimulation with 500ug/ml LPS. The results represent assays in duplicate o f triplicate 
treatment supernatants. The letter c represents untreated cells after 48 hours in culture. 
The vertical bars represent standard errors.
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Figures IV.5a and IV.5b. In situ hybridization of IL-lp mRNA in human 
osteoblast-like cells.
The in situ hybridization was carried out as described in Materials and Methods. 
Grains represent binding of the antisense probe (5a). The entire population of 
osteoblasts can be seen to express IL-lp mRNA. Figure IV.5b shows that very little 
hybridization is observed with the sense negative control probe.
X400
Figures IV.6a and IV.6b. Immunolocalization o f EL-ip protein in human osteoblast-like 
cells in culture. Cells were cultured as described in M aterials and M ethods, and 
stained for endogenous alkaline phosphatase activity (blue stain). IL -lp  expression 
(pink stain) was detected by using a mouse m onoclonal antibody with an alkaline 
phosphatase conjugated secondary antibody. Figure IV .6b is a higher m agnification 
photograph of a single cell and shows the perinuclear and cell m em brane staining.
X1000W
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Figure IV.7. Induction of IL-lp mRNA by TNFa in human osteoblast-like cells.
Total RNA was extracted from cells as described in Materials and Methods. 5ug 
aliquots were loaded into the top slot of the manifold, subsequent vertical slots 
represent two fold dilutions of the RNA sample.
Lane 1 and 6 , untreated cells at 6  and 24 hours. Lanes 2, 3, 4, and 5, treatment with 
17r:g/ml TNFa for 6 , 8 , 12 and 24 hours respectively. All lanes were normalized with 
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Figure IV.8 : TNFa stimulation of the production of EL-1 activity by human osteoblast­
like cells.
Cell supernatants were assayed for EL-1 bioactivity at 12, 24, 36, and 48 hours after 
stimulation with 17r;g/ml TNFa. The results represent assays in duplicate o f triplicate 
treatment supernatants. The letter c represents untreated cells after 48 hours in culture. 
The vertical bars represent standard errors.
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Figure IV.9. The effect o f hydrocortisone on IL-lp mRNA expression.
Northern blot analysis was carried out on total RNA prepared as described in Materials 
and Methods, ten micrograms of total RNA was loaded on each lane.
Lane 1, treatment with IL -la  (200pg/ml) for 6  hours. Lane 2, treatment with both 
IL -la  (200pg/ml) and 10'8M hydrocortisone for 6  hours. Lane 3, no treatment. All 
lanes were normalized using a p-actin cDNA probe, as shown in the panel below.
133
1 2  3 4 5 6  7
Figure IV. 10. Lack of expression o f IRAP m RNA by hum an osteoblast-like cells. 
Northern blot analysis was carried out on total RNA prepared as described in M aterials 
and M ethods, ten m icrograms o f total RNA was loaded on each lane. Each section o f 
the photograph represents 2 N orthern blots which were hybridized together with the 
sam e IRAP probe.
Lane 1, hum an osteoblast-like cells stim ulated w ith LPS. Lane 2, hum an osteoblast­
like cells stim ulated with PM A + LPS. Lane 3, PB M C s stim ulated w ith PM  A + LPS. 
Lane 4, PB M C s stim ulated with LPS. Lane 5, untreated U937 cells. Lane 6, U937 
cells stim ulated with PM A + LPS. Lane 7, U937 cells stim ulated with LPS.
All lanes were normalized using a p-actin cDNA probe, as shown in the panel below.
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IV .6 DISCUSSION
This study confirms that human osteoblast-like cells are capable of expressing both 
IL-lp mRNA and IL-1 bioactivity, suggesting that IL-1 can be produced locally in the 
bone microenvironment without the presence of immune cells.
It was interesting to note that human osteoblast-like cells did not constitutively express 
IL-lp mRNA. This is in contrast to the expression of TGFp mRNA and may reflect the 
fact that IL -1 is released in an active form as opposed to a latent peptide. Indeed, since 
IL-1 is such a potent resorptive agent it is not surprising that it is not constitutively 
expressed.
The amount of IL -1 bioactivity secreted by these cells was comparatively very low, 
since other cell types such as activated monocytes have been reported to express 1 0 , 0 0 0  
times more IL-1 (Dinarello, 1988). However ,the low expression was not surprising 
when it is considered that even though mRNA was detected in the whole population, 
only about 5 % of the cell population seemed to be producing protein. This might be 
due to the fact that the immunolocalization technique was able to detect protein in the 
most highly producing cells only, although this seems unlikely. It has been reported in 
other cell types that the transcription of EL-1 can be initiated without detectable protein 
synthesis (Ikejina et al.1987), suggesting that there is some transcriptional factor which 
suppresses translation of the protein. It is possible that in the heterogeneous osteoblast­
like cell population, there are some cells which have overcome this suppression, 
perhaps due to a differing stage of differentiation.
The perinuclear staining pattern of IL-lp observed in human osteoblast-like cells was 
unexpected, since it has been shown that IL-1 does not contain a leader sequence. IL-1 
has been proposed to be secreted via a novel pathway as opposed to the classical route 
through the endoplasmic reticulum and Golgi apparatus (Rubartelli et al.1990). The 
localized staining pattern might be due to an intracellular pool of IL-1, as IL-1 has been 
shown to be present in membrane bound vesicles in the cytoplasm of monocytes
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(Rubartelli et al.1990). It seems likely that a potent cytokine such as IL-1 would be 
localized in some manner, rather than dispersed throughout the cytoplasm.
The induction kinetics observed for IL-lp mRNA were very similar to those reported in 
different cell types. Fenton et al. (1988) reported that in the monocyte cell line THP1, 
LPS-induced IL-lp mRNA was very labile, and had a short half life of approximately 4 
hours. LPS has been shown to increase the transcription of IL-lp mRNA in a specific 
manner. There is a period of short lived transcription followed by a sharp decrease in 
transcription. Over a longer time course transcription is subsequently initiated and the 
mRNA levels are again elevated. A similar transcription profile was seen with the 
human osteoblast-like cells. TNFa treatment gave rise to a sharp increase in IL-lp 
mRNA which quickly fell to basal levels. Unfortunately the experiments were not 
extended to determine whether a second peak of transcription occurred. The instability 
of IL-lp mRNA is thought to be due to an AU rich sequence in the 3 prime untranslated 
region (Shaw and Kamen, 1986). An AUUUA motif has been postulated to act as the 
recognition sequence for a processing pathway, specifically designed for the 
degradation of mRNAs for certain cytokines and protooncogenes.
The stimulus for IL-lp mRNA induction was quite specific, only "inflammatory" type 
cytokines seemed to initiate the response. TGFp treatment over a 24 hour time course 
did not give rise to any induction of IL-lp mRNA, under conditions which had 
previously been shown to stimulate osteoblast proliferation. This response is cell type 
specific, since TGFp has been shown to induce IL-lp gene expression in human 
monocytes within 2 hours of treatment (Chantry, 1992). The ability of cytokines to 
initiate different responses in specific cell types makes them ideal c e l l : cell signalling 
factors.
The identification of IRAP as a specific inhibitor of IL-1 activity in monocytes 
prompted the search for its expression in other cell types. Other inhibitors including 
TIMP and plasminogen activator inhibitor (PAI) are synthesized by many connective 
tissue cell types (Meikle et al. 1991; Andreasen et al. 1986). Therefore it was thought
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that human osteoblast-like cells might synthesis IRAP. However the expression of 
IRAP seems to be more selective, since a number of different treatments failed to 
induce its expression in human osteoblast-like cells.
In agreement with similar studies, hydrocortisone com pletely suppressed the 
expression of IL -la-induced  IL-lp mRNA. Studies with the myelomonoblastic 
leukeamic cell line U937 showed that glucocorticoids markedly decrease IL-lp mRNA 
by two mechanisms (Lee et al. 1988). In addition to inhibiting transcription, 
glucocorticoids selectively decrease the stability of IL-lp mRNA. It is thought that this 
destabilizing effect is achieved by the selective induction of specific RNAses. It is 
interesting to note that in vivo IL-1 induces ACTH release, and hence adrenal 
corticosteroid synthesis thereby creating a negative feedback loop on its own synthesis. 
IL-1 was shown in this system, in common with others (Warner et al.1987), to induce 
its own mRNA. These two observations seem to contradict each other, however 
autoinduction could take place in the bone microenvironment as opposed to a systemic 
down-regulation via corticosteroids.
In summary the expression profile for IL-lp mRNA in human osteoblast-like cells was 
completely different to that of TGFp (see chapter III). Expression was induced by the 
"inflammatory" cytokines and LPS, but not influenced by the systemic hormones 
1,25 D 3 , PTH, 17-p oestradiol and hydrocortisone, whilst the direct opposite was 
observed for TGFp.
It is tempting to speculate how these basic differences in expression may be relevant to 
the control of bone remodelling. Since IL-1 is such a potent resorbing agent it would 
seem preferable for its expression to be stimulated by agents which give a short 
transient signal, as opposed to a long lasting systemic signal. For this reason it is 
obvious that cytokines would be ideal signalling molecules for IL-1 mediated 
resorption. IL-1 itself could act as a very efficient signal, since it is not constitutively 
expressed, has a short mRNA half-life and has been shown to autoinduce its own 
mRNA in human osteoblasts. In contrast it seems more likely that the control of TGFp
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expression by the systemic growth hormones reflects its role in a less acute stage of 
remodelling, perhaps bone formation. Therefore it would seem from these studies that 
EL-1 expression is modulated by short transient signals, while TGFp expression is 
regulated over a longer time course by the systemic growth factors.
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C h a p t e r  V :  Th e  exp ression  of T G T f i  a n d  XL-ip receptors 
by h u m a n  osteobCast-iike celXs.
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V .l ABSTRACT
The presence of TGFp and IL -lp  receptors on human osteoblast-like cells was 
investigated. This was achieved by analysing the binding of fluorescent labelled 
ligands, by fluorescent activated cell sorting (FACS).
Mink lung cells which had previously been shown to express high levels of TGFp 
receptors, were used to optimize a quantitative FACS analysis system. The number of 
TGFp receptor sites per cell were estimated by calibrating the system with beads 
labelled with increasing numbers of fluorescein isothiocyanate (FITC) molecules. 
Human osteoblast-like cells were shown to express receptors for both these cytokines. 
The binding of both cytokines to the cell surface was shown to be specific, since 
competition was demonstrated with unlabelled ligands. Both receptors were 
demonstrated to be trypsin sensitive, since trypsin treatment markedly decreased ligand 
binding.
Two populations of TGFp receptors were putatively identified. They were shown to be 
present in high numbers of approximately 36,000 and 9,000 sites per cell. It was not 
possible to estimate the numbers of IL-lp receptors, but the low levels of fluorescence 
detected suggested that they were present in much lower levels.
Human osteoblast-like cells were treated with a range of cytokines and systemic 
hormones to determine whether these factors modulated the expression of TGFp and 
IL -lp  receptors. None of the factors tested were shown to modulate TGFp binding 
over an 18 hour treatment period. IL -lp binding also remained unchanged after 
treatment with the systemic hormones 1,25 D 3 , PTH, hydrocortisone and 17-p 
oestradiol. However treatment of the cells with the cytokines IL-lp, TNFa and LPS 
altered IL-1 binding. Both IL-lp and LPS treatment resulted in a modest decrease in 
IL-lp binding over a period of 18 hours. TNFa treatment increased IL-lp binding by 
approximately 40% over the same time period.
140
V.2 INTRODUCTION
There is much recent data to suggest that locally produced cytokines are involved in the 
control of bone remodelling. In previous chapters the expression of two important 
osteotropic cytokines, TGFp and IL-lp has been described. It is very probable that the 
osteotropic activities of many cytokines are mediated via binding to specific cell surface 
receptors on osteoblasts. For this reason the occurrence of osteoblastic receptors for 
these two important cytokines, has been investigated.
Two different IL-1 receptors have been identifed, both are glycosylated proteins o f 
60kDa and 80kDa molecular weight. The expression of the 80kDa form is 
widespread, and its presence on many different cell types including fibroblasts (Solari, 
1990), T cells (Kilian et al.1986), and various connective tissue cells (Bird and 
Saklatvala, 1986) has been demonstrated. The occurrence of the 60 kDa receptor 
seems to be more restricted but it has been identified on B cells (Matsushima et 
al. 1986a, Horuk et al.1987). Both receptors have been shown to bind both IL-1 
forms (Dower et al.1985) as well as the receptor antagonist IRAP (Granowitz et 
al. 1991). The IL-1 receptor complex is rapidly internalized following IL-1 binding, 
which may be a necessary step for its mode of action.
The 80kDa receptor has been cloned (Sims et al. 1989) from a murine cell line. 
Analysis of the predicted amino acid sequence shows that the protein consists of 3 
distinct domains. The extracellular portion consists of 319 amino acids, and contains 3 
immunoglobulin-like subdomains. A stretch of 21 hydrophobic amino acids has been 
identified, and postulated to be a transmembrane section. A large cytoplasmic domain 
of 217 amino acids has also been identifed.
The cDNA sequence of the 60kDa receptor has also been recently reported (McMahan 
et al, 1991). Analysis of the predicted amino acid sequence suggests that its structure is 
closely related to the 80kDa receptor. The ligand binding portion is simlar to the 80kDa 
form, and comprises of 3 immunoglobulin-like subdomains. A single hydrophobic 
transmembrane region has also been identified. Unlike the larger receptor, the 60 kDa
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receptor contains a very short 29 amino acid cytoplasmic domain. It has been 
postulated that this difference in intracellular domain size may highlight a difference in 
signalling mechanisms between the two receptors.
There has been much controversy over the signal transduction mechanism for IL-1. 
Two different mechanisms have been proposed which have been reviewed recently by 
O'Neil et al. (1990) and Mizel, (1990). Mizel presented evidence that IL-1 induces a 
transient increase in cAMP levels via increased adenylate cyclase activity. The 
activation of adenylate cyclase is proposed to involve the interaction with a GTP 
binding protein since the process was shown to be pertussis toxin sensitive.
O'Neil et al. (1990) report that, in agreement with other groups they cannot detect any 
increase in cAMP levels after IL-1 binding. The first detectable signal seen following 
IL-1 binding was a rapid change in protein kinase activity. Two phosphorylation 
changes were identified in fibroblasts, both of which involved the phosphorylation of 
a serine residue. The first phosphorylation substrate was the EGF receptor. The 
second phosphorylation identified was that of a small heat shock protein hsp 27, which 
was phosphorylated within minutes of IL-1 stimulation. Since these phosphorylation 
events seem to be closely associated with IL-1 stimulation, O' Neil et al. postulate that 
IL-1 signal transduction involves the phosphorylation of a unique protein kinase.
Three TGFp receptors have been identified termed type I, II and III, of 53kDa, 80kDa 
and 280-330kDa molecular weight respectively. The gene sequences o f the Type II 
and III receptors have been recently obtained by mammalian expression cloning (Wang 
et al.1991, Lin et al. 1992). Both are glycosylated proteins, with over 50% of the type 
HI receptor (also called betaglycan) consisting of glycosaminoglycan moieties (Segarini 
and Seyedin, 1988). The binding of the 5 different TGFp isoforms to these three 
receptors has not been fully characterised, but a complex network of cross reactive 
ligands and receptors is thought to exist (Cheifetz et al.1987).
The type II receptor has been shown to have a particularly high affinity for TGFpi 
although it also binds the other isoforms. It consists of a cysteine rich extracellular
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domain, linked to a single hydrophobic transmembrane sequence. The intracellular 
transduction mechanism is unknown, but a putative serine/threonine kinase domain has 
been identified on the cytoplasmic portion of the protein (Lin et al.1992).
The type III receptor is an 853 amino acid protein which contains a large N terminal 
extracellular domain, a transmembrane region and a 41 amino acid cytoplasmic tail 
(Wang et al. 1991). A soluble variant lacking the cytoplasmic domain has been shown 
to be secreted by some cell lines (Andres et al.1989). This receptor has been shown to 
be very abundant on the cell surface, and it is estimated that as many as 2 0 0 , 0 0 0  
molecules may be present on the surface of a single cell (Cheifetz et al.1988). Due to 
the fact that it is so abundant and has a 10 fold lower binding affinity than the type I and 
II receptors, it has been postulated that it does not transduce an intracellular signal but 
rather acts as a cell surface reservoir for TGFp.
There are a small number of reports that osteoblasts express both IL-1 and TGFp 
receptors. Primary mouse osteoblast cultures have been shown to specifically bind 
radioiodinated IL-1 (Bird and Saklatvala, 1986). Shen et al. (1990) completed a more 
in depth study of primary mouse osteoblasts by Scatchard analysis, and showed that 
they expressed 3000-15000 receptors per cell with a dissociation constant of 30-200 
pM. Various osteosarcoma cell lines including Saos-2/B10, MG-63, and UMR-106 
(Bird and Saklatvala, 1986, Rodan et al. 1991) have also been shown to express high 
affinity IL-1 receptors.
Wakefield et al. (1981) investigated the occurrence of TGFp receptors in a range of cell 
lines. They identified high affinity receptors in every one of the 30 cell lines studied. 
Therefore it is probable that osteoblasts express TGFp receptors, and there have been 
some preliminary reports to suggest that this is the case (Roberts et al.1987).
This chapter describes the design of a semi quantitative method to assess specifc 
cytokine binding to human osteoblast-like cells. These primary cultures are a 
heterogenous population of cells, containing different cell types including osteoblast 
precursors, pre-osteoblasts and fibroblasts. A popular method for characterising cell
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surface receptors is Scatchard analysis of radioiodinated proteins. Unfortunately it is 
very difficult to interpret the data from such experiments, as the cells are not a 
homogeneous population. The overall 125i_ijgan(j binding observed represents the 
average binding of the whole population, and therefore it is possible to obtain 
artefactual results. In the case of TGFp receptors there is the additional complication 
that the three different receptors are often present on the same cell. This makes the 
interpretation of Scatchard analysis very difficult. For these reasons a FACS analysis 
system was designed to estimate specific cytokine binding. This method has the 
advantage that the fluorescence o f single cells can be determined, therefore distinct 
receptor positive and negative populations can be identified. This method was used to 
identify the presence of IL-lp and TGFp receptors on human osteoblast-like cells. The 
ability of various systemic hormones and cytokines to modulate receptor expression has 
also been investigated to determine whether the osteotropic activities of these factors are 
mediated via receptor mediated events.
V.3 METHODS
Fluorescent activated cell sorting fFACS)
To obtain a satisfactory FACS analysis it was imperative that a single cell suspension 
was obtained. For that reason several different protocols were used to try to obtain a 
homogeneous single cell preparation of human osteoblast-like cells. This proved to be 
very difficult for many reasons. The main problem was that these cells are very 
adherent to each other and to tissue culture plastic. Also in the six weeks it takes for the 
cells to approach confluency, there is a large amount of matrix synthesised to which 
the cells adhere. Initially the cells were trypsinized from the 9 cm^ petri dishes and 
seeded in non-tissue-culture grade petri dishes overnight. This gave quite a 
homogeneous non adherent cell preparation, but there were still large aggregates of 
cells present. Another protocol involved harvesting the cells from the primary cultures,
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seeding the cells at a lower density (5xl05/9cm2  petri dish), and harvesting the cells for 
FACS analysis by trypsinisation. This protocol proved to be unsuitable as the 
trypsinisation resulted in a loss of ligand binding (see results section). The method 
which proved to give the best cell viability and binding was as follows, and was 
adopted for all subsequent experiments. The cells were trypsinized from the confluent 
primary cultures and seeded at a density of 5xl0 5 cells/9 cm2  petri dish. The cells were 
then settled overnight before treatment. The following agents were used in isolation to 
determine whether they affected receptor expression:
IL - lp  (200pg/ml), LPS (500ng/ml), TGFp (25ng/ml), TN Fa (17ng/ml), 17-p 
Oestradiol (10'7 M), Hydrocortisone (10_8 M), 1,25 dihydroxyvitamin D 3  (10_8 M) and 
PTH (10_7 M). All treatments were undertaken for 18 hours unless stated for a 
particular experiment.
The treatments were carried out in serum-free media (lxM EM , 0.1% BSA, lOug/ml 
transferrin, lug/ml insulin, 3x l0  8M sodium selenate, 2mM glutamine, lOOug/ml 
penicillin /streptomyocin). After treatment, the cells were washed in PBS followed by 
PBS/ 2mM EDTA and harvested with a cell scraper. The cells were subsequently 
washed in RDF1 (a commercial buffer containing PBS and BSA), pelleted in a bench 
centrifuge at 1000 rpm for 5 mins, and resuspended in RDF1 at a cell density of 
2 x 107 /ml. 25 ul aliquots of the cell suspension were then dispensed into Becton 
Dickinson FACS tubes, which were kept on ice to prevent cell clumping. lOul of 
biotinylated TGFp (lOug/ml) or phycoerythrin conjugated EL-lp (IL-ip-PE) (6.5ug/ml) 
was then added to the cells and left to bind at 4°C  for 30 min in the dark. Excess 
reagent was then removed by washing the cells in RDF1. For TGFp staining, lOul of 
avidin conjugated FITC reagent (lOug/ml) was then added for 30 min at 4°C  in the 
dark. Excess reagent was removed by washing the cells with RDF1 buffer 3 times to 
prevent high background readings. The cells were finally resuspended in 0.5 ml RDF1 
and immediately analysed on a FASCSTAR PLUS analyser. Alternatively the cells
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were fixed to prevent a loss of ligand binding, by adding an equal volume o f 2 % 
paraformaldehyde/PBS and stored at 4°C.
Double labelling protocol
When the binding of both ligands to the same cells was investigated, a slighlty different 
protocol was used. The method was the same as previously described, but both 
ligands were added in the first 4°C incubation step. Excess ligand was removed using 
the same washing procedure.
Competition binding assays
It was necessary to demonstrate that the binding of the two ligands to the human 
osteoblast-like cells was specific. One method of verifying this specificity was to 
demonstrate competition for fluorescent ligand binding by unlabelled ligand. Since it 
was not possible to obtain large amounts of purified IL-lp and TGFp, it was necessary 
to reduce the volume of cell suspension in the competion assays. This was achieved by 
incubating lOul of cell suspension with 4ul of either IL-lp-PE or biotinylated TGFp in 
LP22 tubes. 50 fold or 100 fold excesses of unlabelled IL-lp or TGFp were added to 
the LP22 tubes, to compete with IL-lp-PE or TGFp-FITC binding respectively.
Assessment of cell viability during FACS analysis.
It was considered necessary to assess the viability of the osteoblast-like cells during 
FACS analysis, as dead cells can often give rise to aberrantly high fluorescence values 
as they bind FITC molecules non specifically on their membranes. Propidium iodide 
was used to distinguish between dead and live cells. This fluorescent dye intercalates 
with double stranded nucleic acids to produce red fluorescence, proportional to the 
nucleic acid content, when excited by blue light. The dye is unable to pass through 
intact cell membranes, however when the cell dies and the integrity of the cell
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membrane fails, it is able to enter and stain the nucleic acids. For this reason this dye 
was used to discriminate between live non-fluorescent cells and dead fluorescent cells. 
The cells were stained with propidium iodide as follows. Immediately prior to FACS 
analysis, a solution of propidium iodide (2.5mg/ml in PBS) was added to give a final 
concentration of 25ug/ml. The sample was then analysed using both the green and red 
fluorescence channels (FL 1 and FL 2 respectively). Figure V. 1 shows a diagramatic 
representation of the cytogram of red versus green fluorescence that was produced. 
The dead cells were recognised as those with a high FL 2 values, and a gate was set so 
that they were not analysed any further.
It was not possible to undertake this type of analysis for the IL-lp binding studies, 
because the propidium iodide greatly interfered with the red fluorescence of the 
phycoerythrin labelled IL-1 p. However over 20 FACS experiments were completed 
and the procedure was optimised so the proportion of dead cells was not greater than 
15% in any case.
Analysis of data
The FACS data was analysed using the program LYSIS II, which gave mean 
fluorescence intensities (MFIs) for the cell populations in each treatment group. Each 
treatment group contained two duplicates. These fluorescence values were converted to 
receptor sites per cell (see results section) for the TGFp binding studies. Unfortunately 
it was not possible to determine the number of IL -lp receptor sites per cell, as no 
calibrated phycoerythrin conjugated beads were commercially available, therefore the 
fluorescence values are reported as MFIs. The Students t Test was used to determine 
whether the treatments gave statistically different binding to the untreated cells.
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V.4 RESULTS
Mink lung cells which have previously been shown to express TGFp receptors were 
used to optimise TGFp ligand binding. The degree of non-specific binding of the 
avidin FITC reagent was determined as shown in fig V.2a, where negligible 
background fluorescence was observed. When the mink lung cells were incubated 
with both biotinylated TGFp and subsequently avidin FITC, a sub-population of the 
cells were seen to be markedly more fluorescent with an 8  fold increase in fluorescence 
intensity. A fluorescence gate was set (dotted line), for analysis purposes, and it was 
estimated that 35% of the mink lung cells bound the TGFp. The TGFp binding 
characteristics of human osteoblast-like cells were then investigated in separate 
experiments as shown in figure V.3. The background fluorescence obtained from the 
non-specific binding of avidin FITC to human osteoblast-like cells is shown in fig 
V.3a. Two positive TGFp binding populations were identified (fig V.3b). One 
population consisting of 61% of the cells was only weakly fluorescent, with a 3 fold 
increase in fluorescence intensity. The other population seen as the second peak in fig 
3b consisted of 39% of the whole population, and was highly fluorescent with a 23 
fold shift in fluorescence intensity. The two populations were shown to have the same 
forward scatter, and side scatter characteristics (data not shown). Therefore the 
differences in fluorescence intensity observed, were not as a result of different size or 
granularity properties of the two populations of cells.
IL -lp  binding was optimised using the D 1 0 N4 M helper T cell line which has been 
shown to express IL-1 receptors. There was a modest degree of binding of IL-1 to 
both D 1 0 N4 M cells (fig V.4c), and human osteoblast-like cells (fig V.4b). Using the 
fluorescence gate shown (dotted line) 30% of the human osteoblast-like cells were 
shown to bind phycoerythrin labelled IL-lp. The positive cells showed a 20 fold 
increase in fluorescence intensity.
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The binding of both TGFp and IL-lp to the human osteoblast-like cells was shown to 
be specific, since competition was demonstrated with unlabelled ligands. It can be seen 
from figure V.5a that treatment of the cells with 50 fold excess of unlabelled TGFp, 
results in a marked reduction in biotinylated TGFp binding. A similar result was seen 
for IL-ip binding (fig V.5b), in this case a 100 fold excess of unlabelled ligand was 
seen to decrease IL-ip binding to near background levels.
Both receptors were shown to be trypsin sensitive. Trypsin treatment reduced the 
binding of both ligands to a level approaching background fluorescence (fig V.6 a and
V.6 b).
The TGFp binding was quantified using commercially available FITC labelled beads. 
These beads gave 6  different peaks of fluorescence as shown in Fig V.7a. The MFI 
value for each peak was proportional to the degree of FITC labelling of the bead. 
Figure V.7b shows the linear relationship between fluorescence and log FITC 
equivalent per bead. This graph was then used to quantify the number o f TGFp 
molecules bound to each cell. The bimodal fluorescence profile of TGFp binding was 
analysed using this calibrated system. It was estimated that the 2 fluorescence peaks 
corresponded to receptors at a density of 30,000 and 9,000 sites per cell.
An attempt was made to analyse the binding of both TGFp (FITC labelled) and IL-lp 
(phycoerythrin labelled) to human osteoblast-like cells by using different fluorescence 
channels. Using this system it was hoped to characterise the binding of both ligands to 
the same cells. Unfortunately this approach did not prove possible, as shown in figure
V.8 . Positive TGFp binding was demonstrated using the green FL 1 fluorescence 
channel when both ligands were present (fig V.8 b). Additionally positive IL -lp 
binding could be demonstrated using the red FL 2 fluorescence channel when the cells 
were incubated with IL-lp-PE alone. However when both biotinylated TGFp, and 
IL-lp-PE were incubated with the cells, no fluorescence above background level could 
be detected on the FL 2 channel (fig V.8 e). This suggested that the biotinylated TGFp 
was interfering with, or masking the IL-lp binding.
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The human osteoblast-like cells were treated with a range of systemic hormones to 
determine whether they modulated TGFp and IL-lp binding. None of the systemic 
growth factors used (including 1, 25 D3 , hydrocortisone, PTH and 17-p oestradiol) had 
any effect on either TGFp or EL-lp binding (figs V.9 and V.10). TGFp binding also 
remained unchanged after treatment with a range of cytokines including IL-lp, TGFp 
and TNFa, (fig V .l 1). Often two populations of positive cells were seen to bind TGFp 
(see figs V.4, V.7a and V.8 a), the number of TGFp binding sites for each population 
was estimated. Neither the proportion of each population, or the degree of TGFp 
binding was affected by any of the treatments. However treatment of the cells with 
the cytokines IL -la , and TNFa resulted in an alteration of IL-lp binding (fig V.12). 
Both IL-lp, and LPS treatment reduced IL -lp binding to approximately 70% of the 
basal level. TNFa treatment gave the opposite effect and increased IL-lp binding by 






Fig. V .l The use o f propidium  iodide for dead cell gating. Cells were incubated with 
25ug/ml propidium  iodide and a cytogram  of red versus green fluorescence produced. 
The cluster o f cells m arked A are live, those m arked B are dead, and those marked C 
are dem onstrating a degree o f breakdown in m em brane integrity. A fluorescence gate 
was set as shown (dotted line), to exclude dead propidium  iodide stained cells from 
subsequent analysis. The green fluorescence (FL-1) is a result o f staining with a cell 
surface marker.
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Fig. V.2 TGFp binding by mink lung cells.
(a) shows the fluorescence profile obtained by analysing mink lung cells incubated with 
the avidin FITC reagent alone. There is a neglible level of non-specific background 
fluorescence (MFI = 3).
(b) Mink lung cells were incubated with both biotinylated TGFp and avidin-FITC 
reagents. Thirty five percent of the mink population stained positively representing an 
8  fold increase in fluorescence intensity.
Fig. V.3 TGFp binding by Human osteoblast-like cells.
(a) Human osteoblast-like cells were incubated with avidin-FITC reagent alone. There 
was a neglible degree background fluorescence (MFI=3).
(b) Human osteoblast-like cells were incubated with biotinylated TGFp and 
subsequently avidin-FITC. A bimodal fluorescence profile was observed, representing 
two populations of positive cells. The first fluorescent peak consisting of 61% of the 
whole population, was weakly fluorescent with a 3 fold increase in fluorescence 
intensity. The second peak consisting of 39% of the population was highly positive 
with a 23 fold increase in fluorescence intensity.
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Fig V.4 IL-1(3 binding to D 1 0N4 M and human osteoblast-like cells.
(a) Human osteoblast-like cells were incubated with PBS alone. A degree of 
background fluorescence was observed (MFI=15), due to the autofluorescent nature of 
the cells.
(b) Human osteoblast-like cells were incubated with phycoerythrin labelled IL-lp. A 
bimodal fluorescence profile was observed. Thirty percent of the human osteoblast-like 
cells were seen to be positively fluorescent with a 2 0  fold increase in fluorescence 
intensity.
(c) The murine, IL-1 receptor positive T helper cell line (D 1 0 N4 M), was incubated 
with phycoerythrin labelled IL-lp. A small proportion of the cells (25%), were seen to 
be positively fluorescent. Note the fluorescence profile of D 1 0 N4 M cells incubated 






Fig. V.5a Competition of biotinylated TGFp binding by unlabelled TGFp.
Non-specific background fluorescence (shaded red) was determined by analysing 
human osteoblast-like cells incubated with avidin-FITC alone.
A bimodal fluorescence profile (shaded grey) was obtained by analysing human 
osteoblast-like cells incubated with biotinylated TGFp and subsequendy avidin FITC. 
The effect of excess unlabelled TGFp on biotinylated TGFp binding, was determined 
by analysing human osteoblast-like cells incubated with biotinylated TGFp plus a 50 
fold excess of unlabelled TGFp, and subsequently avidin FITC. The fluorescence 
profile (shaded green) can be seen to decrease to a level approaching that of 
background fluorescence.
Figure V.5b Competition of phycoerythrin labelled IL-lp binding by unlabelled IL-lp. 
Non-specific background fluorescence (shaded red) was determined by analysing 
human osteoblast-like cells incubated with PBS alone.
The fluorescence profile (shaded grey) was obtained by analysing human osteoblast­
like cells incubated with phycoerythrin labelled IL-lp. By setting a fluorescence gate 
containing 95% of the negative cells, it was estimated that approximately 30% of the 
whole population were positive.
The effect of excess unlabelled IL-lp on IL-lp-PE binding, was determined by 
analysing human osteoblast-like cells incubated with phycoerythrin labelled IL-lp plus 
a 100 fold excess of unlabelled IL-lp. The resulting fluorescence profile (shaded 








avidin- FITC ■  MFI = 60 PBS ■  MFI = 20
Bio-TGFp + avidin-FITC H MFI = 254 IL -lp-PE  H  MFI = 88
Bio-TGFp + avidin-FITC B  MFI = 75 IL -lp-PE  H  MFI = 24
+ 100 fold XS TGFp + 100 fold XS IL-1 p
Fig. V.6 a Effect of trypsin treatment on TGFp binding.
Non-specific background fluorescence (shaded red) was determined by analysing 
human osteoblast-like cells incubated with avidin-FITC alone.
The profile (shaded grey) was obtained by analysing human osteoblast-like cells 
incubated with biotinylated TGFp and subsequently avidin FITC. Two fluorescent 
populations of human osteoblast cells are seen.
The effect of trypsin was determined by analysing human osteoblast-like cells treated 
with trypsin prior to incubation with biotinylated TGFp, and subsequently avidin FITC. 
Trypsin treatment can be seen to markedly decrease TGFp binding.
Fig. V.6 b Effect of trypsin treatment on IL-lp binding.
The red fluorescence profile was obtained by analysing human osteoblast-like cells 
incubated with PBS alone, and represents background fluorescence.
The grey fluorescence profile was obtained by analysing human osteoblast-like cells 
incubated with phycoerythrin labelled IL-lp. By setting a fluorescence gate containing 
95% of the negative cells it was estimated that approximately 30% of the whole 
population were positive.
The effect of trypsin was determined by analysing human osteoblast-like cells treated 
with trypsin prior to incubation with phycoerythrin labelled IL-lp. The fluorescence 
profile (shaded green) shows that the trypsin treatment caused a marked decrease in IL- 
lp binding.
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avidin- FITC Q | M FI= 69 PBS £  MFI = 19
Bio-TGFp + avidin-FITC ^  MFI = 300 IL -lp-PE  H  MFI = 98
Bio-TGFp + avidin-FITC g  MFI = 82 IL -lp-PE  (f§ MFI = 27
+ trypsin + trypsin
Fig. V.7 Calibration of the FACS analyser with FITC labelled beads.
(a) The fluorescence profile o f a mixture of commercially available beads with 
increasing numbers of FITC molecules per bead was analysed. The profile obtained, 
consisted of 6  different peaks, corresponding to the 6  different bead populations. Six 
fluorescence gates were set and a MFI value obtained for each peak.
(b) A graph of the peak MFI vs the log FITC equivalent. It can be seen that the MFI 
for each peak was proportional to the degree of fluorescence. This linear relationship 
was used to quantify TGFp ligand binding, by estimating the number of FITC labelled 






r i u o r a s c B n c a  Ona  Ho 1 a h t
I B 0 IB IB IB




MFI 400  -
- 652.34 + 234.52x R
200  -
2.5 3.5 4.5 5.5 6.5
2 = 0.991
Log FITC equiv per bead
Fig. V . 8  FACS analysis of double labelled cells.
(a) Background green (FL-1) fluorescence due to non-specific avidin-FITC binding
(b) Two positive FL-1 fluorescent populations were seen from an analysis of human 
osteoblast-like cells incubated with biotinylated TGFp and phycoerythrin labelled EL-lp, 
and subsequently avidin FITC.
(c) FL-2 (red) fluorescence profile of human osteoblast-like cells incubated with PBS 
alone.
(d) A population of positive cells were seen on the FL-2 channel from an analysis of 
cells incubated with phycoerythrin labelled IL-lp alone.
(e) No FL-2 fluorescence above background levels was detected in cells incubated with 
biotinylated TGFp and phycoerythrin labelled IL-lp, and subsequently avidin FITC.
(f) The fluorescence profile of cells incubated with biotinylated TGFp and avidin FITC 
on the FL-2 channel. The profile is essentially negative, demonstrating that the green 
fluorescence was not "breaking through" into the red FL-2 channel
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n = 4
Fig. V.9 The effect of the systemic hormones on TGFp binding.
The human osteoblast-like cells were treated with each of the following factors in 
isolation for 18 hours at 37°C; lO'^M 1,25 D3 , 10"^M hydrocortisone, lO'^M PTH or 
lO'^M 17p oestradiol. FACS analysis of TGFp binding was subsequently performed 
and the number of TGFp binding sites were estimated as described in figure V.7. No 
significant change in TGFp binding was observed following any of these treatments. 










1  lO '^I 1,25 D3
B  10^4  Hydrocortisone
□  10'7M PTH
□  10^vl 17-p Oestradiol
n = 4
Fig. V.10 The effect of systemic hormone treatment on IL-lp binding by human 
osteoblast-like cells.
The human osteoblast-like cells were treated with each of the following factors in 
isolation for 18 hours at 37°C; 10"^M 1,25 D3 , lO'^M hydrocortisone, lO'^M PTH or 
lO'^M 17p oestradiol. FACS analysis of IL-lp binding was subsequently performed. 
No significant change in IL -lp binding was observed following any of these 










S  No treatment
Q  200 pg/ml IL-1|3
§H 25ng/ml TGFp
H  500ng/ml LPS
H  17ng/ml TNFa
Fig. V .ll  The effect of cytokine and LPS treatment, on TGFb binding by human 
osteoblast-like cells.
The human osteoblast-like cells were treated with each of the following factors in 
isolation for 18 hours at 37°C; 200pg/ml IL-lp, 25ng/ml TGFp, 500ng/ml LPS, and 
17ng/ml TNFa. FACS analysis of TGFp binding was subsequently performed. No 
significant change in TGFp binding was observed following any of these treatments. 
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n = 4
Fig V.12 The effect of cytokine and LPS treatment, on IL-lp binding by human 
osteoblast-like cells.
The human osteoblast-like cells were treated with each of the following factors in 
isolation for 18 hours at 37°C; 200pg/ml IL-lp, 25ng/ml TGFp, 500ng/ml LPS, and 
17ng/ml TNFa. FACS analysis of IL-lp binding was subsequently performed. IL-lp 
and LPS reduced IL-l/S binding to 70% of basal levels. TNF^ treatment over the same 
time course increased IL-lp binding by 40%.
A Students T test was undertaken to determine whether the differences were statistically 




This preliminary study has shown that human osteoblast-like cells possess cell surface 
binding sites for both TGFp and IL-lp. It was interesting to note that routinely only 
about 30% of the human osteoblast-like cell population were shown to express these 
receptors. This observation might be explained by the idea that this subpopulation 
corresponds to a distinct osteoblast differentiation stage, or cell type.
Analysis of the bimodal TGFp fluorescence profile suggests that two receptor 
populations are present. These two populations are estimated to exist on the osteoblast­
like cells at densities of approximately 30,000 and 9,000 binding sites per cell. These 
values are of a similar magnitude to the number of TGFp receptors estimated on mouse 
fibroblasts by radioligand binding (Wakefield et al. 1981). The existence of a bimodal 
fluorescence profile could possibly be explained by the occurrence of different receptor 
binding affinites.
Even though no estimation of the number IL-lp binding sites could be undertaken, by 
examining the fluorescence profiles it is probably that hum an osteoblast-like cells 
express far fewer IL -1 receptors. This would agree with the findings of many studies 
which estimate that EL-1 receptor levels are fairly low on m any different cell types (Bird 
et al.1988). Osteoblasts are not an exception to th is observation, studies using 
radiolabelled IL -lp estimate that the IL-1 receptor density is approximately 3000 in 
primary cultures of mouse osteoblasts (Bird et al. 1986). The low cell surface density 
of IL-1 receptor and the rapid rate of internalization o f the ligand-receptor complex, 
make this system exquisitely sensitive to low extracellular IL -1 concentrations. IRAP 
has been shown to inhibit several IL-l-induced effects in vitro, however a 10-100 fold 
concentration of IRAP over IL-1 is always required (D inarello 1991). This suggests 
that a low degree of receptor occupancy is required to tranduce the IL-1 signal. It is 
possible that the small (30%) decreases in EL-ip binding that were observed may be 
biologically relevant if these factors are taken into account.
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Both receptors were shown to be trypsin sensitive. An analysis of the predicted amino 
acid sequences of the TGFp (Lin et al.1992, Wang et al.1991) and IL-lp (McMahan 
and et al, 1991, Sims et al.1989) receptors show that there are many putative trypsin 
sites. It has been suggested that a soluble form of the TGFp III receptor may be formed 
by proteolysis at a trypsin site of the extracellular domain .
The large number of TGFp receptors compared to the number of IL -lp receptors 
present on the osteoblast cell surface may explain why no results were obtained from 
the two colour fluorescence experiments. There are several possible reasons why no 
IL -lp  binding was detected in the presence of TGFp ligand. TGFp might have 
preferentially bound to the cell surface, and made access for the IL -lp ligand difficult. 
This could be easily tested by incubating the cells firstly with the IL-lp ligand, then 
with the TGFp ligand. It is more likely that the high levels of green fluorescence 
produced due to TGFp binding masked the red signal from the IL-ip ligand. Before 
two colour fluorescence can be achieved, it is necessary to remove a percentage of the 
green fluorescence that breaks through the red fluorescence channel by setting 
compensation limits. For this reason it is possible that the low levels of red 
fluorescence expected were removed due to the compensation limits. This problem 
could be overcome by using phycoerythrin labelled TGFp and FITC labelled IL-1 p.
The number of TGFp cell surface receptors did not seem to be modulated by any of the 
osteotropic factors studied. This suggests that the activities o f these factors are not 
mediated by a change in the numbers of TGFp receptors. There are several reports 
where the cytokine in question, but not its receptor is modulated by other cytokines 
and hormones (Littlewood et al.1991, Boumpas et al.1991). The fact that TGFp 
receptors are present in high levels might make modulation unfeasible. Obviously the 
modulation of low numbers of receptors would be more easily achieved. Perhaps this 
is why IL-lp receptor levels were shown to be modulated by the treatment of certain 
cytokines.
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There have been reports that TGFp receptor levels are cell density dependent (Newman 
et al.1989). It might be interesting to address this question, although it is possible that 
this is a cell type specific phenomenon.
This preliminary study could form a basis for a more extensive evaluation of 
osteoblastic TGFp and IL-lp receptors. It would be preferable to further validate this 
technique, by using cell lines that are known not to express IL-lp or TGFp receptors. 
Such negative cell lines have been characterised for IL-1 receptors, but it would be very 
difficult to obtain a TGFp negative cell line since most cells seem to possess these 
receptors.
Only one time point was used in this study, due to the fact that the experiments were 
very costly and required large numbers of human osteoblast-like cells from the same 
donor. The time point used (18 hours after stimulation), was chosen so that the data 
could be directly compared with the study of IL -lp  receptors on mouse osteoblasts 
(Shen et al. 1990). However the results from previous studies (Littlewood et al.1991) 
and those reported in other chapters of this thesis highlight the fact that cytokines are 
often expressed in a transient manner by human bone cells. Therefore it is possible 
that the expression of the cell surface receptors for these factors may also be modulated 
at a specific time. Before it can be unequivocally stated that the receptors studied were 
not modulated by several osteotropic factors, it would be necessary to extend the study 
over a series of different time points.
Early time points might be particularly relevant since it is possible that receptor 
mediated events occur rapidly. Previous work suggests that EL-1 cell surface receptors 
are rapidly down-regulated following IL-1 treatment at 37°C. Matsushima et al. 
(1986b) detected a decrease in IL-1 binding as early as 1 hour after stimulation with 
IL-1. Therefore it would be interesting to extend this study to determine at which time 
points IL-lp binding decreases.
FACS analysis can only detect changes in the amount of ligand that is bound following 
different treatments. It is possible that the decrease in IL -lp binding observed
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following treatment with LPS and IL-lp, could be due to a change in the affinity of the 
receptor for its ligand. Scatchard analysis of IL-lp binding would confirm this was the 
case. However as mentioned previously, it is very difficult to interpret the results of 
Scatchard analyses of mixed cell populations. One approach to over come this problem 
might be to sort the human osteoblasts into different cell populations. Presently this 
technique is not available, but with the advent of specific monoclonal antibodies for 
human osteoblast-like cells (Walsh et al.1991) it may be possible to select specific 
osteoblast populations by FACS in the future.
IL-1 production by human osteoblast-like cells following LPS stimulation was 
marginally detectable after 12 hours. It is possible that the decrease in IL-lp binding 
seen following LPS treatment could be due to LPS stimulating the production of IL-1. 
If the levels of IL-1 required for receptor down regulation are low, this may be a 
mechanism by which the inflammatory signal is dampened.
The observation that TNFa treatment gives rise to a small but reproducible increase in 
IL-lp binding cannot be explained by this mechanism. In a similar manner to LPS, 
TNFa treatment of human osteoblast-like cells also results in the production of IL-1 
(see chapter IV). Therefore it was unexpected that TN Fa treatment gave this 
contrasting result. TNFa and IL-1 p are known to act synergistically in several systems 
(Stashenko et al 1985), possibly this upregulation of EL- lp binding may be a method of 
achieving synergy. TNFa could increase IL-lp binding to facilitate an increased IL-1 
signal over a short time course. There is a precedent for this phenomenon, since it has 
been shown that IL-1 stimulation transmodulates the binding of the EGF receptor in 
fibroblasts (Bird and Saklatvala, 1989).
These FACS studies do not give any information about the type of receptor each ligand 
is binding to. To determine which type of IL-1 and TGFp receptors are present on the 
cells it necessary to undertake some biochemical studies of the receptors. Two methods 
which give information about the molecular weight of the receptor are ligand blotting 
and cross linking experiments. The first technique, ligand blotting has been
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successfully employed by several groups to determine the molecular weights of the two 
IL-1 receptors. It involves the purification of cell membranes which are subsequently 
solubilized to give a suspension o f the protein components. The sample is then 
electrophoresed by PAGE to resolve the different protein species. The proteins are then 
transferred and fixed to a nitrocellulose membrane by Western blotting. The molecular 
weight of the receptor is then determined by incubating the membrane with 
radiolabeled ligand, and comparing the radioactive signal with protein markers.
It is probable that the 80kDa type I IL-1 receptor, would be the form present on human 
osteoblast-like cells, since it has been shown to be present on fibroblasts, and mouse 
osteoblasts (Shen et al.1990), and that the distribution of the 60kDa type seems to be 
more restricted. Using the technique outlined it would be possible to confirm this fact. 
The second technique involves binding a radiolabelled ligand to the surface of the cell 
type in question, and then chemically crosslinking the receptor-ligand complex. This 
approach is particularly useful when the ligand binding capability o f a receptor is 
impaired by solubilization and electrophoresis. The molecular weight of the complex 
is then determined by PAGE. Using these two techniques it might be possible to define 
which types of IL-1 and TGFp receptors are present on the surface of human 
osteoblast-like cells.
It is particularly important to determine whether the cell surface binding of TGFPi is 
primarily due to the presence of type III TGFp receptors. This type of receptor is not 
thought to tranduce a signal following TGFp binding, and therefore the exclusive 
presence of this receptor would prohibit the autoinduction of TGFp mRNA observed in 
this cell type (see chapter III).
The observations of this study agree with several of the findings of the Shen study. In 
that study preincubation with IL-1 reduced IL-1 binding, and the IL-lp ligand was 
shown to be rapidly internalized. TGFp treatment was also shown to decrease the 
number of IL-1 binding sites (Shen et al. 1990). No TGFp induced down regulation of 
IL-lp binding was seen in this study. It is possible that the effect is dependent on the
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concentration of the stimulus, since TGFp effects have been shown to be biphasic in 
many systems. The concentration of TGFp used in this study, was greater than 10 fold 
higher than that used in the Shen study, this might explain the difference in the results. 
The Shen study also stated that PTH treatment increased the number of EL-ip receptors 
present on mouse osteoblasts by 50%, in disagreement with the results from this study. 
However they found, in agreement with this study, that the systemic hormones 1,25 
D 3  and 17-p-oestradiol had no effect on IL-1 receptor levels. The differences in results 
between the two studies might be due to the occurrence of species specific 
phenomenon.
In summary, the demonstration that human osteoblast-like cells express cell surface 
receptors for the cytokines TGFp and IL-1 p, further supports the theory that local 
cytokine actions are important factors in the control of bone remodelling.
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C h a p t e r  V I :  T&Fpl a n d  TL~ip ex p ressio n  in  h u m a n  b o n e  as  
d e t e c t e d  b y  i n  s i t u  h yb r id iza tio n .
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VI. 1 ABSTRACT
Recent evidence suggests that cytokines may play an important role in cell : cell 
signalling in bone remodelling. Work described previously in Chapters III and IV 
demonstrates that cultured human osteoblast-like cells are capable of expressing the 
cytokines TGFpi and IL-lp. These in vitro studies have been extended using in situ 
hybridization of RNA probes to decalcified cryostat sections of human bone, to 
investigate cytokine expression in situ.
The tissue for this study was taken from osteophytes of osteoarthritic femoral heads. It 
has been extensively characterised, and shown to contain areas of active bone formation 
and resorption.
TGFpl expression was detected in chondrocytes in the osteoarthritic cartilage. The 
expression was shown to be dependent on the differentiation stage of the cell, with 
immature chondrocytes expressing the most TGFpl mRNA. In contrast, in the same 
areas of cartilage no IL -lp mRNA expression was detected. Newly formed 
fibrocartilage cells at the periphery of the osteophyte also expressed high levels of 
TGFpl mRNA, but only weak DL-lp expression was detected. The osteoblasts laying 
down osteoid on woven bone surfaces expressed high levels of TGFpi mRNA. At 
areas of bone resorption large multinuclear cells reminicent of osteoclasts were shown 
to express high levels of TGFpi mRNA. The adjacent bone marrow tissue also 
contained cells expressing TGFpl.
During intramembranous bone formation newly differentiated osteoblasts expressed 
high levels TGFpi mRNA. Additionally high IL-lp expression was detected at certain 
sites of intramembranous bone formation.
The expression of both cytokines diminished with the formation of mature lamellar 
bone, and was shown to be higher in active osteoblasts (apposed to osteoid) than in 
quiescent lining cells. Transient expression of both cytokines was detected during 




The expression of IL-lp and TGFp in vitro by human bone cells has been discussed in 
chapters III and IV. In this chapter the research has been extended to characterise the 
expression of these factors in bone tissue. Such a study is important, since culture 
conditions are obviously very different from the bone microenvironment. Therefore the 
cytokine expression profiles observed in vitro might differ greatly with those in vivo. 
The following section documents what is known about the localization of TGFp and 
IL-lp in bone tissue.
It is widely accepted that TGFp is incorporated into the matrix o f bone, where it is 
found in levels 200-fold higher than other tissues (Seyedin et al. 1985). 
Immunolocalization studies and different extraction techniques have been used to 
investigate the cellular association and tissue distribution of TGFp in skeletal tissue. 
Ellingsworth et al. (1986) described the localization of a factor termed CEFA (which has 
been shown to be identical to TGFpi) in fetal bovine tissues. CIFA/TGFPi staining 
was shown to be abundant in osteocytes throughout cancellous and cortical bone. A 
similar immunocytochemical study of fetal murine bone was undertaken by Heine et al. 
(1987). TGFp staining was detected in osteoblasts during both endochondral and 
intramembranous ossification. Particularly intense staining was seen in the osteoblasts 
apposed to the membranous bone in the calvariae of 15 day old mice embryos. In the 
long bones during endochondral bone formation, intense staining of TGFp was also 
seen in primary ossification centres. Areas of joint formation, such as articulations 
between vertebrae and long bones also contained high amounts of TGFp.
A very different approach was used by Carrington et al. (1988), where the role of 
TGFp in endochondral bone formation was monitored in vivo. Endochondral bone 
formation was induced in rats by the implantation of demineralised bone matrix. This 
system had been previously characterised, and it was shown that the type of bone 
formation in the resulting ossicle, was indistinguishable from normal endochondral
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bone formation. At various times the implants were removed and extracted with a 
denaturing solution, and the TGFp content quantified by a radioimmunoassay. The 
results showed that the TGFp, which was present in the original bone matrix, was 
removed by macrophage-like cells. After 9 days newly synthesized TGFp was 
detectable, and could only be extracted after demineralisation, which suggested it was 
tightly bound to the bone matrix. The TGFp content of the ossicles was shown to 
increase until 21 days after implantation. The increase was shown to correlate with the 
onset of vascularisation and calcification of the cartilage. The ossicles were also 
removed, sectioned and stained with a TGFp polyclonal antibody. Staining was 
detected initially in inflammatory cells, and later in chondrocytes and osteoblasts. The 
most intense staining of TGFp was found in calcified cartilage and mineralised bone 
matrix, indicating a preferential compartmentalisation of TGFp in mineralised tissue. 
This time dependent accumulation of TGFp in cartilage during its transition to bone, 
suggested that TGFp was an important factor in the regulation of ossification during 
endochondral bone development.
There are many studies which show that chondrocytes express TGFp. Chondrocytes 
within the fetal bovine articular cartilage were shown to contain CIFA/TGFPi although 
those within the growth plate were not stained (Ellingsworth et al. 1986). This finding 
was supported by Pelton et al. (1991) who monitored the expression of three TGFp 
isoforms during fetal skeletal development. Chondrocytes in ribs and vertebrae 
showed strong TGFp3 staining, but only very weak staining for TGFpi and TGFp2- 
TGFP3  staining in the chondrocytes was observed to remain high during chondrocyte 
maturation. Whilst TGFpi and TGFp2 staining was evident with the development of 
hypertrophic chondrocytes. The idea that the TGFp isoforms were expressed in a 
specific developmental manner was further supported by the finding that TGFPi levels 
were especially high in the perichondrium, where very little TGFp2 or TGFp3 staining 
was seen.
A study using in situ hybridization techniques to monitor TGFp and c-fos expression
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in fetal bone development has been reported (Sandberg et al.1988). The initial findings 
of this study using Northern blot analysis suggested that TGFp mRNA was enriched in 
the growth plate, a finding which is directly conflicting with the data of Ellingworth et 
al. (1986). The in situ hybridization of TGFp probes to sections of the fetal human 
bone, confirmed that a select population of chondrocytes in the growth plate and 
epiphyses were expressing TGFp mRNA. These conflicting reports o f expression of 
TGFp in the growth plate could highlight the difference between human and bovine 
fetal chondrogenesis, or more probably, the fact that the two stages of development 
studied were different.
Other bone cell types which have been shown to express TGFp in situ include those in 
the bone marrow particularly platelet producing megakaryocytes (Pelton et al. 1991). 
Despite the fact that EL-1 synthesis has been reported in osteoblasts from many species 
(Lorenzo et al.1990; Keeting et al.1991), there has been very little data presented 
documenting EL-1 expression in bone tissue. This may be due to the fact that IL-1 is 
rapidly turned over and therefore expression is difficult to detect. There has been a 
report of IL-1 expression in normal mouse bone (Takacs et al. 1988). In situ 
hybridization techniques were used to detect IL-1 a  mRNA expression in tissue sections 
of bone, although the cell types expressing this cytokine were not identified.
The results from many in vitro experiments suggest that both IL-1 and TGFp are very 
important osteotropic cytokines. For this reason a study was undertaken to monitor the 
expression of these cytokines in human bone. It was thought that by investigating the 
expression of these factors in situ, it would be possible to understand how cytokines 
were modulated during human bone remodelling. Cryostat cut sections of human 
osteophyte tissue were hybridized with TGFpl and IL -lp RNA probes. Human 
osteophyte tissue was used for two reasons. Firstly, as it has been extensively 
characterised, and shown to contain abundant amounts of all the different bone cell 
types. Secondly, there are many areas of active bone remodelling within the tissue, in 
contrast with other bone tissues such as adult illiac crest where remodelling sites are
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rarely detected. Serial sections were stained using cytochemical techniques for alkaline 
phosphatase and TRAP activity, two enzymes which are highly expressed by 
osteoblasts and osteoclasts respectively. Using this approach it was hoped to determine 
which cells were capable of expressing these cytokines, and to study the temporal 
expression of these factors during osteophyte development.
VI.3 MATERIALS AND METHODS 
Preparation of tissue
Developing osteophytes were dissected from the femoral heads removed from patients 
undergoing hip arthroplasty for osteoarthritis. The tissue was dipped briefly into 5% 
(w/v) polyvinyl alcohol (PVA), and then chilled (-70°C) by precipitate immersion in 
cooled n-hexane (low in aromatic hydrocarbons grade, boiling range 67-70°C). 
Cryostat sections (10 um) of unfixed, undecalcified bone were cut on a modified Bright 
/Hacker cryostat equipped with a finely polished tungsten tipped steel knife. The knife 
was further cooled to -70°C by packing it's shaft with dry ice. The temperature of the 
cryostat cabinet was kept below -25°C. The sections were picked off the knife onto 
TESPA coated glass slides.
The in situ expression of TGFPi, and IL-lp mRNA with corresponding negative 
controls (sense transcripts) was analysed in serial sections of each osteophyte and 
surrounding tissue, starting at the tip of each outgrowth and proceeding downwards in 
the direction of the subchondral bone to disclose the various stages of maturation. 
Fifteen osteophytes were analysed in five separate experiments. Corresponding 
histologies for each group of sections were stained with a modified Wrights stain.
Generation of RNA probes
The TGFpi RNA probe was generated by in vitro transcription from a 300 b.p. cDNA 
template contained in the plasmid pGHTGFB-27. The plasmid was digested with the 
restriction enzymes Hindlll or EcoRI to generate two linear DNA templates containing
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either SP6 or T7 RNA polymerase sites as shown in fig VI. 1. Antisense transcripts 
were generated using SP6 RNA polymerase, and sense transcripts using T7 
polymerase. Both RNA probes were assessed to confirm they were of the same 
specific activity (see chapter II).
IL-lp RNA probes were generated in a similar manner from a 350 b.p. cDNA template 
contained in the plasmid pgem2illbeta. The plasmid was digested with the restriction 
enzymes EcoRl or Pvu II as shown in fig. VI.2, to give two linear templates 
containing T7 and SP6 RNA polymerase sites respectively. Antisense transcripts were 
generated by in vitro transcription using T7 RNA polymerase, and sense transcripts 
by using SP6 RNA polymerase.
In Situ Hybridization
The in situ hybridization of the TGFpl and IL-lp RNA probes was undertaken as 
described in Chapter II 4(iii).
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Figure VI. 1: The generation of TGFBl RNA probes.
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Figure VI.2 : The generation of IL-1 B RNA probes.
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Figure VI.3: The three main stages o f osteophyte development.
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The osteophyte tissue is very complex and has been extensively characterised (Dodds 
and Gowen, 1992). There are three main stages of osteophyte development; the initial 
cartilage formation and calcification stage, followed by woven bone formation and 
remodelling, culminating with the formation of mature lamellar bone. These stages of 
osteophyte development are depicted pictorially in fig VI.3.
CARTILAGE FORMATION AND CALCIFICATION
In certain regions of the osteophyte tissue there were recognisable areas of organized 
cartilage. Three zones of cartilage cells could be distinguished; proliferating and resting 
chondrocytes, hypertropic chondrocytes, and calcified cartilage (fig. VI.4a). The 
expression of TGFp in these areas was shown to be dependent on the differentiation 
state of the chondrocytes. Newly formed chondrocytes expressed moderate levels of 
TGFp mRNA, whereas the expression by hypertrophic chondrocytes was markedly 
lower. No expression was detected in the calcified cartilage zone (fig. VI.4b). Serial 
sections of the same area of cartilage tissue revealed that there was no IL-lp expression 
during the initial cartilage formation phase (fig. VI.4c).
The outerm ost layer of developing osteophytes consisted of newly formed 
fibrocartilage that had differentiated from the surrounding mesenchymal connective 
tissue (fig. VI.5a). Differentiating fibrocartilage cells showed strong TGFpl mRNA 
expression (fig. VI.5b), but only very weak expression of IL-lp (fig. VI.5c). Again 
the expression of TGFp 1 seemed to be dependent on the differentiation stage of the 
fibrocartilage cell. Mature fibrocartilage cells showed a distinct reduction in TGFpl 
mRNA expression compared with the more immature cells. In contrast IL -lp  




Two distinct types of bone formation occur concurrently in the developing osteophyte, 
namely endochondral and intramembranous ossification.
As described previously (see chapter 1.2), endochondral bone formation occurs on a 
cartilage template. This cartilage template is invaded by vascular connective tissue. 
After vascularization the cartilage is extensively remodelled by osteoclasts to form 
woven bone. Subsequently bone is layed down by osteoblasts on the residual 
cartilage.
No TGFpl or IL-lp expression was detected in osteoblasts apposed to the calcified 
cartilage surfaces during the initial phase of cartilage remodelling (data not shown). 
Further remodelling of the calcified cartilage /  woven bone results in the formation of 
trabeculae of woven bone rich in osteoblastic surfaces replacing the cartilage. At these 
sites TGFpl expression was high in active osteoblasts apposed to thick seams of 
osteoid (fig. VI.6a). Again IL-lp expression was rare but discrete areas of expression 
were observed (fig. VI.6c).
In areas of newly formed intramembranous bone large osteoblasts could be seen to 
differentiate from the surrounding connective tissue and form woven bone directly 
without a cartilage template (fig. VI.7a). At these sites, differentiating osteoblasts 
demonstrated strong TGFpl mRNA expression (fig VI.7b and VI.7e). Occasionally 
high levels of osteoblastic IL -lp  expression were detected in discrete areas of 
intramembranous bone formation (fig. VI.7c and VI.8b).
WOVEN BONE REMODELLING
W ithin sections further through the osteophyte blocks extensive osteoclastic 
remodelling of the bone was observed. The marrow between the trabeculae was highly 
cellular and filled with mononuclear stromal cells and migrating osteoclasts (fig VI.9a). 
Very occasionally certain populations of large multinucleated cells (resembling
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osteoclasts) expressed TGFpi mRNA (fig. VI.9b)
LAMELLAR BONE FORMATION
Osteoblasts laying down the lamellar bone that replaced the resorbed woven bone 
(fig. VI. 10a), expressed high levels of TGFpl mRNA. Higher expression was 
detected in the cuboidal active osteoblasts, and less expression within the flattened 
lining cells (fig. VI. 10b). In these areas no osteoblastic IL-lp mRNA expression was 
observed (data not shown). Fully formed osteoblastic sites lined with quiescent 
osteoblast lining cells (fig. VI. 11a) showed weak TGFpl (fig V I.lib ) and little IL-lp 
mRNA expression (data not shown).
TRANSIENT CYTOKINE EXPRESSION DURING OSTEOPHYTE CLOSURE 
With closure of the osteophyte tip, bone formation occurs directly on top of the 
cartilage. During this phase of bone formation TGFpl and IL-lp were observed to be 
transiently expressed. The start of this bone formation phase associated with 
osteophyte closure was also observed to occur on top of areas o f fibrocartilage cells 
(fig. VI. 12a). At this stage, high levels of TGFpi but no IL-lp expression were 
detected in the fibrocartilage cells (fig. VI. 12b and VI. 12c). During osteophyte closure 
osteoblasts were recruited around the periphery of the fibrocartilage cells to initiate bone 
formation (fig. VI.12d). No TGFpl expression was detected at this stage but high 
IL -lp  expression was evident, particularly in the newly recruited osteoblasts 
(fig. VI.12e and VI.12f).
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VI.5 FIGURES
Fig. 4a An area of organised cartilage tissue. There are three zones visible; 
proliferating and resting chondrocytes (R&P), hypertropic chondrocytes (H), and 
calcified cartilage (CC).
Fig. 4b Expression of TGFpj mRNA by chondrocytes: note moderate expression in 
newly formed chondrocytes (single arrow), less expression in hypertropic 
chondrocytes, and no expression in the calcified cartilage zone (two arrows). 
Osteoblasts on trabecular bone surfaces (large arrows) express high levels of TGFp 
mRNA.





x i o o
Fig. 5a Outermost layer of developing osteophyte showing area of fibrocartilage cells 
(FB) which have differentiated from the surrounding mesenchymal connective tissue 
(M.C.)
Fig. 5b High expression of TGFPi mRNA in areas of differentiating fibrocartilage 
cells. Note there is also high TGFpi mRNA expression in osteoblasts on trabecular 
surfaces.
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Fig. 6a High expression of TGFpi mRNA by osteoblasts apposed to trabeculae of 
woven bone (large arrow).
Fig. 6b Negative control showing no binding of sense transcript.
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Fig. 7a An area of intramembranous bone formation; islands of woven bone are
formed directly by osteoblasts (large arrow) without a cartilage template.
Fig. 7b Osteoblasts express high levels of TGFp 1 mRNA at sites of intramembranous 
bone formation (large arrows). Note very high expression in clusters of newly 
differentiated osteoblasts (small arrows).
Fig. 7c Low levels of IL -lp  mRNA expression at d iscrete sites during 
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Fig. 7d Another area of intramembranous bone formation. (Newly differentiated
osteoblasts laying down osteoid highlighted by arrows).
Fig. 7e High expression of TGFpl by osteoblasts in an area of intramembranous bone 





Fig 8a An area of intramembranous bone formation; "bundles" of osteoblasts (arrows) 
can be seen to be laying down osteoid.
Fig. 8b High IL-lp expression by "bundles" of osteoblasts laying down osteoid at a 
site of intramembranous bone formation.












Fig. 9a Extensive bone remodelling by osteoclasts. The highly cellular marrow 
between trabeculae contains mononuclear stromal cells and migrating osteoclasts (arrow 
heads).
Fig. 9b An area of remodelling bone; large multinuclear cells resembling osteoclasts 
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Fig. 10a An area of lamellar bone formation; seams of newly formed osteoid are 
evident (arrow) apposed to lamellar bone (LB).
Fig. 10b Osteoblasts express low levels of TGFpl mRNA during lamellar bone 
formation. Higher levels were detected in plump cuboidal osteoblasts (large arrow), 
and less expression in those with a flattened morphology (small arrow).
Fig. 10c No expression of IL-ip during lamellar bone formation.
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Fig. 1 la  An area of residual woven bone formation.
Fig l ib .  Fully formed osteoblastic sites show weak expression of TGFpi mRNA 







Fig. 12a Tip of the osteophyte showing fibrocartilage cells surrounded by a 
cartilagenous matrix.
Fig. 12b Moderate expression of TGFpl mRNA in fibrocartilage cells (arrows).
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Fig. 12d A more mature stage of osteophyte closure. Clusters of fibrocartilage cells 
can be seen in the centre surrounded by a layer of migrating osteoblasts (arrrows).
Fig. 12e High EL-1(3 expression evident particularly in newly recruited osteoblasts.





Table VI. 1. Summary of TGFS. and IL-1B expression within the developing osteophyte.
CELL TYPE CYTOKINE EXPRESSION
TGFB IL-1B
Connective tissue.
Differentiating fibrocartilage. +++ +/-
Fibrocartilage. +
Forming chondrocyte clusters. + *
Mature chondrocytes. + *
Hypertrophic chondrocytes. + *
Calcified cartilage (chondrocytes).
Osteoblasts.
(a) Differentiating osteoblasts (IMB). +++ i
(b) Intramembranous bone formation. ++ *
(c) Quiescent IMB surfaces. +
(d) Apposed CC (EO). +/-
Trab: (woven) /  "active obs" (osteoid). +++ *
Lining cells. +/-






* TRANSIENT EXPRESSION; generally negative.






This study confirms the expression of the cytokines TGFp and IL-lp in human bone. 
These findings are very important, and are the most compelling evidence that local 
cytokine expression is involved in the control of human bone remodelling. There has 
been a large body of evidence from in vitro experiments suggesting that the cytokines 
TGFpl and IL-lp are important osteotropic factors. However until the completion of 
this study it was possible that the in vitro expression of these cytokines, could be as a 
result of culture conditions.
Many different cell types were shown to be capable of expressing mRNAs for these 
factors as summarised in table VI. 1. The expression of the cytokines was shown to 
occur at specific stages of development. Each cytokine was not expressed by a certain 
cell type continuously, but rather transient expression was observed. Factors such as 
the differentiation state of the cell and the type of bone remodelling seemed to modulate 
the expression of each cytokine.
The expression profile observed for TGFpl confirmed the data from many in vitro 
experiments, where osteoblasts from several different species have been observed to 
express TGFp (Gehron Robey et al.1987; Pfeilschifter and Mundy, 1987). The most 
interesting aspect of TGFpl expression, was the way it seemed to be dependent on the 
differentiation stage of each cell. This phenomenon was seen in both cartilage cells 
and osteoblasts, where the more immature stages expressed much higher levels of 
TGFpi mRNA. It is possible that TGFp itself is acting to promote the maturation of the 
cell, or that it is inducing the expression of another maturation factor. There is 
evidence to support this hypothesis since TGFp has been observed to promote 
chondrocyte maturation in vitro (Morales and Roberts, 1988).
It is possible that TGFp and IL-lp expression by osteoblasts might modulate local bone 
remodelling by acting as autocrine growth factors. It was evident that the expression of 
both the cytokines was particularly high during intramembranous bone formation.
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During this stage large bundles of osteoblasts were observed at sites of bone formation, 
presumably they must result from active osteoblast proliferation. Both TGFp and IL-1 
have been shown to stimulate the proliferation of human osteoblasts in vitro (D. 
Rickard,personal communication). Additionally, work reported in Chapters III and IV 
has shown that both factors autoinduce the expression of their own mRNAs, and 
human osteoblasts express functional TGFpl and IL-lp receptors. Therefore it is 
suggested that during stages of bone formation where large numbers of osteoblasts are 
required to synthesise osteoid, both these factors are concurrently expressed to 
stimulate osteoblast proliferation. In addition, this proliferative signal may be 
amplified by the autoinduction of both of the cytokine mRNAs.
It is possible that IL-lp expression was transient in these circumstances to avoid matrix 
degradation. Since, in addition to stimulating osteoblast proliferation, IL-1 inhibits 
the synthesis of many bone matrix components including type I collagen (Canalis, 
1986). Additionally IL-1 is reported to promote the synthesis of metalloproteinases, 
that degrade extracellular matrix, by chondrocytes (Schnyder et al. 1987). The 
transient expression profile and short mRNA half-life of EL-ip, may allow it to stimulate 
osteoblast proliferation, whilst avoiding inhibiting osteoid synthesis, or promoting 
matrix breakdown.
In contrast, TGFp has been reported to stimulate the expression of certain bone matrix 
proteins including fibronectin, type I collagen (Ignotz and Massague, 1986; Strong et 
al. 1991) and the metalloproteinase inhibitor TIMP (Meikle et aL 1991) by osteoblasts. 
This might explain why TGFp expression is more sustained and expressed highly by 
osteoblasts actively laying down bone matrix.
High TGFp expression was also seen when large numbers of osteoblasts were required 
to synthesize bone during osteophyte closure. In addition to stimulating the 
proliferation of osteoblasts, TGFp has been shown to act as a chemotactic factor for 
these cells in vitro (Pfeilschifter et al.1990). During osteophyte closure TGFp was 
observed to be transiently expressed at a time when there was active osteoblast
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recruitment to the site of bone formation. Therefore it is suggested that this factor is 
transiently expressed by fibrocartilage cells to facilitate this migration.
The fact that TGFp expression was seen in most sites of intramembranous bone 
form ation, whilst IL -lp  expression was transient and rarely observed is very 
interesting. It is important to realise that the expression of only two members o f a 
whole cytokine network were studied in these experiments, and that other factors are 
also probably modulating the expression of these cytokines. It is probable that the rare 
cases of IL-lp expression during intramembranous bone formation are due to some 
unknown locally produced factor.
High levels of TGFp expression were detected in large multinuclear cells during 
lamellar bone remodelling. It is tempting to speculate that these cells were osteoclasts, 
as many were observed in adjacent histology sections during this stage of remodelling. 
There has been one previous report that osteoclasts are capable of expressing TGFp in 
human fetal bone (Sandberg et al. 1988). However these findings would directly 
contravene the whole "coupling factor" theory, where TGFp is thought to couple 
resorption to formation during bone remodelling. The critical prerequisite of this theory 
is that TGFp is synthesized by osteoblasts in a latent form and deposited in the bone 
matrix. Subsequently it is thought to be liberated from the bone matrix and activated 
during further rounds of remodelling by osteoclasts. If osteoclasts could synthesize 
their own TGFp the theory would have to be substantially modified.
This highlights a property of TGFp which is important to consider when interpreting 
this entire in situ study, namely that it is assumed that TGFp is in a latent form. 
Therefore if this doctrine is accepted no TGFp activity can occur until this factor is 
activated by acidification or proteolysis (Oreffo et al.1989). The fact that TGFp is 
expressed during distinct stages of osteophyte development suggests that it is not just 
secreted in a latent form, but rather that it may be activated in at its site of synthesis, by 
an as yet uncharacterized mechanism. There is some evidence to support this theory 
since it has been reported that chick chondrocytes produce active TGFP3  in certain
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circumstances (Loverige and Roberts,personal communication).
High transient expression of IL-1 (3 mRNA was also detected during osteophyte closure, 
particularly by the layer of osteoblasts surrounding the central fibrocartilage cells. By 
examining subsequent sections during osteophyte closure it was observed that as 
TGFpi expression was "switched o ff ', IL-lp expression was "switched on". This 
differential expression of the two cytokines at distinct stages of osteophyte 
development, further supports the hypothesis that the local production of these two 
factors is important in the regulation of bone and cartilage remodelling.
It is possible that the expression of these two cytokines could be irrelevant to bone 
remodelling. Other cytokines might be the critical factors controlling the remodelling, 
the TGFpl and IL-lp expression might just be coincidental. This is thought unlikely 
for two reasons. Firstly, there has been such a large amount of data documenting the 
osteotropic effects of TGFpi and IL-lp in vitro, and secondly, if expression was 
coincidental it is very unlikely to occur at distinct stages of differentiation or 
osteophyte development.
There are many problems and pitfalls with the experimental design and interpretation of 
in situ experiments. The main problem is that a section just highlights the expression 
of a factor at a certain time point. If the expression of the factor is "switched" on and 
off quickly it is possible to miss the expression. This problem is particularly relevant in 
the case of cytokines (including IL-lp) which are transiently expressed and have very 
short messenger RNA half-lives. It was expected that large amounts of IL -lp 
expression would be detected in osteoblasts during active woven bone remodelling, 
since IL-1 has been shown to be a potent bone resorptive agent in vitro (Gowen et 
al. 1983). However very little expression was detected in these stages, and it is 
possible that due to the aforementioned reasons IL-lp went undetected.
The other possible criticism of this study was the choice of tissue. As mentioned 
previously, osteophyte tissue was chosen because it contains an abundance of bone cell 
types within areas of very active bone remodelling, that are not easily found in normal
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adult human bone. It is possible however that as this bone forms as part of a disease 
process, the remodelling observed may not reflect true bone remodelling. From an 
extensive characterisation of this tissue (Dodds and Gowen, 1992), it is thought that 
whilst the kinetics of bone remodelling are accelerated, the actual phases of bone 
remodelling that occur are very similar to normal human bone remodelling. For 
example the process of intramembranous bone formation that was observed, where 
osteoblasts differentiate from the mesenchyme and lay down areas of osteoid, has been 
previously described to occur in normal bone tissue (Baron, 1991).
The main problem of investigating human bone remodelling is that the experimental 
design cannot be manipulated to investigate the affect of other osteotropic factors. 
Therefore it is necessary to compliment these studies with in vitro experiments of 
human bone cells. It would be very advantageous to monitor the expression of the 
cytokines at the protein level during the various stages of bone remodelling by 
immunlocalization techniques, since some studies have documented mRNA expression 
without translation into protein (Ikejina et al.1987). Unfortunately this was not 
possible in this tissue for technical reasons.
Further studies on normal human bone would lead to a greater understanding of human 
bone remodelling. It is possible to obtain iliac crest biopsies from patients with 
metabolic bone disorders or those on clinical drug trials. In certain cases such patients 
are injected with compounds (for example tetracyclin) which are deposited in the bone 
matrix during phases of bone formation. These compounds are fluorescent when 
viewed under u.v. light, and thus phases of bone formation and the time between such 
formation phases can be monitored. If in situ hybridization of cytokine probes was 
carried out in serial sections of these bone biopsies, it might be possible to determine at 
which stages of the bone remodelling cycle each cytokine was expressed. Preliminary 
pilot studies for this type of work have been carried out. Unfortunately the iliac crest 
tissue is very difficult to work with and much tissue is lost during the long in situ 
hybridization technique.
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It is hoped that with the advent of more sophisticated techniques, such a study could be 
undertaken in the future.
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C h a p t e r  V V l :  O steopontin  exp ression  in  the ctevetopiny 
osteophyte a s  cCetecteci by i n  s i t u  hybricCization.
199
VII. 1 ABSTRACT
Over recent years several noncollagenous matrix proteins of bone have been isolated 
and characterised. One such protein osteopontin, has been shown to be synthesized by 
osteoblasts and deposited in the bone matrix where it is thought to bind to 
hydroxyapatite.
In this study, in situ hybridization techniques have been used to investigate the 
expression of osteopontin mRNA by bone cells in a variety of bone environments. 
Cryostat sections of human osteophyte and osteoclastoma tissue were hybridized with 
an antisense RNA probe for osteopontin.
There was a very distinct pattern of osteopontin mRNA expression in these tissues. 
Osteoblasts actively secreting osteoid adjacent to the bone surface expressed high levels 
o f osteopontin mRNA. Osteopontin expression was also detected in low levels in 
chondrocytes and in very high levels in fibrocartilage cells at the periphery o f the 
osteophyte.
However the most striking feature of osteopontin expression was the high levels o f 
osteopontin mRNA detected in osteoclasts. Osteoclasts in resorption lacuna and those 
removed from the resorption sites both expressed osteopontin mRNA. In addition, the 
whole population of osteoclasts in the osteoclastoma tissue expressed high levels of 
osteopontin mRNA. Populations of mononuclear cells in resorption lacunae were also 
shown to express high levels of osteopontin mRNA.
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Vn.2 INTRODUCTION
Osteopontin was first isolated from mineralised bone matrix by Franzen et al. (1985). 
It was originally named bone sialoprotein I as it was found to contain many sialic acid 
moieties (Franzen and Heinegard, 1985). Osteopontin has been shown to be a minor 
matrix component of bovine bone; the amount detected in different bone matrices was 
species dependent, but was on average approximately 2 % of the non collagenous 
proteins (Franzen and Heinegard, 1985). In addition to containing sialic acid moieties 
osteopontin has been shown to be heavily glycosylated as a result of post translational 
modifications. This often gives rise to different molecular weight species due to 
varying glycosylation patterns (Zhang et al.1990). For this reason osteopontin 
migrates anomalously on SDS PAGE, and has an estimated molecular weight between 
45kDa - 75kDa. Sedimentation analysis seems to give a more reproducible estimate 
of 44kDa (Franzen and Heinegard, 1985). Osteopontin binds tightly to hydroxyapatite 
in bone presumably via an acid rich stretch of nine aspartic acid residues. It appears to 
form an integral part of the mineralised matrix since it can only be extracted under 
denaturing conditions (Fisher et al.1987).
Osteoblasts obtained from many species have been shown to be capable of synthesizing 
osteopontin in vitro, including osteoblasts isolated from fetal rat calvariae and the rat 
osteoblast cell line ROS 17/2.8 (Prince et al.1987). Synthesis of osteopontin by 
normal human bone cells has not been documented, but it has been suggested that it is 
not a major secretory product of these cells (Gehron Robey, 1989). Osteopontin is also 
synthesized by chondrocytes, where it's expression seems to be restricted to areas of 
active cartilage remodelling (Castagnola et al.1991).
Osteopontin has been immunolocalized in osteoblasts, osteocytes and preosteoblasts in 
the woven bone of neonatal rats (Mark et al.1987). In the same study the intracellular 
localization of the osteopontin was shown to be the Golgi apparatus, presumably since 
that was the site for the extensive glycosylation o f the protein. In situ hybridization
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studies of developing mouse limb buds suggested that osteopontin mRNA was present 
in fibroblast-like cells internal to the periosteum and it's associated matrix (Nomura et 
al.1988). Analysis of the temporal expression of osteopontin during embryogenesis 
revealed that it was expressed 14 days postcoitum in calvariae in a similar manner to 
osteonectin (Nomura et al.1988). Electron microscopy studies have localized 
osteopontin to electron dense regions of mineralised matrix (Reinholt et al.1990), 
particularly in regions of the bone surface where osteoclasts are anchored. Therefore it 
may act as a means of attachment for these cells to the bone surface (Reinholt et 
al.1990).
For a long time it was assumed that osteopontin was a specific bone matrix protein. 
However a study using Northern blot analysis by Yoon et al (1987) showed this was 
not the case. Osteopontin RNA transcripts were detected in high levels in bone and 
kidney. However recent work suggests that the kidney form may be genetically distinct 
(Gotoh et al. 1991). Lower levels of osteopontin expression were also detected in 
skin, muscle, cartilage, heart, intestine, liver, spleen and testes. Subsequent 
immunolocalization studies demonstrated that neuronal cells in the brain and inner ear 
express both osteopontin mRNA and protein (Nomura et al. 1988).
Even though osteopontin is not a bone specific protein, its expression is modulated by 
osteotropic factors. The synthesis of osteopontin by osteoblasts is stimulated by 
1,25 D 3  (Prince and Butler, 1987) and TGFp (Noda and Rodan, 1989) and inhibited 
by parathyroid hormone (Noda and Rodan, 1989) and dexamethasone (Yoon et 
al.1987). Further evidence that osteopontin may be important in bone metabolism 
arises from an analysis of the osteopontin promoter. In addition to a vitamin D 
responsive element a sequence which confers oestrogen responsiveness has also been 
discovered (Craig and Denhardt, 1991).
Sequence analysis of the osteopontin gene reveals that it contains an RGD tripeptide 
sequence and therefore may interact with integrin receptors (Kiefer et al.1989). It has 
been postulated to be a ligand for the vitronectin (avp3 ) receptor (Reinholt et al.1990). 
Osteopontin may also be important in cell growth as it can be shown to promote
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collagen independent cell spreading and attachment of ROS 17.28 cells and normal 
human osteoblasts in culture (Gehron Robey et al.1989).
Despite extensive studies on osteopontin in several species its precise function in bone 
formation and remodelling remains to be fully elucidated. For this reason a study of the 
expression of osteopontin in human bone was undertaken. In situ hybridization of 
RNA probes for osteopontin to cryostat sections of human bone and osteoclastoma 
tissue was used to investigate its expression at different stages of bone remodelling. 
Human osteophyte tissue was used for two reasons: the tissue contains areas of active 
bone formation and resorption, and therefore is rich in the various cell types o f bone. 
Secondly, this tissue has been extensively characterised (Dodds and Gowen 1992) 
Osteoclastoma tissue was used as a rich source of osteoclasts and stromal cells that 
were not in a bone environment. Serial bone and osteclastoma sections were stained 
with a Wrights stain to visualize the histology of the tissue. Two enzymes that are 
expressed highly by osteoblasts and osteoclasts, alkaline phosphatase and tartrate 
resistant acid phosphatase (TRAP) were visualized by cytochemical methods to 
distinguish osteoblasts and osteoclasts in the sections. Using this approach the aim of 
the study was to define which cell types were capable of expressing osteopontin 
mRNA and to characterise the bone microenvironments in which the transcription of 
this protein was initiated.
VII.3 MATERIALS AND METHODS
The tissues were prepared in exactly the same manner as described in chapter VI.
In situ hybridization.
Sense and antisense RNA probes for osteopontin were prepared as follows. 
Preparations of the pOp/10 plasmid were linearized with the restriction enzymes Xbal 
or Xho 1, to generate two linear templates each containing a T7 or T3 RNA polymerase 
site as shown in fig VII. 1. Antisense RNA transcripts were generated with T7 RNA 
polymerase from the first template using the Manheim Boeringer in vitro transcription
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kit. Similarly sense transcripts (to be used as a negative control) were generated from 
the other template using T3 RNA polymerase. After the synthesis of the RNA probe, 
the DNA template was removed using 2 units of DNAse I (RNAse free) at 37°C for 15 
mins. This step was necessary, otherwise the DNA template could compete for RNA 
binding sites within the sections. The specific activity of both the antisense and sense 
RNA probes was assessed as described in chapter II, and both probes were analysed 
by vertical gel electrophoresis to confirm the majority of transcripts were of full length. 
The in situ hybridization of the osteopontin RNA probes was undertaken as previously 
described in chapter II. Since the osteopontin cDNA template was approximately 1500 
bp, the RNA probe gave rise to a greater degree of background binding than the smaller 
(300bp) probes for IL -lp  and TGFp. To reduce this non specific binding to an 
acceptable level, an additional high stringency wash of lxSSC /50% formamide at 
40°C was performed after the hybridization step.
Alkaline phosphatase and TRAP staining was undertaken as described in Chapter II.
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The three main stages of osteophyte development; cartilage formation and calcification, 
woven bone formation and remodelling, and lamellar bone formation are described in 
chapter VI (see figure VI.3). The profile of osteopontin expression by human bone 
cells is described in the following section at these stages of osteophyte development.
CARTILAGE FORMATION AND CALCIFICATION
The primary phase of osteophyte development involves the calcification and 
remodelling of cartilage. During these initial stages of cartilage calcification 
(fig. VII.2a), low osteopontin expression was detected in the newly recruited 
osteoblasts (fig VII.2b). Figure VII.3a shows a histological section of an area of 
remodelling cartilage; areas of proliferating, resting and hypertropic cartilage are 
present, together with a zone of calcified cartilage. Low levels of expression were 
detected in mature chondrocytes (fig VII.3b), but in areas of calcifying cartilage no 
expression was detected (fig VII.3b). In contrast, areas of differentiating fibrocartilage 
cells at the periphery of the osteophyte (fig VII.3a) expressed high levels of 
osteopontin (fig VII.3c). Fibrocartilage cells differentiating from the connective tissue 
(fig.VII.4a), also showed high osteopontin expression (fig. VII.4b).
In common with the expression profile of osteoblasts, low expression was detected in 
osteoclasts (fig. VII.5b), during the initial stages of cartilage resorption (fig VII.5c).
WOVEN BONE FORMATION AND REMODELLING
The residual calcified cartilage was remodelled into woven bone by osteoclastic 
resorption followed by bone formation. In contrast to the initial stage of cartilage 
calcification distinct clusters of osteoclasts were observed to express very high levels of 
osteopontin at sites of active woven bone remodelling (fig. VII.6 a). The expression of 
osteopontin by osteoclasts was examined in several different environments. It was
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demonstrated that osteopontin expression was not restricted to resorbing osteoclasts, as 
it was also detected in osteoclasts distant from the bone surface (fig. VII.7a and 
VII.7b).
Osteopontin expression was also investigated in the osteoclastoma tissue; figure VII.8 a 
illustrates the histology of one of the osteoclastomas, and shows the osteoclasts 
surrounded by stromal and mononuclear cells. The entire population of osteoclasts in 
the osteoclastoma tissue (fig. VII.8 b) were shown to express high levels of osteopontin 
mRNA, further confirming the observation that a bone environment was not necessary 
for expression.
In areas of newly forming intramembranous bone (fig. VII.9a) osteoblasts expressed 
high levels of osteopontin mRNA (fig VII.9b). High osteopontin expression was also 
particularly evident in osteoblasts that were differentiating from the surrounding 
connective tissue (fig. VII. 10a) at the periphery of the forming osteophyte. Figure 
VII. 10b shows the extremely high levels of osteopontin mRNA expressed in such an 
area.
The expression of osteopontin by the osteoblasts was shown to be dependent on their 
stage of differentiation. Osteoblasts that were plump and apposed to thick osteoid on 
the bone surface (fig. VII. 11a) expressed high levels of osteopontin (fig. V II.lib ). 
With the progression from cuboidal active osteoblasts (fig VII. 12a) to flattened 
quiescent lining cells osteopontin expression decreased markedly (fig. VII. 12b).
One very unusual finding was that populations of mononuclear cells within resorption 
sites (fig. VII. 13a) expressed high levels of osteopontin mRNA (fig. VII. 13b). This 
pattern of expression was seen in several resorption lacunae (another example is 
shown in figure VII. 14 a,b and c). The identity of the mononuclear cells was not 




In areas of lamellar bone the expression of osteopontin seemed to be down-regulated. 
Osteopontin expression could only be detected in occasional osteoclasts as shown in 
fig. VII. 14. Distinct populations of osteoblasts in lamellar bone expressed high levels 
of osteopontin (fig.VII. 16), but the majority of cells showed very little osteopontin 
expression .
Therefore in summary the expression of osteopontin was analysed in twelve 
osteophytes in four separate experiments and four different osteoclastom as. 
Osteopontin expression was detected in chondrocytes, osteoblasts, and osteoclasts as 
shown in Table VII. 1. The level of expression was dependent on several factors 




Figure VII.2a An area of calcifying cartilage.
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Figure VII.3a Initial stages of cartilage calcification; including areas of proliferating and 
resting chondrocytes, hypertropic chondrocytes, together with a zone of calcified 
cartilage. The cartilage is apposed to an area of newly differentiated fibrocartilage cells 
(arrow).
Figure VII.3b Osteopontin expression is detected in immature chondrocytes, but very 
little expression was seen in the calcified cartilage zone. Note high expression in 
fibrocartilage cells.






Figure VII.4a Histology of an area of differentiating fibrocartilage cells (arrows).
Figure VII.4b High expression of osteopontin by fibrocartilage cells
Figure VII.4c Sense RNA probe negative control
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Figure VII.5a An area of residual calcifying cartilage.
Figure VII.5b. Osteopontin expresion is undetectable in newly recruited osteoclasts 
(arrows).








Figure VII.6 a At sites of woven bone remodelling, clusters of osteoclasts expressed 
high levels of osteopontin.
Figure VII.6 b Negative control showing low level of background hybridization.
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Figure VII.7a An osteoclast away from the bone surface.
Figure VII.7b Osteoclast distant from the bone surface expressing high levels of 
osteopontin mRNA.
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Figure VII.8a Histology of a section of osteoclastoma showing osteoclasts (arrows) 
and stromal cells.
Figure VII.8b High osteopontin expression in osteoclasts, note low expression in 
occasional mononuclear cells.
Figure VII.8c Sense RNA probe negative control.
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Figure VII.9a. An area of intramembranous bone formation where osteoblasts have 
differentiated from the mesenchymal tissue, and deposited bone matrix.






Figure VII. 10a At the tip of the developing osteophyte, sites o f diminished 
endochondral bone formation occur. Osteoblasts differentiate from the surrounding 
connective tissue and lay down bone directly onto the cartilage.
Figure VII. 10b High osteopontin expression in osteoblasts in this area.




Figure VII. 1 la  Osteoblasts actively laying down osteoid at sites of bone formation.
Figure VII. 1 lb  Osteoblasts express high levels of osteopontin. Note the upper bone 
forming surface with thicker osteoid shows higher expression than the lower area.
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Figure VII. 12a A phase o f bone formation by osteoblasts. The histological changes 
from left to right are as follows: Plump active osteoblasts (arrow) to flatter quiescent 
osteoblasts on mineralised osteoid.
Figure VII. 12b Osteopontin mRNA expression by osteoblasts, note plump active 
osteoblasts express higher levels of osteopontin than flatter more quiescent osteoblasts.
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Figure VII. 13a Low magnification of mononuclear cells in a resorption site.
Figure VII. 13b High osteopontin expression in mononuclear cells in resorption lacunae.
Figure VII. 13c Sense RNA probe negative control
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Figure VII. 14a High magnification of another resorption site.
Figure VII. 14b High expression in mononuclear cells in resorption lacunae.











Figure VII. 15a Occasional osteoclasts expressing osteopontin on surfaces o f lamellar 
bone.
Figure VII. 15b Sense RNA probe negative control.
Figure VII. 16a Distinct population of osteoblasts expressing osteopontin in lamellar 
bone,
the majority of cells show very little osteopontin expression. Note also weak 









The expression of osteopontin mRNA has been demonstrated in a variety o f different 
cell types in human bone as summarized in Table VII. 1. This study has confirmed 
previous data from cell culture experiments, which suggested that osteoblasts were the 
main osteopontin producing cell type. The expression of osteopontin by osteoblasts 
was dependent on the maturation stage of the cell. Differentiating osteoblasts expressed 
high levels of osteopontin, in contrast to quiescent lining cells where very little 
expression was detected. These observations suggest that osteopontin is synthesized at 
quite an early stage in bone matrix formation, possibly before the onset o f 
mineralisation. These observations are supported by Mark et al.(1987) who detected 
osteopontin expression in a preosteblast population in rat bone. This expression profile 
is similar to many matrix components including osteonectin (Bianco et al.1988).
High levels of osteopontin expression were detected in osteoblasts in areas of 
intramembranous bone formation. This expression probably reflects the fact that 
during intramembranous bone formation there is a large "burst" of matrix protein 
expression to form islands of osteoid. It would be interesting to monitor the expression 
of other bone matrix proteins, particularly osteocalcin, during intramembranous bone 
formation.
It is interesting to note that certain populations of chondrocytes also expressed 
osteopontin. The expression decreased with maturation of the cartilage: differentiating 
fibrocartilage cells expressed high levels of osteopontin mRNA whilst chondrocytes in 
calcifying cartilage expressed no osteopontin mRNA. This expression profile was very 
similar to that observed for osteoblasts. Since chondrocytes and osteoblasts are 
thought to arise from a common precursor they may share the expression of some 
matrix proteins.
Presumably there must be a different regulatory mechanism for the expression of 
osteopontin by osteoblasts and other connective tissue cells, since during the initial
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stage of cartilage formation and calcification, high expression was detected in 
fibrocartilage cells but not in newly recruited osteoblasts. It is possible that some of the 
non collagenous proteins of bone perform some of their functions within the cells, or in 
non mineralised matrix long before calcification. Alternatively osteopontin may 
facilitate c e il: cell interactions by binding to the integrins on the cell surface. This idea 
is supported by the finding that many transformed tumourogenic cell lines express 
aberrantly high levels of 2ar, the mouse equivalent of osteopontin (Craig et al.1988). 
The most surprising feature of osteopontin expression was the large amount of mRNA 
detected in certain populations of osteoclasts; as it has been previously assumed that 
osteoblasts were the major synthetic cell for osteopontin. Osteopontin has been 
postulated to be a ligand for the vitronectin receptor (avp3 ) (Reinholt et al.1990) which 
is expressed on the cell membrane of osteoclasts from many species (Davies et 
al.1989). Zambonin-Zallone et al. (1988) demonstrated that the vitronectin receptor 
was particularly enriched in dot-like adhesion structures called podosomes. These 
structures are thought to facilitate the adhesion to bone via a specific matrix recognition 
event. Furthermore osteopontin has been shown to be highly enriched at regions of 
the bone surface where osteoclasts were anchored. Therefore it is likely that 
osteoclastic attachment to the bone surface is via osteopontin-vitronectin receptor 
interactions. Studies with monoclonal antibodies to the vitronectin receptor have 
shown that the perturbation of vitronectin receptor binding blocks osteoclastic 
resorption (Chambers et al.1986).
This study has shown that osteoclasts express osteopontin mRNA, suggesting that 
osteoclasts may facilitate their own attachment to bone, and are therefore not restricted 
to sites of osteoblastic osteopontin synthesis for attachment. The idea that osteoclast 
derived osteopontin is involved in attachment is further supported by the observation 
that osteoclasts only expressed osteopontin mRNA during the active woven bone 
resorption stage and lamellar remodelling, and not during the initial cartilage 
calcification resorption stage. Presumably this means that osteopontin synthesis was 
only required during the resorption of bone. Osteopontin expression was not
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dependent on attachment to bone since high levels of osteopontin mRNA were detected 
in many osteoclasts distant from the bone surface. Furthermore, the entire population 
of osteoclasts in the osteoclastoma tissue expressed osteopontin mRNA. It is possible 
that the osteoclasts in the osteoclastoma tissue might not express osteopontin mRNA 
with the same expression profile as osteoclasts in bone, due to their aberrant 
environment. It must also be noted that in situ studies only highlight expression at a 
particular time point, therefore it is possible that osteoclasts distant form the bone 
surface which are expressing osteopontin may be preparing for resorption, or are in a 
post-resorptive phase.
Recently Bianco et al. (1991) demonstrated that osteoclasts in human fetal bone 
expressed both BSP mRNA and protein. BSP is thought to be a cell attachment factor 
and it is possible that osteoclasts express these two sialoproteins to facilitate attachment 
to the bone surface. The results of these studies have far reaching implications, as it has 
been previously presumed that sialoproteins located in osteoclasts were present as a 
result of phagocytic engulfment from the bone matrix.
The expression of osteopontin in certain mononuclear cells in resorption lacunae was 
unexpected, and it is tempting to speculate on the origin and function of these cells. It 
is possible for instance that their expression of osteopontin is a "post-resorptive" signal 
to recruit osteoblasts to initiate bone formation in the resorption lacunae. It has been 
reported that certain C terminal fragments of another bone matrix protein, osteocalcin, 
are chemotactic for osteoblasts (Lucas et al.1988). Perhaps osteopontin peptides share 
this property and encourage osteoblast recruitment to resorption lacunae. Alternatively 
these cells might be fission products of mature osteoclasts as recent data suggests that 
osteoclasts are " broken down " by phagocytic mononuclear cells after resorption has 
taken place (Video demonstration ICCRH meeting Copenhagen 1991). A panel of 
monoclonal antibodies specific for a range of cell types reacted to serial sections may 
identify these cells in the future.
In summary this study confirms that human osteoblasts are capable o f expressing 
osteopontin mRNA in bone. Whilst osteoblasts may be the primary osteopontin
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synthesizing bone cell, the data highlights the fact that other cell types in the bone 
microenvironment are capable of expressing osteopontin, including osteoclasts and 
"post-resorptive” mononuclear cells.
Table VII. 1: Osteopontin mRNA expression in human bone and osteoclastoma tissue.










Osteoblasts forming intramembranous bone ++
Quiescent osteoblasts
Osteoblasts apposed to trabeculae +
Osteoclasts resorbing cartilage ±
Osteoclasts remodelling bone ++++
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The aim of this project was to characterise the expression o f the cytokines TGFp and 
IL -ip  and the bone matrix protein osteopontin by human bone cells. This aim was 
largely achieved, and this study represents the first report of cytokine expression in situ 
in human bone. The following sections describe how the results obtained from this 
study compare with those from research groups in the same field. The pitfalls and 
limitations of the in vitro and in situ techniques will also be discussed. The role of the 
osteoclast in bone remodelling will be evaluated in the light of the novel data that was 
obtained in this study.
In vitro studies
The tissue culture experiments provided a simple system where the effect of 
exogenously added agents on cytokine expression could be studied. There are several 
advantages of such a simple system, the primary advantage being that the experimental 
design is very flexible and the effect of many different time points and concentrations of 
agent on cytokine expression can be evaluated. In addition, the experiments are 
relatively easy to perform and the model is a "clean" system where no unknown factors 
are present. One major disadvantage of this type of experiment is a certain variability 
between cells derived from different bone donors. The donors varied in age and sex, 
and a large number suffered from bone diseases such as osteoporosis and 
osteoarthritis. Whilst the same trends in cytokine expression were seen for all the bone 
cell populations studied, often the magnitude and time course of the responses differed. 
The results of the in vitro studies which investigated the modulation o f TGFp and 
EL-lp expression have been confirmed by other workers. Keeting et al. (1991) verified 
that human osteoblast-like cells express IL-lp mRNA, and that the transcription of this 
cytokine is induced by IL-1, TNFa and LPS treatment. Studies from the same group 
also confirmed that the expression of TGFp mRNA by human osteoblast-like cells was
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upregulated by systemic hormones, including PTH and 17-p oestradiol (Oursler et al.
1991).
It is important not to underestimate the limitations of in vitro studies. In a recent 
review, Nathan and Spom (1991) proposed that the expression of cytokines by a 
variety of different cell types is highly influenced by the microenvironment of the cell. 
They coined the phrase "cytokines in context" to describe how the response of cells to 
cytokines could be markedly affected by the extracellular matrix in which most cells are 
embedded. It is reasonable to expect that the phenotype of human osteoblast-like cells 
may be altered during culture on a plastic surface. This change in environment could 
alter the whole cytokine expression profile of the cells.
A study has been undertaken to evaluate the effect on phenotype of culturing human 
osteoblast-like cells on different matrices. The expression of alkaline phosphatase, an 
important osteoblast secretory product, has been shown to be reduced by culturing 
these cells in collagen gels. Additionally, culture on a laminin substrate gave rise to a 
reduction of both alkaline phosphatase and osteocalcin production by human osteoblast­
like cells (J. Clover , personal communication).
Human osteoblast-like cells in culture have been shown to express a l, a2, a3 and |3l 
integrin subunits (J. Clover, personal communication). These subunits are thought to 
facilitate attachment to a variety of different substrata including collagen, laminin and 
fibronectin. There is evidence that adherence to matrix may induce cells to produce 
cytokines in certain environments. Examples include the observation that GM-CSF 
transcription is induced in macrophages following adherence to a fibronectin surface 
(Thorens et al. 1987). Similarly adherence to a type IX collagen matrix has been 
shown to induce IL-1 expression by human monocytes (Dayer et al. 1986). Since it 
has been shown that human osteoblasts have the means to adhere to different 
substrates, it is important to determine the influence of the matrix on their cytokine 
expression.
In addition to providing an environment for the bone cells, the extracellular matrix 
might also determine the response of the bone cells to certain growth factors. For
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example, it has been shown that many growth factors, including TGFp, IGFI, IGFII 
and FGF are present in the extracellular matrix in a complexed form (Yamaguchi et al 
1990; Canalis 1988; Vlodavsky et al 1987). FGF has been shown to bind to certain 
heparan sulphate proteoglycans and this interaction is thought to be a prerequisite for 
receptor binding (Yayon et al. 1991). Therefore, since the exogenously added growth 
factors in this study were not in this complexed form, it is possible that certain effects 
could not be observed. In the case of TGFp it has been suggested that this protein is 
associated with the small extracellular proteoglycan decorin. This association results in 
a reservoir of TGFp close to the cell surface. It is possible that this proteoglycan 
complex is necessary to achieve the correct concentration and conformation of TGFp 
required for maximum biological effect. This "juxtacrine’ regulation of human bone 
cell function may be an important factor in modulating cytokine expression.
It is not only the cell : matrix associations that are perturbed when osteoblasts are 
removed from the bone microenvironment to be cultured. Many cell : cell interactions 
are also lost, including the direct contact between osteoblasts, and the communication 
these cells make with osteocytes and bone marrow tissue. Obviously during culture an 
artificial manner of contact is adopted between the human osteoblast-like cells. It is not 
unreasonable to expect that this perturbation of cell : cell contact may also affect the 
expression of many factors, including cytokines.
It is also possible that during the length of time the human osteoblast-like cells are in 
culture (approximately 6 weeks), their phenotype might not be maintained. In other cell 
types, including chondrocytes, culture conditions have been shown to promote 
"de-differentiation" of the cells (Aydelotte, 1988). The reasons for this 
"de-differentiation" are not totally clear, but are thought to be related to a radical change 
in environment. Since the tissue culture conditions used were far removed from a 
natural bone microenvironment, it is important to question whether the cells represent 
an authentic osteoblast phenotype. The only way this question can be addressed is by 
comparing the expression profiles of cytokines in vitro with those in situ..
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In situ studies
The results from the in situ hybridization studies confirmed that cytokine expression by 
human osteoblasts is not just a tissue culture artefact. Both TGFp and IL -ip were 
shown to be expressed by osteoblasts in situ. The expression profiles observed in situ 
shared certain similarities with those seen in vitro. This was particularly true for IL-lp 
expression, where the short lived expression observed in vitro mirrored the transient 
expression seen in situ. However there were some differences in the results obtained 
from the two approaches. Whilst TGFp expression was constitutive in culture, the 
expression observed in situ was seen to alter during the different stages of osteophyte 
development. This was not unexpected since the osteoblasts in the bone environment 
receive many different signals to those in culture. The in situ studies did not just 
confirm the results of the in vitro experiments, but served as an extension of the project 
to characterise cytokine expression during bone remodelling.
The fact that the cytokines were shown to be expressed by distinct cell types at certain 
stages of osteophyte development is the most compelling evidence reported so far that 
cytokines have a primary role in the control of local bone remodelling. The importance 
of this fact cannot be underestimated since, before this study, the impact of cytokine 
expression on human bone remodelling had not been extensively addressed. The 
in situ studies detected cytokine expression at the mRNA level, no experiments were 
completed to confirm that functional proteins were present.
The detection of cytokine mRNAs in human bone cells, however, does not necessarily 
indicate that these factors are active in the local bone environment. There are many 
mechanisms by which the actions of cytokines may be modified after mRNA synthesis. 
These different "levels of control" are described in the following sections.
(a) Transcriptional and post-transcriptional modulation.
Studies by Howell et al. (1992) suggest that there is a post-translational regulation of 
the IL-2 pathway in chronically inflamed rheumatoid synovium. IL-2 mRNA was 
detected in tissue from 18 needle biopsies by in situ hybridization techniques. 
However immunolocalization studies showed no IL-2 protein could be detected in any
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of the samples. The idea that IL-2 expression may be regulated in a post- 
transcriptional manner is further supported by the observation that isolated synovial 
lymphocytes fail to produce IL-2, despite the high levels of IL-2 mRNA detected by 
Northern blotting (Combe et al. 1985; Buchan et al. 1988).
Such factors as the biological half-life of the mRNA may be important for the regulation 
of cytokine expression. Studies on the newly characterised interleukin, IL-12 suggest 
that it may contribute to the control of IFNy expression by T cell blasts (Chan et al.
1992). In conjunction with IL-2, IL-12 treatment has been shown to modulate the 
IFN-y mRNA half-life in these cells. T cell blasts were stimulated with IL-2 and IL-12 
for 4 hours and then treated with the RNA synthesis inhibitor actinomycin D. Northern 
blot analysis of the RNA revealed that the IFN-y mRNA half-life was doubled. IL-2 or 
IL-12 alone failed to give this mRNA stabilization, highlighting the fact that cytokines 
may interact together in a complex network.
In the same study EL-12 was also shown to also have an effect on the transcription of 
the IFN-y gene. After a 2.5 hour stimulation with IL-12, the transcriptional rate of the 
IFN-y gene was increased by 3-fold in the T cell blasts.
(b) Post-translational modification.
Post-translational modifications occur after the synthesis of the cytokine protein. 
Common modifications include the derivatization o f amino acid moieties or 
glycosylation of the polypeptides. Another modification is the proteolysis of a proform 
of the cytokine within the cell, to give an active molecule which is subsequently 
secreted. The activity of IL-lp is controlled in this manner: a 33kDa proform is 
synthesized which is cleaved into an active 17kDa polypeptide. Recently, the protease 
which carries out this cleavage has been cloned (Cerretti et al. 1992). This 
"convertase" is unusual in the fact that it requires proteolytic processing before it is 
active. This activation step may be catalysed by another enzyme or may be due to an 
autocatalytic event. This example illustrates how the biological activity of IL-lp may be 
controlled in several ways, even after it has been synthesized.
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(c) Synthesis in a latent rather than active form.
TGFp has been shown to be expressed by osteoblasts from several species in a latent 
form (Gehron-Robey 1988). For this cytokine to be biologically active it is necessary 
for the LAP peptide to be removed by proteolysis or acidification (Lyons et al. 1988). 
Obviously this extra activation step means that there are additional points at which the 
action of this cytokine may be modulated. The activity of this cytokine might be 
restricted to specialized acidic environments (eg under the ruffled border of osteoclasts) 
where activation may take place. One advantage of the synthesis of a cytokine in a 
latent form is that the signal is very long lived, using this mechanism it is possible to 
lay down deposits of cytokines in the matrix for signalling over a long time course.
(d) Presence on cell membrane rather than secretion.
It has been suggested that IL -la  is cell membrane-associated rather than secreted. It is 
probable that the occurrence of a cytokine on the cell surface of the cell restricts the way 
in which the cytokine can be used to signal to other cells. In this case it would be 
necessary for the target cell to make close contact with the signalling cell for the 
cytokine signal to be mediated. However this mechanism makes the signal highly 
specific since only the target cell receives the signal. EL-la is thought to be involved in 
B cell:T cell signalling using this mechanism (Dinarello, 1989).
(e) Cytokine binding proteins.
Several proteins have been shown to be capable of binding cytokines and growth 
factors. Binding may cause permanent or temporary inactivation of the ligand as in the 
case of (X2  macroglobulin cytokine binding (Lamarre et al 1991), or increase cytokine 
activity (Wang et al. 1991). There are cases where the derivatization of the ligand 
increases its activity: for example high density lipoprotein (HDL) conjugated LPS 
stimulates human peripheral blood monocytes to a greater degree than unconjugated 
LPS.
Recently, several specific high affinity binding proteins have been found for the IGF 
growth factors. Osteoblasts from several species have been shown to synthesize these 
binding proteins (IGFBPs) in addition to the IGFs themselves (Ernst and Rodan,
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1990). The binding of the IGF to the IGFBP is thought to be reversible and may be a 
protective mechanism to prohibit premature degradation of these growth factors.
The occurrence of anti-cytokine antibodies in the circulation raises the question as to 
whether these binding proteins alter the biological activity of cytokines. A study by 
Bendtzen et al. (1989) demonstrated that specific autoantibodies to EL-la and TNFa 
were detectable in the serum of apparently normal adults. The frequency of detectable 
autoantibodies to IL -la  and TNFa in the population was 24% and 48% respectively. 
The most prevalent subtype of antibody detected was IgG4. Cytokine-antibody 
complexes were shown to undergo limited lattice formation and complement activation 
suggesting that they would be cleared at a low rate. The function of these 
autoantibodies is not known but it is possible that they may prolong the existence 
and/or the activity of cytokines in the circulation.
IL - la  was shown to bind avidly to the Fab fragments of these IgG molecules with a 
dissociation constant of < 5x l0_11M. It is interesting to note that this avidity is at least 
an order of magnitude higher than that between IL -la  and other target cells such as 
fibroblasts and endothelial cells (kd> 5xlO"10) (Dower et al. 1985). In contrast, 
lymphoid cells have a greater affinity for this cytokine (kd< 10_12M) (Lowenthal et al. 
1986). Therefore, IL-1 may be released in an active form to specific target cells 
containing high affinity binding sites via this mechanism.
(f) Modulation of the receptor.
It does not seem to be the case that cytokine receptors on human osteoblasts are 
modulated by cytokines. This is in contrast with many other cell types where a 
cytokine stimulation signal markedly alters cytokine receptor levels, for example with 
immune cells, whearby EL-1 is a very potent stimulator of IL-2 receptor expression on 
the surface of T cells (Leonard et al. 1985).
Soluble receptors for several cytokines have been shown to be produced in certain 
circumstances. The soluble receptors are produced by two mechanisms. The first is 
the shedding of a fully formed receptor from the cell surface, this has been shown to be 
the case for TNFa (Seckinger et al. 1990a), IL-2 (Robb et al 1987) and IL-1 (Symons
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et al. 1991). Soluble TNFa receptors have been detected in nanogram amounts in the 
urine of patients with high fever or cancer (Lantz et al. 1990). It is thought that the 
binding of the ligand to the shed receptor results in a extension of its activity since the 
receptor complex is difficult to clear. The second mechanism is post-transcriptional, 
whereby the primary transcript is alternatively spliced to give a shorter transcript coding 
for a receptor without a transmembrane domain. Such alternative splicing has been 
demonstrated to take place during the formation of the soluble IL-4 receptor (Mosely et 
al. 1989)
(g) Interference with receptor binding.
The existence of a naturally occuring IL-1 receptor antagonist (IRAP) suggests that 
there is yet another control point for cytokine activity. IRAP has been shown to 
compete with IL-1 for receptor binding, which is thought to result in the abrogation of 
IL-1 activity. Seckinger et al. (1990b) demonstrated that recombinant IRAP could 
block IL-l-induced bone resorption and prostaglandin production, in both the fetal rat 
long bone and rat calvariae models. Interestingly PTH- and TNFa-induced resorption 
was not blocked, which probably reflects the fact that these effects are independent of 
an IL-1 receptor signal transduction pathway. Intravenous injection of IRAP produces 
no symptoms or changes in the parameters associated with IL -1 bioactivity. Healthy 
human volunteers injected with massive doses of IRAP (lOmg/kg) show no significant 
changes in metabolism. If the equivalent amount of IL-1 was injected the subjects 
would be very ill (Dinarello and Thompson 1991). Whether there are similar 
polypeptide receptor antagonists for other cytokines is an important question to be 
addressed in the future.
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The role of osteoclasts in bone remodelling
The results from the in situ studies also raise an important question of the role of 
osteoclasts during bone remodelling. The fact that human osteoclasts have been shown 
to express osteopontin mRNA questions the purely resorptive nature of this cell type. 
In addition, human osteoclasts have been shown to be capable of expressing TGFp and 
IL-6 mRNA (parallel study with A. Littlewood). This might highlight a means by 
which osteoclasts can signal to other bone cell types. It has been previously proposed 
that the communication between osteoclasts and osteoblasts is one way, ie. osteoblasts 
produce signalling factors that control osteoclastic resorption. However, there is no 
reason why this signalling mechanism should be unidirectional. Indeed, it is highly 
probable that a bidirectional means of communication would be preferable. If this was 
the case osteoclasts could signal to osteoblasts in a variety of instances including after 
the cessation of resorption. During repair of human bone fracture it is observed that the 
fracture callus is remodelled in a specific and highly controlled manner. The excess 
bone formed is resorbed on one side of the bone, and formed on the other. From 
observing instances like this it seems highly probable that active osteoblast: osteoclast 
"cross talk" exists. Using in situ hybridization and immunolocalization techniques it 
might be possible to address this question further. Unfortunately at present it is not 
possible to manipulate human bone to investigate the effect of various factors during 
remodelling.
In view of the results of this and other studies it is proposed that human bone 
remodelling is controlled by two main groups of factors, the cytokines and the systemic 
growth hormones. It is thought that the systemic growth hormones control the overall 
skeletal development, whilst cytokine production controls local bone remodelling. 
The two different control mechanisms may be superimposed upon each other. 
Circulating hormones may act on bone cells either directly or indirecdy to modulate the 
synthesis or effects of cytokines, which in turn may control bone remodelling. An 
overall scheme for the role of TGFp, IL-1 p and osteopontin in the control of human
236
bone remodelling is shown in figure VIII. 1. It can be seen that the schem e represents a 
complex netw ork o f  cytokine expression. However, it only represents a small portion 
o f  the overall netw ork that is thought to occur in bone remodelling. Hopefully with the 
advent of more sophisticated techniques it will be possible to unravel the m echanism  o f 
human bone rem odelling so that the problems of many bone diseases may be addressed 
in the future.
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